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Abstract
The Zika virus (ZIKV) outbreak in the Americas between 2015 and 2017 took the world by
surprise. Within two years, over 1.5 million suspected or confirmed cases were reported.
However, the true incidence is likely much higher, due to under-reporting and asymptomatic
infections that are undetected. As of July 2019, 87 countries had reported ongoing or past
circulation of ZIKV. ZIKV infection results generally in mild and transient symptoms. The
disease caused by ZIKV is often asymptomatic or mild. However, infection during pregnancy
can result in severe adverse congenital outcomeswithmicrocephaly asmost prominent. This
was first noted in clusters of infants born with disabilities linked to ZIKV infection in Brazil
in 2015, making ZIKV a disease with a serious public health impact. In this thesis, I explore
different aspects of the ZIKV epidemic. I use different epidemiological methods to provide
insight in theZika virus as a causeof adverseoutcomes, ZIKVas a sexually transmitteddisease
and the risk of future ZIKV outbreaks.
InChapter 1, Iprovidean introduction to thehistoryofemerging infectionsandtheemergence
of ZIKV specifically. I describe the investigation of causality, the use and accumulation of
evidence during disease outbreaks, and how disease transmission can be investigated using
mathematicalmodels.
In Chapter 2, I provide insight in how evidence accumulates during an outbreak andmore in
general during new causal questions. Case reports and case series were the first studies to
appear, followedbybasic research (invivoand invitro studies). It tookmorethanayearafter the
onset of the ZIKV outbreak for robust epidemiological studies to be published. Establishing
early public health guidance thus requires a broad approach taking into account all evidence
available. We have to make do with the low quality evidence. To minimize further delays,
evidence should be accessible as soon as it becomes available through rapid and open access
dissemination.
In Chapter 3, I extend a systematic review that was conducted earlier, and turn it into a living
systematic review. I introduce the concept and implementation of living systematic reviews
in the context of an emerging disease. I assess the evidence on the causal relation between
ZIKV infection and adverse congenital and auto-immune neurological outcomes, published
between May 30, 2016 and January 18, 2017, using a framework based on the causality
dimensions of BradfordHill. During this period, the evidence expanded that ZIKVwas indeed
a cause of congenital abnormalities and Guillain-Barré syndrome (GBS). I provide a proof of
concept for the use of living systematic reviews to synthesize evidence about an emerging
pathogen such as ZIKV.
In Chapter 4, I assess the evidence published between January 18, 2017 and July 1, 2019. I
quantify the strength of association of the relation between maternal ZIKV infection and
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congenital adverse outcomes and between ZIKV infection and GBS. I found that the strength
of association between ZIKV infection and adverse outcomes from case-control studies
differs according to whether exposure to ZIKV is assessed in themother (odds ratio (OR) 3.8,
95% CI: 1.7–8.7, I2=19.8%) or the foetus/infant (OR 37.4, 95% CI: 11.0–127.1, I2=0%). In cohort
studies, the risk of congenital abnormalities was 3.5 times higher after ZIKV infection (95%
CI: 0.9–13.5, I2=0%). The strength of association between ZIKV infection and GBS was higher
in studies that enrolled controls from hospital (OR: 55.8, 95% CI: 17.2-181.7, I2=0%) than in
studies that enrolled controls at random from the same community or household (OR: 2.0,
95%CI: 0.8–5.4, I2=74.6%). The heterogeneity between the studies could be partly explained
by the heterogeneity in methods and sampled populations. Studies suffered from bias and
uncontrolled residual confounding.
InChapter 5, I present a framework to systematically assess theevidence for ZIKVas a sexually
transmitted disease. I reviewed all available literature and concluded that the risk of sexual
transmission of ZIKV is likely small, but relevant for certain risk groups. I found that in semen
viral RNA could be detected for a median period of 34 days (95% CI: 28–41 days) and 35 days
(noCI given)basedon twocohort studies. Aggregateddata aboutdetectionofZIKVRNAfrom
37 case reports and case series indicate amediandurationof 40days (95%CI: 30–49days) and
amaximumduration of 370 days in semen. In human vaginal fluid, themedian duration was
14days (95%CI: 7–20days) and themaximumdurationwas 37days. Infectious virus inhuman
semen was detected for a median duration of 12 days (95% CI: 1–21 days) and amaximum of
69days. I highlight thepoor quality of the evidence and theneed for systematic observational
studies that evaluate the risk of sexual transmission of ZIKV.
In Chapter 6, I present predictions on the future risk of ZIKV, based on data from Managua,
Nicaragua, using mathematical modelling. The risk of a new outbreak in the next decades
is low due to herd immunity. However, a next outbreak will disproportionally hit people in
the young reproductive age hardest (age 15–29 years). Vaccination could curb this risk: Early
introduction of vaccination in 15-year-old girls has the capacity to extend the herd immunity
andbe of benefit to thewhole population. Introduction of a vaccine needs to happenwithin a
decadeafter the2016outbreak toachieve thisprotection. Thedurationof immunity following
ZIKV infection has impact on the speed at which outbreaks will reoccur.
In Chapter 7, I present an overview of the main findings and I discuss the interpretation and
implications of these results. I discuss the strengths and limitations of the work, and outline
follow-up questions emerging from thework.
In this thesis, I establish and use different frameworks andmethods that help tomake sense
of the limited evidence that is available during disease outbreaks. ZIKV has been introduced
on the American continent, and it is likely there to stay, thus we have to accept that ZIKV will
continue to re-emerge. At the same time, due to the climate change, the European temperate
region also becomes more suitable for vector-borne disease such as ZIKV. With the ZIKV
epidemic on the wane, we now have time to consolidate findings and implement the lessons
learnt. We need to be prepared for the re-emergence of ZIKV but also for the emergence of
newdiseases. The tools andmethods I present in this thesis, will help us to bemore prepared
for a next outbreak.
viii
Chapter 1
Introduction
“The man of science who cannot formulate a hypothesis is only an accountant of
phenomena.”
–Pierre Lecomte duNoüy (December 20, 1883 – September 22, 1947)
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The Zika virus (ZIKV) outbreak in the Americas between 2015 and 2017 took the world by
surprise. Within two years, over 1.5 million suspected or confirmed cases were reported [1].
However, the true incidence is likely much higher, due to under-reporting and asymptomatic
infections that go undetected [2]. As of July 2019, 87 countries had reported ongoing or past
circulation of ZIKV [3]. ZIKV infection results generally in mild and transient symptoms. The
true burden of the disease lies in the adverse outcomes it causes. Infection during pregnancy
can result in adverse congenital outcomes with microcephaly as most prominent. This was
first noted in clusters of infants born with severe disabilities linked to ZIKV infection in
Brazil in 2015 [4], making ZIKV a disease with a serious public health impact. This raised
the question whether ZIKV was the cause of these adverse outcomes and catalysed research
interest. From the beginning of 2016, over 300 scientific publications started to appear per
month, where before 2016 that was the total size of all the published research. In this thesis I
explore different aspects of the ZIKV epidemic.
With the research described in this thesis, I use different epidemiologicalmethods to provide
insight in the Zika virus as a cause of adverse outcomes, the risk of Zika virus as a sexually
transmitteddiseaseand the riskof futureZikavirusoutbreaks. This introductory chaptergives
an overview of five topics: In the first section, I introduce the history of emerging infections.
In the second, I describe the emergence of Zika virus and the outbreak in the Pacific region
and the Americas. In the third section, I describe the investigation of causality, in the fourth
section I provide insight in how evidence accumulation during disease outbreaks and the
use of evidence. In the fifth section, I describe the investigation of disease transmission
usingmathematical models. The chapter ends with an outline of the aims of the subsequent
chapters of this thesis.
1.1 Thehistory of emerging infections
Infectious disease and disease outbreaks have likely always been part of human history.
Throughout the centuries, emergence and re-emergence of infectious disease have had
substantial impact [5]. One of the first documented outbreaks is the Plague of Athens (430
BC) of which the exact aetiology is still disputed today; first hypothesized to be caused by a
wide variety of pathogens ranging from smallpox and typhus to Ebola [6], but most likely
caused by typhus based on ancientmicrobial DNA samples [7, 8]. The impact of the outbreak
was vast with a mortality rate of at least 25% [9]. The outbreak likely altered the outcome
of the Peloponnesian War by depleting the Athenian military of its personnel and some of
its most important leaders [10]. Disease outbreaks shaped history, where larger outbreaks
have economic and political consequences. The introduction of disease into populations
that have not been in contact with these, means that infections can spread without being
restricted by pre-existing immunity. Examples are the introduction of infectious disease that
were common in Europe – such asmeasles and smallpox – following the Spanish discovery of
America [11]. Until the beginning of the 1900s, infectious disease caused around half of the
total humanmortality [12].
Recent history is similarly filled with examples of emergence and re-emergence of infectious
disease on a large scale. In the last decades, we have seen the emergence of severe acute
respiratory syndrome (SARS) [13], theH1N1 Influenza pandemic [14],Middle East Respiratory
Syndrome (MERS) [15], and the re-emergences of Ebola [16] (Figure 1.1). Disease that all
posed their unique challenges, but all had substantial global impact. For example, SARS
infected over 8,000 individuals, with amortality rate reaching 10% [17]. Themacro-economic
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impact of SARS was estimated at US$30–100 billion, or around US$3–10 million per case
[17]. The frequency and scale on which outbreaks occur does not seem to diminish: Between
2011-2017, theWorld Health Organization (WHO) described a total of 1,307 epidemic events,
in 172 countries [18]. Where the ZIKV outbreakwas themost recent pandemic.
Figure 1.1: Important infectious disease outbreaks that occurred between 2002 and 2015.
Reproducedwith permission from [19], CopyrightMassachusettsMedical Society.
1.2 Zika virus
ZIKVwas discovered in 1947. The virus was isolated from a captive, sentinel rhesusmonkey in
the Zika forest of Uganda during routine surveillance for yellow fever [20]. In 1948, the virus
was isolated fromtheAedesafricanusmosquito; thefirsthumancasesweredetected inUganda
and Tanzania in 1952, in a study that showed the presence of neutralizing antibodies against
ZIKV in sera [21]. Before 2007, ZIKV caused sporadic outbreaks in Asia and Africa [22].
ZIKV is a flavivirus, closely related to dengue virus (DENV) and from the same family as the
yellow fever virus. The virus ismainly transmitted throughmosquitoes from the Aedes family.
ZIKV isolateshavebeengrouped into twomajor lineages,AfricanandAsian,where theAfrican
lineage is ancestral to the Asian lineage [23].
1.2.1 TheZika virus epidemic
The first documented outbreak of ZIKV occurred on Yap Island, Micronesia, in 2007. Here,
after the outbreak, 5005 of the 6892 (73%) sampled individuals had detectable antibodies
against ZIKV [24]. In 2013, ZIKV caused a larger outbreak in French Polynesia, in the south
pacific, where the outbreak affected up to 49-66% of the people [25]. Here an increase in
cases of Guillain-Barré syndrome was observed that coincided with the outbreak [26]. The
virus spread to several countries in the Pacific Ocean: Easter Island, the Cook Islands andNew
Caledonia [27]. From there, the virus spread to the Americas.
Between 2015–2017, ZIKV caused an epidemic in theAmericas. The reported number of cases
in the Americas peaked between February andMarch 2016 (Figure 1.2). This peak wasmainly
driven by the large number of cases from Brazil; in other countries the outbreak occurred
later [28]. Subsequent large outbreaks in the next year were not observed, likely due to the
occurrence of herd immunity (Section 1.5.1). Localized outbreaks did occur [28].
3
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Figure 1.2: Reported cases of Zika virus in 2016 and 2017. Suspected and confirmed cases
according to case definitions implemented by countries. The total number of cases per week
is aggregated from the Caribbean, Central America and South America and based on data
from PAHO and https://github.com/andersen-lab/zika-epidemiology/tree/master/paho_case_
numbers.
During the epidemic in the Americas, it became clear that ZIKV infection during pregnancy
causes congenital abnormalities,witha reducedneonatalheadcircumference (microcephaly)
as most prominent [29] (Chapter 3 and 4). TheWHO convened a working group with experts
fromdifferentdisciplines, andon the31st ofMarch2016, basedonassessmentof theavailable
evidence, this ’Zika Causality Working Group’ determined that sufficient evidence existed to
indicate that ZIKV infection during pregnancy causes congenital abnormalities and that ZIKV
infection can trigger GBS [30]. During the outbreak, sexual transmission of the virus was also
observed (Chapter 5).
1.2.2 Transmission routes
ZIKV is primarily transmitted by mosquitoes of the Aedes family (Figure 1.3). Direct
human-to-human transmission occurs either through vertical transmission – in utero from
mother to embryo or foetus – (Chapter 3 and 4) or through sexual transmission (Chapter 5).
Mosquito transmission
A.aegypti ismainly responsible for the currentoutbreak in theAmericas [31, 32]. Themosquito
is well adapted to urban settings, tends to bite indoors and feeds multiple times per cycle of
egg production, increasing the probability of transmission. The time spent at home, and the
body surface area of children was found to be correlated with risk of mosquito bites [33]. A.
albopictushas been shown to be able to transmit Zika virus inAfrica and in laboratory settings.
Aedesmosquitoes also transmits CHIKV andDENV.
The A. aegypti that is found throughout the Americas, originated from Africa [34]. Humans
have shaped the evolution and spread of the mosquito. The species was likely introduced
to the New World by slave trade ships between the sixteenth and eighteenth centuries. A
secondarywave of invasion to theAsian-pacific region likely occurred in the 20th century [34].
Reservoirs. In Africa and Asia, ZIKV can circulate between non-human primates and
mosquitoes [31]. This sylvatic cycle forms a reservoir for the disease and is likely responsible
for periodic reintroduction of the virus in the human population (Figure 1.3). These spill-over
events result in low-level endemic circulation. In Africa or Asia, no outbreaks of the scale
4
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Figure 1.3: The urban and sylvatic cycle of the Zika virus. Source: https://www.cfr.org/
backgrounder/zika-virus.
of the one in the Americas have been documented. Likewise, no adverse outcomes were
reporteduntil recently (Chapter 4). For example, in 2017, Angola experiencedaZIKVoutbreak
with adverse congenital outcomes, linked to the outbreak in Brazil [35]. The presence of a
disease reservoir in the Americas has not been established yet. Newworldmonkeys, residing
in tropical regions of Central and SouthAmerica, have been shown to potentially sustain ZIKV
infection and thus contribute to a sylvatic cycle in the Americas [36, 37].
Vertical transmission
In pregnant women, ZIKV can pass the blood-placenta barrier and infect the embryo or
foetus. Here, the virus has a tropism for the developing brain and disrupts the normal growth
[38]. ZIKV antigen and viral RNA have been detected in amniotic fluid and placental tissues
from ZIKV-infected women and in fetal and newborn tissues diagnosed with congenital Zika
syndrome [39, 40]. In vivo and in vitro evidence has corroborated this (Chapter 3). Live virus
has been detected in breast milk [41]. However, so far, transmission related to breast feeding
has not been reported [41, 42]. ZIKV canpotentially be transmitted via blood transfusion [43].
Sexual transmission
Unique to human arthropod-borne flaviviruses, ZIKV can be transmitted through sexual
intercourse as well (Chapter 5). A first case of sexual transmission of ZIKV was reported in
2008. A male traveller was infected in Senegal, and transmitted the disease to his partner
in the United States of America through sexual contact [44]. During the outbreak in the
Americas, the Centers for Disease Control and Prevention (CDC) and the European Centre for
Disease Prevention and Control (ECDC) reported increasing numbers of cases of ZIKV that
were apparently transmitted through sexual intercourse [45, 46]. The majority of cases were
men traveling back from ZIKV endemic countries, infecting their female sexual partner who
did not travel. Both in the American and European region, one percent of the cases originated
from sexual transmission via travellers [45, 46]. The exact impact of sexual transmission in
an endemic setting remains difficult to quantify, since infection through mosquito-borne
and sexual transmission are indistinguishable [47] (Chapter 8.2). In animalmodels, ZIKV has
been demonstrated to persist in the testes and semen [48]. Similarly, persistence of viral RNA
has been demonstrated in semen inmen (Chapter 5, [49]).
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1.2.3 Pathogenesis and clinical disease
ZIKV is neurotropic in the developing brain and has a tropism for reproductive tissues and
cells, such as the testes and semen in men and the placenta in pregnant women [50]. Some
of these properties of ZIKV have been observed in other flaviviruses. Like ZIKV, the flavivirus
bovine viral disease virus causes congenital abnormalities such as malformation and/or
demyelination of the central nervous system in cows [51]; Japanese Encephalitis virus, which
is transmitted bymosquitoes and causes encephalitis in humans, is sexually transmissible in
pigs and causes reproductive disorders there [52]. The combination of the potential for sexual
transmission and adverse congenital outcomes in a mosquito-borne disease are unique
to ZIKV. Phylogenetic analysis revealed that epidemic strains have accumulated multiple
mutations, potentially resulting in an increased virulence of the virus [53].
Signs and symptoms
Infectionwith Zika virus is often asymptomatic, with up to 50–73%of the infected individuals
notexperiencingany symptoms, dependingon thegeographical locationof theoutbreak [54].
The median incubation period for symptomatic infection is 6 days (95% CI 4–8) (Figure 1.4)
[55]. Symptomatic infection results in a transient flu-like illness with maculopapular rash,
often with conjunctivitis. Symptoms resolve naturally after 2–7 days and can be similar to
those caused by DENV and chikungunya virus (CHIKV) infection. However, DENV can cause
serious complicationswith rapid onset of capillary leakagewith orwithout haemorrhage that
can lead in some cases to death [56]. Symptomatic CHIKV infection can be accompanied by
severe joint pain [56].
Still, much remains to be learned, particularly
about the frequency and spectrum of ZIKV
sequelae in pregnancy and how we can assess
and reduce risk. ZIKV-related birth defects can
have long-standing financial, social, and health
effects on affected families and communities
(98). Hence, the threat from ZIKV cannot purely
be assessed based on immediate clinical outcomes
but also must account for its lifelong effects.
The potential range and effect of ZIKV
Transmissibility and potential
range of ZIKV
Transmission of ZIKV in a population is a func-
tion of local ecology, the natural history of ZIKV,
and the population’s susceptibility to infection.
The suitability of the local environment for ZIKV
transmission and the effect of ZIKV’s natural
history are captured by the basic reproductive
number R0, the number of secondary infections
expected from a single case in a population with
no preexisting immunity (e.g., French Polynesia
before 2013). R0 is a function of both disease and
setting and will vary between locales based on
the local environment, human behavior, vector
abundance, and, potentially, interactions with
other viruses. The combined effect of these fac-
tors and susceptibility will be captured by the
reproductive number R, which is related to R0
by the equation R = R0 × S, where S is the pro-
portion of the population susceptible to ZIKV.
This value, combined with the generation time
(the time separating two consecutive infections
in a chain of transmission), tells us the speed at
which ZIKV will spread in a population. As we
consider how to assess the range and effects of
ZIKV, we rely both on previous experience with
ZIKV and related viruses and on an assessment
of factors likely to influence R and R0.
The size of an outbreak after an introduction
will depend on R (R0 in a ZIKV-naive population)
(99), with small, self-limiting outbreaks becoming
more likely as R approaches one, and increasing
epidemics with larger Rs. Hence, ZIKV can suc-
cessfully spread to a new region if R > 1, which
requires, among other factors, sufficient density
of the vector population. ZIKV has been isolated
frommultiple Aedes genus mosquitoes (23–26, 38),
including A. albopictus and A. aegypti, which have
a large global range (Fig. 2B) (100). Although
ZIKV has been occasionally isolated from or
experimentally passed to other genera, includ-
ing Culex species, there is no current evidence
that they contribute substantially to its spread
(22, 23, 101). It is unclear whether all areas
across the range of these mosquitoes are at risk
for ZIKV epidemics. Dengue, a virus that is also
transmitted by Aedes mosquitoes, has caused epi-
demics throughout the Americas (Fig. 2C) but has
not achieved sustained transmission in the conti-
nental United States, despite widespread vector
presence (100, 102, 103). The reasons for this may
include not only climate but also differences in
built environments and social factors (104), all
of which are likely to affect ZIKV transmission.
Several groups have attempted to map ZIKV’s
potential global range based on currently avail-
able data. These maps have been constructed
around combinations of environmental, vector
abundance, and socioeconomic factors (105–109).
There is wide agreement that much of the world’s
tropical and subtropical regions are at risk for
ZIKV spread, including major portions of the
Americas, Africa, Southeast Asia, and the Indian
subcontinent, as well as many Pacific islands and
Northern Australia. These maps differ notably in
the extent of risk projected in the southeastern
United States and inland areas of South America
and Africa, with Carlson and colleagues suggest-
ing a more limited range (107), particularly in
the continental United States, than Messina et al.
and Samy et al. (108, 109). These maps are im-
portant attempts to refine estimates of ZIKV’s
global range beyond those based solely on the
distribution of dengue or Aedes mosquitoes but,
as noted by the authors, are based on limited
evidence and should be refined as we learn more
about ZIKV. These analyses are, arguably, best
interpreted as an assessment of the risk of initial
postinvasion ZIKV epidemics, not its long-term
persistence. Whether ZIKV will in fact spread
throughout these areas is uncertain; similar vi-
ruses have failed to spread to or take hold in
areas theoretically at risk (e.g., yellow fever in
Southeast Asia) (110).
R0 in ZIKVoutbreaks in Yap Island andFrench
Polynesia was estimated to be between 1.8 and
5.8 (111–113), corresponding to 73.2 to 99.9% of
the at-risk population becoming infected in an
uncontrolled outbreak, based on classic epidemic
theory (4) [although the true relationshipbetween
R0 and final attack rates for ZIKV will be some-
what more complex (99)]. Serosurveys in French
Polynesia suggest that 66% of the population was
infected (46), which is somewhat lower but not
inconsistent with these projections. Preliminary
estimates of R0 from Colombia vary by location
and range from 1.4 to 6.6 (114, 115). These are
similar to R0 estimates presented by Ferguson
et al. for 13 countries in the Americas (116) and
recent estimates of R0 for Rio de Janeiro (117).
aaf8160-4 12 AUGUST 2016 • VOL 353 ISSUE 6300 sciencemag.org SCIENCE
Fig. 3. Schematic of the course of human and mosquito infection. Symp-
toms develop, on average, 6 days (95% range, 3 to 11 days) after ZIKV infec-
tion (64). Approximately 9 days (95% range, 4 to 14 days) after infection,
antibodies start increasing: The first antibodies detectable will be IgM, which
will later decline as IgG antibodies increase, then persist indefinitely (the
timing of the IgM/IgG switch is for illustrative purposes only and is not meant
to indicate the actual length of IgM persistence).Viremia likely starts to increase
before symptoms appear, and the magnitude and length of viremia will shape
the risk of infection of susceptible mosquitoes that bite this host. After an
incubation period, this infected mosquito will be able to transmit infection to
susceptible humans (19). The interval from the initial to the subsequent
human infection is the generation time of ZIKV, Tg [for estimates, see (116)].
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Figure1.4: InfectiondynamicsofZik virus (ZIKV). If sympt msdevelopafterZIKV infection, this
is typicallyafter6days (95%range: 3–11). Approximately9days (95%range: 4–14)after infection
antibodies st rt increasing; first IgM, ollowed by IgG antibodies. V r mia starts o incr ase
before potential symptoms appear. Susceptible mosquitoes will be infected by feeding during
viremia. After an incubation period, infected mosquitoes are able to transmit the infection
to susceptible humans. Reprinted with permission from the American Association for the
Advancement of Scienc (AAAS) from [57].
In rare cases ZIKV triggers Guillain-Barré syndrome (GBS), an auto-immune neurological
diseases [58]. Infection during pregnancy can result in vertical trans ission and adverse
congenital outcomes. In November 2015, in Brazil, the first clusters of congenital
abnormalities that coincidedwithmatern l ZIKV infectionwere reported [4].
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Adverse outcomes
Adverse congenital outcomes. Infection during pregnancy, and particularly early pregnancy,
is linked with several congenital outcomes, and possibly adverse pregnancy outcomes. ZIKV
has been compared to the ‘TORCH’- pathogens. TORCH pathogens are infectious agents that
cause congenital abnormalities, when infection occurs during pregnancy; The acronym is an
abbreviation of the pathogens Toxoplasma gondii, other, rubella virus, cytomegalovirus and
herpes simplex virus. Somehave opted that ZIKV belongs in this category or have dubbed the
group of disease ‘TORCH-Z’ pathogens [59].
Foetal infection has been linked with adverse pregnancy outcomes, and a wide spectrum
of congenital abnormalities. Microcephaly, or a reduced head circumference, is the most
prominent adverse outcome. However, vision and hearing abnormalities, joint contractures,
epilepsy, heart abnormalities have been linked to infection as well [29]. The spectrum
of disease has been described as congenital Zika syndrome and consists of 1) severe
microcephaly with partially collapsed skull; 2) thin cerebral cortices with subcortical
calcifications; 3) macular scarring and focal pigmentary retinal mottling; 4) congenital
contractures; and 5) marked early hypertonia and symptoms of extrapyramidal involvement
[60]. The risk of congenital Zika syndrome in infant born towomen infectedwith ZIKV during
pregnancy ranges from 5 to 14% [61].
Guillain-Barré syndrome. GBS is an auto-immune disease resulting in an acute peripheral
neuropathy and is the most common cause of acute flaccid paralysis [62]. Antibodies attack
the axolemmal or Schwann cells and affect function of the neurons [62]. Symptoms last a few
weeks to several months. Most people make a full recovery, some have permanent damage.
Treatment is aimedat reducing thenumber of antibodies attacking these cells, byperforming
plasmapheresis and administering intravenous immunoglobulins. Additional treatment is
symptomatic: Supportive care, sometimes withmechanic ventilation is provided. The global
baseline incidence of GBS has been reported between 0.6–4 cases per 100,000 per year [62].
Approximately two-thirds of the GBS patients had an infection within the previous 6 weeks
that causedaflu-like illness or gastroenteritis. It is believed that infections trigger an immune
response that cross-reacts with antigens of axolemmal or Schwann cells.
Throughout the Americas, during the ZIKV epidemic, an increase in GBS incidence was
reported [63]. At a population level, Mier-Y-Teran-Romero et al. (2018) showed that the
estimated incidence of GBS ranged between 1.4 (0.4–2.5) and 2.2 (0.8–5.0) per 10,000 ZIKV
infections comparing surveillance/reported cases fromBrazil, Colombia,DominicanRepublic,
El Salvador, French, Honduras, Puerto Rico, Suriname, Venezuela, andMicronesia [63].
1.2.4 Immunity
In immunocompetent individuals, thehost’s immunesystemrecognizesandprocessesaZIKV
infection. The infection induces a cellular and a humoral immune response [64]. Humoral
immunity is immunity from serum antibodies produced by plasma cells. Antibodies,
or immunoglobulins (Ig), bind to the virus and facilitate clearing it from the body. IgM
eliminates pathogens in the early stages of B cell-mediated immunity before there is
sufficient IgG (Figure 1.4) [65]. IgG can persist for years to decades following infection [66].
Protective immunity against flaviviruses is often assumed to be life-long. This was the case
for DENV, until recent evidence showed the possibility of homotypic reinfection [67]. It
is currently unclear whether protective immunity after ZIKV infection is indeed life-long.
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Early evidence from French Polynesia and Fiji might suggest that immunity wears off [68].
However, reinfectionwithin the same individual has not been described so far.
ZIKV shares a largepart of its genetic identity and structural homologywithotherflaviviruses,
including DENV, resulting in cross-reactivity between infections. In an experimental setting
where animals have been pre-exposed to DENV, antibody-dependent enhancement occurs,
meaning that a secondary infectionwithZIKV ismore severe than inDENV-naive animals [69,
70]. In humans, a large cohort showed that prior DENV exposure might result in less severe
ZIKV disease, contrary to the in vivo findings in animal models [71]. However, this might be
dependent on the time between the two infections; a shorter time between DENV and ZIKV
infectionmaybeprotective, a longer time could result in enhancement of the disease severity
[72]. Currently,muchof our knowledge comes fromanimalmodels, someofwhich lack innate
immune signalling [73].
1.2.5 Diagnosis
ZIKV infection can be diagnosed by detecting the pathogen directly in bodily fluids or
by detecting antibodies against the virus in the serum of infected individuals. During
active replication of the virus, one can detect the viral ribonucleic acid (RNA) using reverse
transcription polymerase chain reaction (RT-PCR) or one can isolate and culture the virus
(Figure 1.4). When the infection causes an immune-response in the host, ZIKV-specific
antibodies can be measured. Immunoglobulin M (IgM) is the first antibody to appear in
serum after infection, followed by an isotype-switched IgG response. A plaque reduction
neutralization test (PRNT) can be performed to determine the neutralizing effect of the
antibodies in the serum [74]. A serum sample is prepared in a series of dilutions,mixedwith a
viral suspension and incubated on cells. The number of plaques that form due to infection of
the cells at a certain dilution is compared against the number of plaques formed under cells
incubated with the viral suspension without serum. The dilution that yields a 50% reduction
in plaques – noted as PRNT50 – correspondswith howmuch antibody is present.
Diagnostic tests for ZIKV are not perfect. The proportion of infections correctly detected by
a test (sensitivity) or the proportion of absence of infection correctly detected (specificity)
depends on themethod used, the timing of the test and other factors such as cross-reactivity.
Viral RNA in the blood can only be detected during viremia. If the patient is sampled during
this period the method has a high specificity. The sensitivity is reduced when the sampling
is not performed during viremia, meaning we cannot rule out disease with a negative test.
Viral culture methods have the capacity to detect infectious virus. However, viral culture is
technically challenging and false negative results can occur. The window of detection is like
that of viral RNA, and thus also limited to viremia.
The detection of antibodies against ZIKV has limitation as well. Previous circulation of DENV
has been shown to cross-react in antibody tests, causing false positive results (a positive test,
in absence of a true infection). Test algorithms try to take into account these complicated
patterns [75].
Early in the epidemic, the case definition of ZIKV was unclear and, because of limited
availability of diagnostic tests, sometimes based on symptomatology or clinical suspicion.
The quality and availability of diagnostic test has improved over the last years, but is still far
from perfect. Evenwhen the same tests are conducted, between lab heterogeneity decreases
comparability of results [76].
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ZIKV RNA has been detected in a wide range of bodily fluids: Blood, semen, saliva, fluids of
the female genital tract, anal secretions and breast milk [41]. However, the presence of viral
RNA does not necessarily mean the presence of infectious virus. Samples that contain viral
RNA have often not been culturable (Chapter 5), although the inability to isolate virus does
not prove the absence of infectious virus [77].
1.2.6 Treatment andprevention
Currently, there is no vaccine or specific antiviral treatment against ZIKV infection. Treatment
is targeted at alleviating and managing symptoms [78]. Interventions are targeted at
mitigating the risk of exposure, especially in women of reproductive age and pregnant
women.
Vector control
Vector control is one of the most broadly used interventions, due to the lack of vaccines
and antiviral treatment. Control strategies are tailored to the behaviour of the vector. For
Aedes aegypti, mechanical measures, such as reduction of small bodies of standing water
can reduce breeding sites. Chemical methods, either with larvicides or adulticides or the
use of repellents can be applied. The use of biological methods, such as introducing the
Wolbachia bacterium to reduce vector competence has been explored with varying results
[79]. Early results from surveillance data comparing citieswhereWolbachia is used to suppress
circulation of flaviviruses, and cities where the intervention are not used, are promising [80].
A larger trial is currently under way [81].
A recent control approach used genetically modified (GM) A. aegypti mosquitoes designed
to contain a dominant lethal gene that results in death of its offspring. Release of these
mosquitoes has been effective in reducing populations of A. aegypti by up to 85% [82].
However, after large scale release in Brazil it became clear that offspring of the GM
mosquitoes survived and produced offspring that also made it to sexual maturity [83]. As a
result, unintended incorporation of portions of the transgenic strain genome into the target
population occurred [83].
The basis of WHO’s Integrated Vector Management (IVM) program is the simultaneous
use of multiple strategies for vector-borne disease prevention. It is believed that no single
intervention will be sufficient to control the disease, similar to DENV vector control [84]. An
increase of insecticide resistance contributes to the challenge of vector control [85].
Vaccine development
Immunity conferred by vaccination that protects against infection, would protect pregnant
women against adverse outcomes or through herd immunity the whole population against
outbreaks. An ideal vaccine is immunogenic, safe and cost-effective. Promising results from
phase I clinical trials showed levels of neutralizing antibody titres that were considered
protective against reinfection [86, 87]. Some vaccines have already entered phase II trials [88].
However, there are still several hurdles to take before we have access to a vaccine [89]. First,
due to a substantial reduction of circulation of ZIKV, the evaluation of vaccine efficacy has
stalled at themoment. Second, it is unclear if neutralizing antibodies induced by vaccination
are sufficient to the unborn child against vertical transmission [90]. Last, it remains to be
investigated if vaccine-induced antibodies will cross-react with other Flaviviruses. Keeping
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in mind the unexpected outcomes observed during a clinical phase III trial of the Sanofi
Pasteur’s CYD-TDV (Dengvaxia) dengue vaccine: It became clear that the vaccine could put
previously uninfected children at a higher risk of a severe case of dengue fever [91, 92].
1.2.7 Public health response
The outbreaks of microcephaly and GBS triggered a large public health response, initially in
Brazil. The ministry of health of Brazil responded in November 2015 by declaring a national
emergency [93]. Subsequently, on 1 February 2016, the WHO declared a Public Health
Emergency of International Concern (PHEIC) [94]. This increased awareness and PHEIC
catalysed the amount of resources that became available to counteract and monitor the
outbreak, including the causal associations between clinical disease and ZIKV.
During the ZIKV outbreak, the WHO emphasized the necessity of data sharing, and
standardization of research efforts [95]. WHO, CDC and several research consortia initiated
or supported cohorts that investigated different aspect of the outbreak. They set out a
research agenda with efforts to harmonize research, improve data sharing and standardize
and improve diagnosticmethods [95].
WHO and CDC developed rapid guidance on testing [75, 96], pregnancy [97, 98], mosquito
control [99, 100] and sexual transmission [101, 102]. Interim guidance on the prevention of
sexual transmission of ZIKV, in 2016, initially advised the use condoms or abstain from sex
for six months after return from travel to endemic countries. This was later reduced to three
months formen and twomonths for women, based on evidence presented in Chapter 5.
1.3 Causality
To establish the link between ZIKV infection and congenital abnormalities and adverse
neurological outcomes as a ‘causal’ link requires careful assessment. In daily life,
understanding cause and effect is often an intuitive process, where evidence helps us
establish causal links. We try to answer the ‘Why?’ inmany instances. In epidemiology and in
science as a whole, causal questions are pivotal or as Kenneth Rothman phrases it: “Outside
of the physical sciences, much of scientific knowledge comprises of a collection of causal
statements” [103].
Since antiquity, philosophers and scientist have tried to understand andexplain fundamental
concepts of causation. Aristotle introduced inductive and deductive reasoning to come to
conclusions, where in the first wemove from specific observations to broader generalizations
and theories, in the latter we move from the more general to the more specific [104]. He
viewed causality as the doctrine of four causes: thematerial, the formal, the efficient and the
final cause. In the 17th and 18th century, Francis Bacon, David Hume and John Locke shaped
ourmodern viewson causality. Theyused inductive reasoning, arrivingat generalization from
repeated observations. The logical necessity (all A are B, C is A, therefore C is B) is not present
in inductive reasoning. Hume challenged inductive reasoning and its fallibility. The 19th
century philosopher John Stuart Mill described methods of inductive reasoning to address
issues of causation [105]. Early in the 20th century, the philosopher Karl Popper introduced
the concept of falsifiability [106]. Popper provided insight in how scientific knowledge grows
[107]. Contrary to Bacon, who believed that a crucial experiment may establish or verify a
theory, Popper postulated that it can atmost refute or falsify a theory [107].
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Similarly, the cause of diseases has been subject of investigation for centuries. Before
technological advancements were made to detect most pathogens, different theories tried
to establish the cause of disease. Up to the nineteenth century people believed the miasma
theory that postulated that disease were caused by amiasma (ancient Greek for pollution), a
noxious formof ‘bad air’. JakobHenle already suggested in 1840 that a ‘Contagiumanimatum’
or ‘Contagium vivum’ existed [108]: Living microorganisms that caused infections. The germ
theory was postulated through observations by Louis Pasteur, Robert Koch and John Snow
and replaced the miasma theory. It states that microorganisms known as pathogens can
cause disease. Pasteur demonstrated that the growth of microorganisms was responsible for
spoilage of beverages, not the air the beverage came into contact with [109]. Snow identified
drinkingwater as the source of cholera in London [110]. Kochwas able to isolate anthrax using
purified cultures isolated fromdiseased animal [111]. Koch built upon JakobHenle’s work and
provided a framework for identifying acute diseases associated with microorganisms [112].
The Koch’s postulates state that: 1) The microorganism must be found in abundance in all
organisms suffering from the disease, but should not be found in healthy organisms. 2) The
microorganismmust be isolated from a diseased organism and grown in pure culture. 3) The
cultured microorganism should cause disease when introduced into a healthy organism. 4)
Themicroorganismmust be reisolated from the inoculated, diseased experimental host and
identified as being identical to the original specific causative agent.
Often one cause or one pathogen alone, is not enough to explain an effect or disease. Simply
put, not all become ill after infection. Kenneth Rothman proposed the concept of sufficient
component causes, the idea that aminimum set of factors and circumstances that, if present
in a given individual, will produce the disease [103]. Different individuals have different sets
of components that combine to produce a sufficient cause. Causes can be necessary and/or
sufficient. The concept of sufficient-component cause is widely used in epidemiology as
a framework for teaching and understanding multicausality: The concept that a complete
causal mechanism involves a multitude of factors [113]. The complexity of multicausality is
described as theweb of causation [114].
In the 20th century, Sewall Wright, Jerzy Neyman and Ronald A. Fisher contributed to the
conception of the statistical theory of causal inference we know today. Although Neyman
and Fisher had conflicting views about statistical models [115], they viewed causation as
conceptually different from correlation, and investigated how causal inferences could be
made from correlational data [116]. Wright described the use of a schematic representation
of a causal system, called a ‘path diagram’, now used in the form of Directional Acyclic Graphs
(DAGs) [117]. The first randomized experiments in agriculture were designed byNeyman and
Fisher and are considered the ‘gold standard’ for causal research [118]. Recent advancements
in conceptualizing causality are made by thinking in counterfactuals, and using DAGs to
think about causality, but mechanistic explanation of causes remain as important as the
probabilistic link between cause and effect [119].
In other disciplines, such as pharmacovigilance research or the investigation whether drugs
causesideeffects, causality isassessedusingavarietyofmethodssuchas 1)expert judgement,
where professional opinions are basedon all available evidence, 2) probabilisticmethods and
3) scales and algorithms [120]. None of these methods is free of flaws and hampered by a
certain level of subjectivity.
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1.3.1 BradfordHill viewpoints
The statistician Sir August Bradford Hill proposed a set of criteria to help assess a causal
relation. Hill’s criteria were an expansion of a set of criteria formulated in a landmark report
by the Advisory Committee to the US Surgeon General on Smoking and Health [121, 122],
which, in turn, were inspired by thework of Hume and John StuartMill.
An inventory of an association’s 1) strength, 2) consistency, 3) specificity, 4) temporality, 5)
biological gradient, 6) plausibility, 7) coherence, 8) experimental evidence, and 9) analogy,
helps to provide insight in its causality. The viewpoints were not intended to be strict criteria
but are often interpreted as such [123]. The viewpoints illustrate that one should consider a
plethora of evidence which is in line with that the statement that “Robust causal inference
comprises a complex narrative, created by scientists appraising, from diverse perspectives,
different strands of evidence produced by myriad methods” [124] or what others describe as
“triangulationwith different sources of evidence” [125].
1.3.2 Epidemiological studies that investigate causation
One of the main objectives in epidemiological research, is to find causal relations [113]. The
randomized controlled trial is considered the best study design to discover these causal
relations, especially when we can assign the exposure as is the case with interventions. By
correctly randomizing exposure and assuming a sufficient sample size, the difference in
outcome is caused by the exposure. In a perfect RCT, in the absence of other sources of bias,
confounding factors are distributed at random. Unfortunately, many causal relations are not
feasible to explore in RCTs, either due to ethical or practical constraints. For example, the
distribution of the exposure to ZIKV infection is assigned by a non-random process. These
exposures can be studied in observational studies.
In observational studies, the researcher does not randomly assign the exposure, he or she
merely observes the outcome as a result of the exposure [126]. The internal validity – the
ability to measure what the study sets out to measure – can be compromised by bias. In
this context bias refers to a deviation from the truth [127]. Bias is often grouped in three
categories: selection bias, information bias and confounding [127, 128]. Selection bias
originates from issues with the comparability of groups of subjects. Information bias arises
from the incorrect assessment of the exposure or outcome. Confounding occurs due to an
extraneous variable that is associated with both the outcome and the exposure, but not part
of the causal pathway. Due to non-randomassignment of the exposure, observational studies
are more sensitive to bias and confounding compared to RCTs. Controlling for confounding
assumes we understand and are able to measure confounders. We are always at risk of
uncontrolled unidentified confounders [129].
Confounding can be controlled through the study design or in the analysis of the data. As
discussed above, randomization reduces the probability that an uneven distribution of
confounders occurs. Matching groups by confounder, or restricting to a certain stratumwithin
the confounder are other approaches of controlling confounding during the study design
[103]. During the analysis, confounding and bias can be controlled using stratification or
multivariablemodelling approaches [103]. More advancedmethods use propensity scores or
instrumental variables [130, 131].
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1.4 Evidence accumulation and synthesis
As disease outbreaks emerge, data is collected. The scientific community responds with an
increased interest and research effort, resulting in an increase in peer-reviewed publications
about the disease (Figure 1.5). Often the first source of epidemiological data is from
surveillance systems. Cases or suspected cases are actively or passively collected and reported
to health authorities, who periodically report these through websites or other channels. The
detail of description is limited and sampling is often not systematic. However, the speed
with which new cases arise is informative, and can inform mathematical modelling efforts
(Section 1.5.1). Case reports and case series enable discovery of new associations [132, 133].
As outbreaks propagate and the capacity to respond is increased, the systematic collection
of data improves. Anecdotal observations are reported in case reports or case series. These
generate hypotheses that often inspire the conduct of studies designed to challenge these
hypotheses. In the ZIKV outbreak, an observed increase in congenital abnormalities and a
hypothesized causal link with maternal ZIKV infection sparked much of the research from
2016 onwards. In parallel, basic research investigates the biology and pathogenesis of the
disease. Most research is disseminated through publication in peer-reviewed journals.
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Figure 1.5: The increase of peer-reviewed publications indexed in MEDLINE after large disease
outbreaks. The Severe acute respiratory syndrome (SARS) outbreak started November 2002,
theH1N1fluepidemic started early 2009, themostwidespread Ebola outbreak inAfrica started
December 2013 and the Zika epidemic started end of 2015. MEDLINE indexed publications are
retrieved using the search terms ‘Ebola’, ‘Zika’, ‘SARS’ and ‘H1N1’.
1.4.1 Collation of evidence: systematic reviews
To summarize the large body of (medical) research and to assess the best available evidence
for public health decisions, systematic reviews are conducted. These are collations of
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empirical evidence according to predefined protocols, driven by research questions, often
formulated as PICOs, specifying the Population, Intervention or exposure, Control, and
Outcome of interest [134]. Methods are applied to attempt to identify or minimise bias
[135]. Systematic reviews can include a meta-analysis: a statistical analysis of the results of
independent studies, aimed at producing a single estimate of an effect [135].
The workflow of a systematic review consists of 1) formulating review question, 2) defining
inclusion and exclusion criteria, 3) locating studies, 4) selecting studies, 5) assessing study
quality, 6)extractingdata, 7)analysingandpresentingresults, and8) interpretingresults [135].
The analysis and description of the results can either be qualitative and quantitative.
1.4.2 The living systematic review
Systematic reviews in fields where evidence accumulates rapidly such as research on
emerging diseases, quickly become outdated. A solution is keeping systematic reviews up
to date in the form of living systematic reviews. Elliot et al. (2014) defined living systematic
reviews as “high quality, up-to-date online summaries of health research that are updated
as new research becomes available” [136]. The rapid accumulation of evidence requires
a streamlined approach of data collection and extraction [137]. Living systematic reviews
require reviewers to define its properties on forehand in a protocol, such as the frequency of
searching, screening and extraction. Criteria for updates of the publication are determined
and stopping criteria are defined [138].
Automation andmachine learning
Current technology facilitates establishing and maintaining living systematic reviews [137];
application programming interfaces (API) allow computers to access databases withmedical
literature and this enables us to perform searches automatically. Software can index and
deduplicate searches, and provide reviewers periodic updates of this information (Chapter
3). Machine learning can facilitate screening by classifying on potential relevance based on
earlier decisions. These methods rely on pattern recognition and inference. Typically, an
algorithm is ‘trained’ using a dataset compiled by humans. The algorithm ‘learns’ a set of
rules and applies these to future data. Training of the algorithm can be iterative as output
is verified and used to improve the algorithm. Specific eligibility criteria, such as a certain
study design, can be translated into an algorithm classifying studies. Algorithms have been
successfully trained and applied to detect RCTs [139]. In systematic reviews it is crucial to
correctly reject publications that are not eligible for inclusion and to avoid falsely rejecting
relevant information. Experiments with classifiers have shown promising results: The RCT
classifier was shown to be able to exclude 60–80% of irrelevant records retrieved from a
database search while maintaining a sensitivity of over 99% [139]. However, for other study
designs results are less promising.
The current consensus is that automation is unable to perform the full eligibility assessment
[137], but it can facilitate the process and decrease the workload. An even more challenging
task for automation is data extraction, which is hindered by theway information is published.
There is no uniform form, enormous heterogeneity in how information is presented within a
published article, and research is often shielded off by paywalls or unlicensed for text-mining
[140].
The fields of living systematic reviews and bioinformatics are evolving rapidly, and promising
results show advancement in automation of data extraction and bias assessment [141].
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Marshall et al (2016) showed that “Risk of bias assessment may be automated with
reasonable accuracy. Automatically identified text supporting bias assessment is of equal
quality to the manually identified text in the Cochrane Database of Systematic Reviews.”
[141].
1.4.3 Quality of the evidence: risk of bias and certainty of evidence
Not all publications hold the same amount of evidence. The quality of the evidence of
individual studies or the certainty of the conclusions, depends on the study design, the
sample size, and validity of the study. Imperfect study design, conduct, analysis, or reporting
can cause themeasured effect to be underestimated or overestimated [142]. Risk of bias tools
are designed to assess the extend of bias and reflect the confidencewe have in the results.
For outcomes from the aggregation of multiple studies, the certainty of evidence can
be considered as the certainty that a true effect lies within a chosen range [143]. In the
context of recommendations, the certainty of evidence reflects our confidence that the
estimates of effect are adequate to support the decisions [143]. One of the most widely
adopted frameworks to assess the certainty of evidence has been developed by the grading
of recommendations assessment, development and evaluation (GRADE) working group
[143]. By judging the risk of bias, inconsistency, indirectness, or publication bias of outcomes
of a systematic review, we classify the quality of the evidence of outcomes as very low,
low, medium or high (Chapter 8.1). Quality or certainty of evidence is correlated with the
study design. Depending on the public health problem, different study designs might be
appropriate and valuedmost. To evaluate the effect of interventions, typicallymeta-analyses
of RCTs are considered as themost trusted source of information.
1.4.4 Evidence aggregation: meta-analyses
In the quantitative accumulation of evidence, we summarize the effect measures of multiple
studies in one measure of effect with its corresponding uncertainty. In these meta-analyses,
statistical techniquesareused tosummarize the resultofmultiple studies [144]. Bycombining
information from all studies, meta-analyses providemore precise estimates of themeasures
of effect than those derived from the individual studies. However, precise estimates do not
represent the true effect per se, in presence of bias or confounding, which plays especially a
role in observational studies [135].
The simplest way to aggregate multiple studies would be to calculate the mean of the effect
sizes. However,moreprecisestudiesareconsideredtocarrymore informationandthusshould
havemore influence in theanalysis. This is expressed throughassigningaweight, for example
the inverse of the variance. The effect size and the weight are used to calculate a weighted
average [145]. If all the weights are the same then the weighted average is the same as the
meaneffect size. Dependingontheanticipatedheterogeneitybetweentheconductedstudies
we choose an appropriate model. In a fixed-effect model we assume that there is one true
effect sizewhich is shared by all the included studies. We assume that the differences among
study results occur only due to chance. The random-effect model is appropriate if the true
effect could vary from study to study and the model allows addressing heterogeneity that
cannot be explained by other factors [145, 146].
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Heterogeneity
Studies are never exactly the same: The underlying true effects in each study are often not
identical, populations andmethods can vary and random variation occurs. This variation can
cause heterogeneity between the studies. Heterogeneity is any kind of variability among
studies in a systematic review [135, 147]. The amount of heterogeneity can be formally
quantified by calculating the weighted sum of squared differences between individual
study effects and the pooled effect across studies, or Cochran’s Q. The I2 is the percentage
of variation across studies that is due to heterogeneity rather than chance, and is calculated
from the Q and the degrees of freedom [147]. The I2 can be interpreted as the percentage
of variation across studies that is due to heterogeneity rather than chance. Identifying the
factors that cause the heterogeneity and stratifying the results by these factors or performing
meta-regression using co-variates [148], allows us to quantify, visualize, and explain the
heterogeneity.
1.4.5 Translating evidence into guidance
Evidence from systematic reviews is often used to inform public health guidance. For
example, a systematic review provides evidence on which intervention is preferred and
this evidence is incorporated in guidelines by recommending the use of the intervention.
Evidence translates into decisions through guidelines. Not only the evidence on the effect
measure is used, evidence on the impact of the decision or recommendation are incorporated
as well [149]. The broadly used ‘evidence-to-decision framework’ described by Alonso-Coello
and colleagues, helps to use evidence in a structured and transparentway to informdecisions
in recommendations [149]. The evidence is viewed in a broader perspective, judgingwhether
theproblem is apriority, themagnitudeof thedesirable andundesirable effects, the certainty
of the evidence, consideration of how stakeholders value the main outcomes, the balance
between desirable and undesirable effects, resource use, acceptability, and feasibility [149].
Aswith systematic reviews, guidelines become outdated as new evidence becomes available.
New evidence might change decisions and timely incorporation is crucial. Living systematic
reviews could result in living guidelines, making the whole cycle of evidence from discovery
to implementation dynamic and capable to incorporate changes [136]. Establishing public
health guidance in an emerging disease setting presents additional challenges due to a lack
of evidence and a need for a rapid response [150].
1.5 Risk of transmission
In order to properly respond to disease outbreaks, we need to understand and quantify the
risk of disease transmission. One of the tools to achieve this is amathematicalmodel.
1.5.1 Mathematicalmodels
Mathematical models are descriptions of systems using mathematical concepts and
language. In infectious disease modelling, a distinction is made between models that
describeapopulationas compartments (compartmentalmodels) or as individuals (individual
or agent-based models). In the compartmental model, an interrelation of a set of equations
describes the overall behaviour of a disease in a population. In one of the simplest forms
the population is divided in different states, represented by compartments: susceptible,
16
1.5. RISKOF TRANSMISSION
1
infectious and recovered, the ‘SIR’ model [151]. Movement between compartments occurs
at specific rates. In the individual based model or agent-based model, the properties and
behaviourof individuals ismodelled. Bothapproachessimulate thebehaviourofan infectious
disease in a population and help increase the understanding of the disease transmission
dynamics and interventions.
Models can be dichotomized based on whether a model allows randomness: Deterministic
models function in the absence of randomness in the development of future states of the
system; stochastic models take into account randomness. Randomness or chance plays
an important role when the number of infectious individuals is small [152]. The model
parameters can be inferred by fitting the model to the data (theory or data driven) or by
assuming parameter values based on external knowledge (hypothesis or assumption driven)
[153]. The function of amodel can be to describe observations or the forecast or predict events
in the future [153].
A central measure in infectious disease modelling is the reproduction number (R0) [154].
The reproduction number is defined as the average number of secondary cases caused by
an infectious individual in a fully susceptible population [155]. The R0 is partly inherent
to the disease, but also depends on the region, the environment, and the population’s size,
age-distribution and density. The value ofR0 is as Klaus Dietz describes: “The magnitude
ofR0 allows one to determine the amount of effort which is necessary either to prevent an
epidemic or to eliminate an infection fromapopulation, it is crucial to estimateR0 for a given
disease in a particular population” [154]. If theR0 is ≤ 1, we will only see minor outbreaks
that go extinct; with values above 1, large outbreaks are likely to occur.
As soon as infections occur, the number of susceptible individuals declines. The effective
reproduction number is the average number of secondary cases per infectious case in
a population with both susceptible and non-susceptible individuals. The effective
reproduction number is the product of the basic reproduction number and the fraction
of the host population that is susceptible. As an outbreak progresses and people become
immune after infection, the effective reproduction number will decline. The outbreak will
stop when the effective reproduction number is equal or smaller than 1. When a sufficiently
large proportion of the population is immune either by previous infection or vaccination an
outbreakwill not occur; this phenomenon is called herd immunity [156].
Mathematical models of infectious disease can be used to increase the understanding
of the behaviour of a system, to infer counter-factual scenarios, to evaluate the effect of
interventions and to predict future behaviour of the system. Transmission parameters that
cannot be directly measured in observational studies due to practical or ethical constraints
can be inferred from a model [157]. For the sexual transmission of ZIKV, the duration of
infectiousness is an important parameter that drives the required duration of protection [47].
However, it can not be measured directly. By extending models with economic outcomes,
we can explore whether interventions are worth implementing. Models balance between
complexityandusability. An idealmodel is simpleyet informativeandcaptures theproperties
of a system that are for the research question relevant. We apply the principle of choosing the
simplest, valid model to answer complex questions. This principle is referred to as Occam’s
razor or that unnecessarily complexmodels should not be preferred to simpler ones [158].
Since models are a simplification of the reality, they require us to make assumptions. In the
simplest models, we assume for example homogeneous mixing, or that the probability of
transmission is the same for everyone. The validity of the assumptions can either be formally
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tested by testing model fit, by performing sensitivity analyses, or by reasoning. Seino (2005)
underlines that ‘the awareness of assumptions’ bridges the ‘real world’ to the ‘mathematical
world’ [159].
1.5.2 Modelling of ZIKV
ZIKV is a vector borne disease and, depending on the context, this vector can be explicitly
modeled. A common way to model vector transmission are Ross-Macdonald models [160],
originally designed to investigate the transmission of malaria. These are compartmental
models where the infection of the host and the vector is modeled. The distribution of
vectors varies over time and space, adding to the complexity of the problem [161]. However,
depending on the purpose of the model, simpler models ignoring the vector can fit to the
data equally well [162].
In ZIKV research, mathematical models have been applied for a variety of purposes. The
examples below illustrate the use of modelling during the ZIKV outbreak for different
purposes:
InferringR0
The basic reproduction number for ZIKV has been inferred from data from the South Pacific,
Brazil and Colombia using differentmodels. Estimates range from 1.4-1.7 for the FrenchWest
Indies, 1.9-2.2 for French Polynesia, 2.1 for Salvador Brazil to 4.3-5.8 for Yap Island [163–166].
Differences in R0 are a result of the spatial heterogeneity but also model structure and
assumptions [163].
Explaining observed transmission patterns and the risk of adverse outcomes
Zhang et al. (2017) modeled the spread of ZIKV at a larger scale, throughout the Americas.
They used a meta-population model consisting of a set of local populations connected by
the movement of individuals between the different populations based on data. The model
provided insight in the timing of introduction of ZIKV in Brazil, and the projected number of
newborns fromwomen infected by ZIKV [167].
Inferring the risk of sexual transmission
Gao et al. (2016) and Towers et al. (2016) were the first to model sexual transmission using
ODE based models [168, 169]. They concluded that the contribution of sexual transmission
to the total transmission of ZIKV was limited. Moghadas et al. modeled ZIKV in Colombia
using anABMandparameters described in literature to explore the impact of transmissibility
of asymptomatic individuals and sexual transmission [170]. They estimated that the fraction
of cases due to sexual transmission is estimated below 4%of the cumulative incidence.
Predicting future risk of ZIKVepidemics
Several authors studied the time to a next ZIKV outbreak. Kucharski et al. concluded that it
would take 12-20 years before ZIKVwould re-emergence in FrenchPolynesia [164]. Netto et al
(2017) used a SEIRmodel to show that in Salvador, Brazil, the effective reproduction number
was insufficient to cause a new outbreak during the subsequent years [171]; Lourenço et al.
(2017) showed the same for thewhole of Brazil: herd immunity should protect the population
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from a new outbreak in ‘the coming years’ [172]. Fergurson et al. (2016) concluded that the
herd immuntiy causedby thewidespreadepidemicwouldprovideamultiyearwindowbefore
new large-scale outbreaks occur [173].
19
CHAPTER 1. INTRODUCTION
1
1.6 Aims andoutline of the thesis
Theoverall aimof this thesis is to providemore insight in the epidemiology of theZika virus in
theAmericas, andhowevidence emergesduringdisease outbreaks and informspublic health
decisions. I discuss ZIKV as a cause of adverse outcomes (Chapter 2-4), ZIKV as a sexually
transmitted disease (Chapter 5 and supplementary Chapters 8.1-8.3) and the future risk of
ZIKV outbreaks (Chapter 6). At the end of the thesis I discuss the findings and provide an
outlook for future research (Chapter 7).
Specific objectives of the thesis are:
• To describe how the evidence of ZIKV as a cause of adverse outcomes accumulates and
what lessons can be learned from this (Chapter 2).
• To investigate ZIKV as cause of adverse outcomes and to establishmethods for a living
systematic review (Chapter 3).
• To continue the living systematic review and focus on a quantification of the strength
of association and the bias and heterogeneity in the evidence (Chapter 4).
• To investigate the risk of sexual transmission of ZIKV (Chapter 5).
• To investigate the future risk of transmission of ZIKV, using a mathematical model
based on data fromManagua, Nicaragua (Chapter 6).
• To put the results in context and provide an outline for future research (Chapter 7).
Supplementary Chapters 8.1-8.3 provide context for Chapter 5 and aim:
• To use the evidence of sexual transmission to formulate guidelines to prevent sexual
transmission (Chapter 8.1).
• To describe the research agenda to investigate the sexual transmission of ZIKV
(Chapter 8.2).
• To place ZIKV as sexually transmitted infection in the context of emerging and
re-emerging sexually transmitted infections (Chapter 8.3).
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2.1 Abstract
Causality is a principal theme in epidemiological research. Establishing that an exposure
causes a specific health outcome is based on evidence andmay informguidance about public
health measures. The Zika virus (ZIKV) outbreak in the Pacific and the Americas between
2013–2016 presented with the aetiological causal questions whether ZIKV infection causes
congenital abnormalities and Guillain-Barré syndrome. Earlier conducted systematic reviews
collected evidence to answer these questions. The objective of this study was to examine
the body of evidence that was used to establish the causal relation between ZIKV infection
and adverse outcomes. We hypothesised that the temporal sequence would follow a certain
structure, where case reports and series come first, followed by in vivo and in vitro studies.
Case-control studies are followed by cohort studies and eventually trials. We assessed 1)
how long it takes before findings from a specific study design appear, 2) how publication of
preprints could reduce the time to publication and 3) how time to publication evolves over
time.
We included 346 publications published between March 6, 2014 and January 1, 2019. In the
2013–2016 ZIKVoutbreak, case reports and case serieswere thefirst study designs to emerge.
Basic research studies appeared rapidly after this. Publicationofmore robust epidemiological
study designs, such as case-control and cohort studies, appeared between 400–700 days
after ZIKVwasfirst detected in the regionof the study origin. Thedelay due to thepublication
process of basic research and epidemiological research was lower at the beginning of the
outbreak. A year after the declaration of the PHEIC, the publication delay rose to 150 days.
Only a small proportion of publications was available as preprints (16/346).
The accumulation of evidence over time in new causal problems seems to follow a hierarchy
where case reports and case series are rapidly followed by basic research. During the ZIKV
outbreak, robust epidemiological studies, such as case-control studies and cohort studies,
took 400-700 days to appear. Causal inference based on a wide spectrum of evidence is
therefore essential for early public health guidance in emerging causal problems. Publishing
preprint does reduce the delay, and especially in epidemiological research this is an
underused tool.
2.2 Introduction
Causality is a principal theme in epidemiological research. Establishing that an exposure
causes a specific health outcome is based on evidence and may inform guidance about
public health measures. The concepts and types of evidence required to conclude that an
association is causal are the subject of ongoing debate. Vandenbroucke proposed a hierarchy
of evidence based on the best chance for discovery and explanation of phenomena [133].
Observations published in case reports and case series, or findings in data and literature
drive discovery. Verification of these discoveries happens in observational studies and in
randomized controlled trials, given that exposures can be randomized.
The Zika virus (ZIKV) outbreak in the Pacific and the Americas between 2013–2016 presented
several aetiological causal questions. In 2013–2014, ZIKV caused an outbreak in French
Polynesia [58, 174]. During this period, investigators documented some severe neurological
conditions, including 40 people with Guillain-Barré Syndrome (GBS). GBS is usually a rare
sporadic condition. Often triggered by infection, an autoimmune response affects the
peripheral nerves, leading ascending paralysis, which can be fatal if it involves the respiratory
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nerves [62]. At the time, the reports did not attract much attention and the investigators
refrained frommaking a causal connection because dengue was also circulating at the time
[174]. Then, in November 2015, the ministry of health in Brazil reported a cluster of births
affected by microcephaly in the north east, where ZIKV was circulating [93]. Microcephaly is
a birth defect, indicative of impaired brain development, which can be caused by congenital
infection. In December 2015, the Pan American Health Organization announced heightened
surveillance owing to an “increase of congenital anomalies, Guillain-Barré syndrome, and
other neurological and autoimmune syndromes in areas where Zika virus is circulating” [175].
TheWorld Health Organization (WHO) declared a Public Health Emergency of International
Concern (PHEIC) on 1 February 2016 because of the severity of these clinical conditions and
their temporal associationwith ZIKV circulation [94]. Retrospective assessment of the French
Polynesia outbreak identified an increase in adverse congenital outcomes as well [176].
The PHEIC and the extensive outbreak catalysed the research on ZIKV. Early public health
guidance about the prevention of ZIKV infection and its potential consequences was based
on limited evidence, however [101].
Systematic reviewsweredeveloped toaddress thePHEIC recommendation for researchabout
the causal relationships between ZIKV infection and adverse congenital outcomes, including
microcephaly andbetweenZIKVandautoimmuneoutcomes, includingGBS [29]. The reviews
organised thefindingsarounda ‘causality framework’with tendimensionsderived fromthose
proposed by Bradford Hill [29, 123]. An expert committee reviewed the evidence collected
by these systematic reviews up to May 2016 and reached the conclusion that “the most likely
explanationof theavailableevidence”was thatZIKV isacauseofadversecongenitaloutcomes
anda trigger ofGBS [30]. This reviewhas been kept up todate as a living systematic review, by
periodically incorporating new results [177, 178]. The additional evidence has reinforced the
conclusions of causality.
A temporal sequence for the emergence of evidence was already hypothesised during the
planning of the systematic reviews in early 2016 (Figure 2.1). Acknowledging that ‘astute
observations’ of new causes of disease often start an aetiological investigation [132], case
reports and case series were eligible for inclusion in the systematic reviews. These study
designs are often excluded from systematic reviews because they are the lowest level of the
“hierarchy of evidence”. That hierarchy applies to evaluation research but Vandenbroucke
proposed a reverse hierarchy for discovery in which ‘anectodal’ forms of evidence are at the
top [133]. Cross-sectional, case-control and retrospective follow-up studies follow because
they are quickest study designs that include a control group. Prospective cohort studies take
longer to set up and RCTs only provide additional information if a treatment or vaccine is
available. In addition to epidemiological studies, basic and clinical laboratory science start
early in the search for causes.
23
CHAPTER 2. ZIKA VIRUS AS A CAUSE: EVIDENCEOVER TIME
2
Case reports
Case series
Case-control
Animal experiments
Cross sectional studies
Cohort studies Trials
Basic research/in vitro
Time
Figure 2.1:Hypothetical accumulation of evidence over time, by study design.
The objective of this study was to examine the body of evidence that was used to establish
the causal relation between ZIKV infection and adverse outcomes. We hypothesised that the
temporal sequence would follow Figure 2.1. We assessed 1) how long it takes before findings
from a specific study design appear, 2) how publication of preprints could reduce the time to
publication and 3) how time to publication evolves over time.
2.3 Methods
2.3.1 Included studies/Reviewmethods
We analysed records of studies that were included in published systematic reviews [29] and
two updates [177, 178] of the relationships between ZIKV and congenital abnormalities and
GBS. The methods of the original review and updates are described elsewhere [29, 177]. The
included studies reported evidence about any of the questions of the causality framework,
based on the Bradford Hill dimensions of causality. Until January 18, 2017, we included
epidemiological and basic research study designs; after that date we continued the review
of evidence from epidemiological study designs only (Figure 2.2). Here we analyse studies
collected until January 1, 2019.
2.3.2 Extracted information
For all included studies, we retrieved the received and published date, the location of the
study and the study design (Table 2.1). For epidemiological studies, we extracted the study
location and the number of patients with both exposure and the outcome according to the
case definition provided in the publication. We excluded modelling studies or surveillance
and outbreak reports.
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Table 2.1: Information used in the analyses: Variables retrieved from PAHO, extracted from
included studies (publications), and variables calculated from the data. Abbreviations: PAHO,
Pan American Health Organization; PHEIC, Public Health Emergency of International Concern;
ZIKV, Zika virus.
Variables Explanation Source
Introduction date Date the state (forBrazil) or country reported
the first case or cases of ZIKV according to
PAHO [179]
PAHO
Publication date The first date a publicationwas available Publication
Received date The date the publicationwas received by the
journal the publication appeared in
Publication
Accepted date The date the publication was accepted for
publication by the journal the publication
appeared in
Publication
Study design Epidemiological studies: Case report, case
series, case-control study, cohort study; Basic
research: in vivo or in vitro studies
Publication
Outcome Guillain-Barré syndrome or congenital
abnormalities
Publication
Sample size (N) For epidemiological studies: The total
number of patients with the outcome and
positive ZIKV exposure according to criteria
of publication
Publication
Total time to
publication from
introduction
The time between introduction date and
publication date in days
Calculated
Total time to
publication from
PHEIC
The time between February 1, 2016 and the
publication date in days
Calculated
Publication delay The time between the received date and the
publication date in days
Calculated
2.3.3 Introduction date
We considered the date the first case of endemic ZIKV was reported in each state for Brazil,
or country for the rest of the region (Figure 2.2) [179]. We assigned 16 July, 2015 as the date of
ZIKV introduction if the state inBrazilwasnot explicitly reported.Weassigned 1October 2013
as the introduction date for French Polynesia [180].
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Figure 2.2: Map of South and Central America showing the timing of the first reported case of
Zikavirusaccordingto thePan-AmericanHealthOrganization [179]bystate forBrazil, bycountry
for all other regions. NA: Not available.
2.3.4 Publication date
We defined the publication date as the earliest date the publication was available. If the
publisher’s website did not state an exact date, we assigned the ‘epub’ date from MEDLINE
via PubMed or ‘page created’ date for specific online journals (EID and MMWR). We also
recorded the date themanuscript was received by the publisher (received date) and the date
of acceptance for publication (accepted date).
2.3.5 Total time to publication
We defined the time to publication as the time between introduction of ZIKV virus in the
region and the publication date. For basic research studies, many of which were done in
countries unaffected by ZIKV, we assigned the time to publication as the time between 1
February 2016 (the PHEIC declaration) and the first available publication date.
2.3.6 Publication delay
The delay resulting from the publication process (publication delay) was defined as the time
between the ‘received date’ and the first available publication date.
2.3.7 Analysis
Weprovide a descriptive analysis of the total time to publication and the publication delay by
publication. Of thesedurations,weprovide themedianand interquartile range (IQR)by study
design and over time. We compare the publication delay by threemonth period (quarter).
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2.4 Results
During the period of the first review [29] and subsequent update [177], we screened 2,847
publications. During the remaining period, between January 7, 2017 and January 1, 2019, we
screenedanadditional 2,594publications. Figure2.3 shows theevolutionof the volumeof the
published ZIKV research over time is provided.
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Figure 2.3: Research volume by month between 2016 and 2019, retrieved from MEDLINE via
PubMed using the keywords ‘Zika’ and ‘Zika virus’.
2.4.1 Included studies
Weincluded346publicationspublishedbetweenMarch6, 2014and January 1, 2019 (Table2.2
and Figure 2.4). Up to January 18, 2017, we included 171 publications. Most publications were
epidemiological study design (94/171), 77 out of 171 studieswere basic research studies (either
research on animal models or in vitro laboratory-based research). Between January 18, 2017
and January 1, 2019, we restricted our search to publications of epidemiological study design,
and included another 175 publications. For 220/269 epidemiological studies, a date of ZIKV
introduction was known. The time between received and published was reported in 204 out
of 346 studies. In 16/204 of these studies there was no publication delay, usually because the
first publication datewas as a preprint.
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Table 2.2:Overview of counts and completeness of data per study design and outcome. Studies
published up to January 1, 2019 for epidemiological studies reporting on at least one individual
withZIKVexposureandoutcomeof interest, anduptoJanuary17, 2017 forbasic researchstudies.
Abbreviations: CA, congenital abormalities; GBS, Guillain-Barré syndrome.
Study design/parameter CA GBS Total
Epidemiological studies
Case report 54 28 82
Case series 85 30 115
Case-control study 10 9 19
Cohort study 35 0 35
Cross-sectional study 14 4 18
Total epidemiological studies: 198 71 269
Introduction date available 159/198 61/71 220/269
Basic research studies
Animal experiments 24 0 24
In vitro experiment/other 51 2 53
Total basic research: 75 2 77
Total: 273 73 346
Publication delay available 167/273 37/73 204/346
Studies with a zero publication delay 16/167 0/37 16/204
2.4.2 Total time to publication
Figure 2.5A shows the comparison of publications published between the PHEIC and the
end of the second review period (January 18, 2017). We saw the first case reports and case
series published after 44 and 77 days, respectively. Basic research emerged rapidly after the
PHEIC. In this period a limited number of case-control studies was available. The earliest
publication of a case-control study for GBS, was a result of a retrospective study looking back
at the French Polynesia outbreak [176]. The median total time to publication was longer for
more robust study designs (cohort studies, case-control studies). We see a similar pattern for
epidemiological studies if we consider the data up to January 1, 2019 and consider the time to
publication between the regional introduction of ZIKV and the publication date (Figure 2.5B).
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Figure 2.5: Time to publication, by study type. A. The time from the PHEIC declaration (1
February 2016) to thedate of publication for studies includedup to January 18, 2017. B. The time
fromintroductionofZIKV in the region inwhichastudywasconducted to thedateofpublication
for epidemiological studies included up to January 1, 2019. The box plots show the median an
interquartile range, solid black shapes are studies of congenital abnormalities, grey shapes are
studies of GBS.
2.4.3 Publication delay
Figure 2.6 shows the delay between receipt of manuscripts by a journal and the data of first
publication, from the first quarter of 2016 to the end of 2018. Four out of seven basic research
studies published in thefirst quarter of 2016 appearedaspreprints (onwww.bioRxiv.com) and
had a median publication delay of zero days. The median publication delay increased with
time to 107 days (IQR: 66–107 days) by the fourth quarter of 2016. During the same period
for epidemiological study designs, themedian publication delay increased from 19 days (IQR:
14–22) in the first quarter of 2016 to above 97 days (IQR: 63–138) from the fourth quarter of
2016. In the last quarter of 2018, the publication delay rose to 264 days (IQR: 144–392). On
average, the publication delay accounted for 20% (IQR: 11–33%) of the total time from the
PHEIC to first publication.
2.5 Discussion
In the 2013–2016 ZIKV outbreak, case reports and case series are the first study designs
to emerge. Basic research studies appeared rapidly after this. Publication of more robust
epidemiological study designs, such as case-control and cohort studies, appeared between
400–700 days after ZIKV was first detected in the region of the study origin. The delay due
to the publication process of basic research and epidemiological research was lower at the
beginning of the outbreak. A year after the declaration of the PHEIC, the publication delay
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Figure2.6:Publicationdelay,byquarterandbystudydesign. Theblack lineconnects themedian
publication delay (black dots) and the interquartile range (grey ribbon) for all included studies.
rose to 150 days. Only a small proportion of publications was available as preprints (16/346).
2.5.1 Strengths andweaknesses of the study
A strength of this study is the pre-specified hypothesis about the time to publication of
aetiological research and the use of data from systematic reviews that had screened and
selected studies that addressed the causal relationship between ZIKV infection and its
adverse outcomes. We calculated additional measures related to the time to publication of
research, including delays due to the publication, and thus the time that could have been
gained by publishing preprints.
The limited information extracted about each study was a limitation. The time between
introduction of ZIKV and the actual publication of a research study is dependent on factors
both within and between study designs. There is substantial variation in the time to
publicationwithin the study designs. We did not quantify several factors that likely influence
this duration suchas the size of theoutbreak, the research capacity or outbreakpreparedness.
Small outbreaks or small population sizes limit the opportunity to enrol sufficient patients
with adverse outcomes, and unless involved in multi-centre/multi-region studies, these
regions are less likely to produce high quality epidemiological studies. The same holds
true for regions with limited research capacity, such as appropriate diagnostic facilities and
expertise. Outbreak preparedness likely increased over time, with funding increasing after
the PHEIC, meaning that initiation of studies started relatively late for regions that were
affected earliest by the outbreak. Countries that were affected later in time by ZIKV, might
have already had surveillance and diagnosticmethodology in place.
The publication delay is a proxy measure, which could not be calculated for all studies; for
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only 59% (204/346) studies the “received date” was provided. It is unclear whether these data
aremissing at random. Furthermore, the recorded publication delay could only be calculated
for the journal in which a study was published. The true publication delay includes the time
taken up by rejection and resubmission. The publication date also ignores dissemination of
the findings at conferences or within collaborations. However, here the information is only
available toa limitedaudience. The timingofZIKV introduction is alsoaproxymeasure,which
does not capture the first actual case, but signals themoment at which the health authorities
and the research community noted the introduction in that region and thus serves its purpose
as aproxy forwhen research start intensifying. Phylogenetic data suggest that ZIKVwasoften
introducedmonths before formal detection and notification [167].
2.5.2 Interpretation of thefindings
The sequence of emergence of evidence about causality was not exactly as hypothesised
(Figure 2.1). While case reports and case series were the first types of study to be published,
findings from animal research were also published quickly. This finding might have been
influenced by the more frequent use of preprints to disseminate laboratory research than
clinical science [181]. In our study, the time taken to publication of case-control studies and
cohort studies was similar, particularly for studies of congenital outcomes. Case-control
studies are widely assumed to be quicker to organise and conduct than cohort studies
[132, 133]. In the ZIKV outbreak, one case-control study about GBS was published soon after
the PHEIC declaration because it used data already collected from the earlier ZIKV outbreak
in French Polynesia. An important consideration is the short duration of pregnancy. The
cohorts that were fastest to produce results, were cohorts that were already in place for
other disease (Dengue, influenza) [182]. Follow up of the outcomes of a disease exposure in
pregnancy takes a matter of months. It might therefore not be possible to extrapolate this
finding to other conditions in which the outcome takes years to develop.
The rapid, and sustained, publication of a large body of research about ZIKV is a rich resource
for meta-research about causality. The declaration of the Ministry of Health of Brazil in
November 2015 [93] and thedeclaration of thePHEICbyWHO in February 2016 [94] catalysed
the ZIKV research effort across many different disciplines and resulted in an increase in
research funding and aWHO-initiated research agenda [95]. Some of the observed patterns
in study design and time publication are influenced by the type of outcome. Investigation of
GBS, which is very rare, estimated at 4/10.000 ZIKV infections [63], is likely to be restricted to
case-control as cohort studies would take too long to enrol enough participants.
We provide empirical evidence about publication delays during an outbreak of an emerging
infection. WHO and others have encouraged rapid dissemination and timely open access to
data to help the response during public health emergencies [183]. The ZIKV outbreak and
2013–2016 Ebola virus outbreak in West Africa, emphasised the need for rapid sharing of
data. However, the publication delay returned to an average observed in across disciplines
within a year after the declaration of the PHEIC; the age of the average preprint before it
is published by a journal across different scientific disciplines is 166 days [184]. In medical
research, publication of preprints is still underused [181] but the launch of the MedRXiv
preprint server (www.medRxiv.org) in June 2019might signal a change.
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2.5.3 Implications for public health, policy and research
Looking back at the ZIKV outbreak and how evidence accumulated on the adverse outcomes
will provide guidance for a next outbreak. It provides insight in how evidence accumulates
in new causal questions. Specifically for disease outbreaks, we can increase preparedness
by the lessons learnt from the Zika virus outbreak. Especially, since disease outbreaks or
disease re-emergence continue to happen due to extraneous pressure such as shifts in
climate, population growth and increased movement of people either due to displacement
or voluntarymovement [185].
In a disease outbreak with adverse outcomes that are new or incompletely understood, the
full spectrumof evidence needs to be assessed to establish causality. Early in an outbreak, we
needanecdotal evidence to drive discovery andexplanation [133]. Studies across thedifferent
scientific disciplines are informative while we wait for robust epidemiological studies. Here,
different frameworks can help us assess the evidence such as Bradford Hill dimensions [123].
We rely on a wide spectrum of evidence in line with how Krieger et al. phrase it: “Robust
causal inference instead comprises a complexnarrative, createdby scientists appraising, from
diverseperspectives, different strandsof evidenceproducedbymyriadmethods.” [124]. Rapid
consensus on causality is often needed to form public health guidance.
Not one outbreak or emerging causal question is the same, thus deconstructing other causal
problems based on study design and timing of evidence will provide more insight in how
evidence accumulates. The ZIKV outbreak in the Americas was unique by its size; making
rare non-pathognomonic outcomes visible. Also, the 2015–2017 outbreak in the Americas
benefited from the outbreak in 2013 in French Polynesia. Much data was collected there,
and retrospective analyses confirmed the association between ZIKV infection and adverse
outcomes [176]. This resulted in the publication of a case-control study on GBS, rapidly after
the declaration of the PHEIC [176]. Likewise, Cauchemez et al. used amodelling approach to
estimate the risk of adverse congenital outcomes in French Polynesia retrospectively [186].
2.5.4 Conclusion
The accumulation of evidence over time in new causal problems seems to follow a hierarchy
where case reports and case series are rapidly followed by basic research. During the
ZIKV outbreak, robust epidemiological studies, such as case-control studies and cohort
studies, took 400–700 days to appear. Causal inference based on a wide spectrum of
evidence is therefore essential for early public health guidance in emerging causal problems.
Publishing preprint does reduce the delay, and especially in epidemiological research this is
an underused tool.
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3.1 Abstract
Background. The Zika virus (ZIKV) outbreak in the Americas have caused international
concern due to neurological sequelae linked to the infection, such as microcephaly and
Guillain-Barré syndrome (GBS). TheWorldHealthOrganization stated that there is “sufficient
evidence to conclude that Zika virus is a cause of congenital abnormalities and is a trigger of
GBS”. This conclusion was based on a systematic review of the evidence published until June
30, 2016. Since then the body evidence has grown substantially, leading to this update of that
systematic reviewwith new evidence published from June 30, 2016 – January 1, 2017, version
2.
Methods. We review evidence on the causal link between ZIKV infection and adverse
congenitaloutcomesandthecausal linkbetweenZIKVinfectionandGBSor immune-mediated
thrombocytopaenia purpura. We also describe the transition of the review into a living
systematic review, a review that is continually updated.
Results. Between June 30, 2016 and January 1, 2017, we identified 2413 publications of which
102 publications were included. The evidence added in this version confirms the conclusion
of a causal associationbetweenZIKVandadverse congenital outcomes. Newfindings expand
the evidence base in the dimensions of biological plausibility, strength of association, animal
experiments and specificity. ForGBS, thebodyof evidencehasgrownduring the searchperiod
for version 2, but only for dimensions that were already populated in the previous version.
There is still a limited understanding of the biological pathways that potentially cause the
occurrence of autoimmune disease following ZIKV infection.
Conclusions. This systematic review confirms previous conclusions that ZIKV is a cause of
congenital abnormalities, including microcephaly and is a trigger of GBS. The transition to
living systematic review techniques andmethodology provides a proof of concept for the use
of thesemethods to synthesise evidence about an emerging pathogen such as ZIKV.
3.2 Introduction
Outbreaks of Zika virus (ZIKV) infection in the Americas have caused international concern
owing to the severity of neurological sequelae linked to the infection (WHO statement IHR
2005). During 2016, the number of countries affected by the ZIKV outbreak had grown
from 33 countries (WHO situation report 05.02.2016) to 75 countries (WHO situation report
05.01.2017). By March 9 2017, 31 countries had reported microcephaly or other congenital
central nervous system (CNS) abnormalities potentially associatedwithZIKV infection and23
had reported an increase in the incidence of the immune-mediated condition Guillain-Barré
syndrome (GBS) or laboratory confirmed ZIKV in persons with GBS (WHO situation report
10.03.2017). The causal association between ZIKV and adverse neurological outcomes has
now been examined in many systematic and non-systematic reviews of research [187, 188].
Case reports of other conditions in people with ZIKV infection, including immune-mediated
idiopathic thrombocytopaenia purpura (ITP), have also been published [189–192].
The World Health Organization (WHO) based its assessment, that there is “sufficient
evidence to conclude that Zika virus is a cause of congenital abnormalities and is a trigger
of GBS” (WHO Zika causality statement) [29], on a review of systematically identified
studies up to May 30 2016 and nonsystematically identified studies up to July 29, 2016. The
review addressed specific questions about 10 dimensions of causal associations, based on
the work of Bradford Hill [123] and organised as a causality framework (Supplementary
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Table 1) that covers: temporality (cause precedes effect); biological plausibility of proposed
biological mechanisms; strength of association; exclusion of alternative explanations;
cessation (reversal of an effect by experimental removal of, or observed decline in, the
exposure); dose-response relationship; experimental evidence from animal studies;
analogous cause-and-effect relationships found in other diseases; specificity of the effect;
and the consistency of findings across different study types, populations and times. The
review included 108 articles about congenital abnormalities or GBS but there was no, or
insufficient evidence to answer questions in several dimensions of the causality framework
[29]. The causality framework included questions about ITP, but the review authors judged
the number of published articles to be too low to assess causality. Since theWHO statement
and accompanying publication, about 200 scientific publications every month are being
added to the body of evidence about all aspects of research about ZIKV.
A living systematic review would help to overcome some of the challenges of keeping up
to date with the high volume of ZIKV research publications. A living systematic review is
a systematic review that is “continually updated, incorporating relevant new evidence as
it becomes available” [136], which can help in fields where evidence is emerging rapidly
and where new review outcomes might change policy or practice decision [10]. Technical
solutions are available to facilitate the reviewing process, such as automated searching and
deduplication and computer-assisted screening of article titles and abstracts, increase the
efficiency and speed of a review team and transform the review into a living document.
This article aims to fulfil two separate objectives. First, we update our systematic review [29]
with new evidence published from June 30, 2016 – January 1, 2017, about all 10 dimensions
of the causal associations between ZIKV and (a) congenital brain abnormalities, including
microcephaly, in the foetuses and offspring of pregnant women and (b) GBS/ITP in any
population. Second, we describe the transition of the review into a living systematic review.
3.3 Methods
3.3.1 Classic protocol
Weperformedthereviewaccordingtotheprotocol registered inPROSPEROCRD42016036693
(PROSPERO protocol). The eligibility criteria, information sources and search strategy, study
selection and data extraction are the same as reported in the protocol and in the previous
publication [29]. Inbrief, the search coversPubMed, EmbaseandLILACSelectronicdatabases;
the Pan American Health Organization (PAHO), WHO, the Centers for Disease Control and
Prevention (CDC) and the European Centre for Disease Prevention and Control (ECDC)
websites; and several preprint databases (BioRxiv, PeerJ and ArXiv). Search terms included
‘Zika virus’ and ‘ZIKV’ and corresponding MESH terms. Two reviewers screen and select
articles for inclusion and extract data independently. We included publications that held
information on at least one of the ten dimensions of the causality framework, regardless of
the study design [29]. We gathered publications systematically from June 30, 2016 – January
1, 2017, for this update. We refer to the original publication as version 1 [29] and to this
current update as version 2. Reporting of the results follows the Preferred Reporting Items of
Systematic reviews andMeta-Analyses (PRISMA) statement (Supplementary File 1) [134].
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Figure 3.1: Living systematic review automation. Blue boxes and arrows represent the
conceptual steps in a systematic review process. Automation is divided in three modules.
Module 1 is the automation of the searching and deduplication of information from different
data sources. Module 2 partly automates screening. Module 3 automates the production of
tables and figures and outputs the data to a web platform (Data visualisation). Blue arrows
represent automated information flows; red arrows represent manual input. The blue-red
dashes arrow represents a blended form where reviewers verify automated decisions of the
system. Thewhite boxes show the practical implementation of the system and the data flow.
3.3.2 Fromsystematic review to living systematic review
To keep up with the quantity of published research, we developed a living systematic review
workflow (Supplementary File 2). Wehave identified threemodules that couldbeautomated
(Figure 3.1). As ofDecember 2017,module 1, searching anddeduplication, andpart ofmodule
3, the output of the report have been automated. Reviewers can be notified daily with a list of
new unique search results so that screening can be performed instantly. Following manual
data extraction and synthesis, the output can be updated semi-automatically. We use the
online database Research Electronic Data Capture (REDCap) [19] to maintain the references,
perform screening and extract data into piloted extraction forms. We plan to update the
review twiceper yearwith formal peer reviewedupdates (Figure 3.2), and continually through
aweb platform.
We synthesised the findings as narrative summaries of the evidence according to causality
dimension and outcome, as previously described [29], and compare them with the previous
review (version 1). We use the term ‘confirmation’ to summarise findings of new studies
included in version 2 if they report the same findings as those in version 1. We use the term
‘expansion’ of evidence if studies included in version 2 provide newfindings.
3.4 Results
Between June 30, 2016 and January 1, 2017, we identified 2,413 publications. After
deduplication, we retained 1700 unique records. Based on screening of title and abstract,
we discarded 1025 publications, retaining 675 items; after screening of the full text, 102
publications were included. Figure 3.3 shows the PRISMA flow diagram for this review [134].
Seventy-seven publications held information on one or more dimensions of the causality
framework on adverse congenital outcomes and 26 on GBS or idiopathic thrombocytopaenia
purpura. Table 3.1 compares the included publications, study types and the causality
dimension(s) they address in version 1 [29] and version 2 of the review.
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Figure 3.2: Timeline of review conduct, publication and transition to a living systematic review.
Version 1 (v1, [29]) and version2 (v2, this version) classic,manual systematic review. During2017
automationof theworkflowwas conducted resulting in aprojected version 3 (v3) and4 (v4)with
more rapid throughput. LSR, living systematic review.
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Figure 3.3: PRISMAflowdiagramof included studies.
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Condition and version number Adverse congenital outcomes GBS/ITP
v1,N v2,N v1,N v2,N
Study type
Case report 9 13 9 5
Case series 22 12 5 11
Case-control study 0 3 1 1
Cohort study 1 8 0 0
Cross-sectional study 2 1 0 1
Controlled trials 0 0 0 0
Ecological study/outbreak report 5 4 19 7
Modelling study 2 0 0 0
Animal experiment 18 8 0 0
In vitro experiment 10 22 0 0
Sequencing and phylogenetics 3 3 2 0
Biochemical/protein structure studies NA 3 NA 0
Total: 72 77 36 25
Causality dimensions
Temporality 21 21 26 21
Biological plausibility 25 42 4 0
Strength of association 3 5 2 4
Alternative explanation 18 23 6 12
Cessation 2 0 6 2
Dose-response relationship 0 0 0 0
Experiment 20 11 0 0
Analogy NA NA NA NA
Specificity 0 4 0 0
Consistency NA NA NA NA
Table 3.1: Summary of included publications by study type and on which causality dimension
theyprovide evidence. Onepublication canaddressmultiple causality dimensions. Comparison
between the current (v2) and previous publication (v1, [29]) stratified by outcome. GBS/ITP,
adverse autoimmune outcomes (Guillain Barré syndrome/idiopathic thrombocytopaenia
purpura).
3.4.1 Adverse congenital outcomes
A detailed overview of the new evidence is provided in Table 3.2 and Supplementary Table
2. In the search period for review version 2, an additional 548 cases of adverse congenital
outcomesweredescribed in 30 studies [40, 193–223]. Adverse congenital outcomesdescribed
were: clinicalmicrocephaly [40, 194–202, 206, 207, 209–213, 215, 216, 218–220, 223], imaging
confirmed brain abnormalities [196–201, 207, 209–216, 218–221, 223], intrauterine growth
restriction [196, 198, 212, 213, 218, 221], ocular disorders [196, 197, 201, 207, 212, 218, 220, 221]
and auditory disorders [207, 208, 220].
Temporality
This update confirms the previous conclusion that ZIKV infection precedes the adverse
congenital outcomes. We found an additional 21 publications in which ZIKV infection
preceded the adverse congenital outcome at an individual level [194, 196–198, 201, 203, 207–
209, 211–213, 215, 217, 218, 220, 221, 223–225] and at a population level [224, 226]. Infections
in thefirst trimesterandsecondseemedtobe related to themostadverseoutcomes [196,212].
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Cohort studies of pregnant women from French Guiana and Brazil found a higher proportion
of congenital abnormalities in babies born frommothers infected in the first and the second
trimester [196, 212].
Biological plausibility
This update includes an additional 42 studies [40, 193, 195, 203, 204, 209, 210, 213, 217–219,
221, 227–256], some of which expand the evidence base. Whereas review version 1 found
inconclusive evidence ofwhether ZIKVparticles in infantswere capable of replication, both in
vivoandexvivo studiesnowdemonstrate that this is the case [195, 217, 231, 235, 245, 249, 250].
Furthermore, there was a strong expansion of the evidence clarifying how ZIKV causes
adverse congenital outcomes. ZIKV uses receptors from the TAM family to enter cells
[240, 243–245, 247, 249],where the virus induces cell death, primarily indevelopingneuronal
cells [228, 234, 238, 248, 251, 252, 254, 256].
Strength of association
We included five publications that confirm a strong association between ZIKV infection
and adverse congenital outcomes [196, 199, 206, 212, 216]. The strength of association at an
individual level was high but imprecise, owing to small sample sizes. Estimates from cohort
studies [196, 212] appeared to be lower than those from case-control studies [199, 206, 216].
The definition of the outcomes and the outcomes assessed, varied between studies. The
risk of any adverse congenital outcomes was higher and more variable than the risk of
microcephaly. The risk ratio for microcephaly between ZIKV unexposed and exposed was 4.4
(95% CI: 0.2-80.8) in a cohort in Brazil [196] and 6.6 (95% CI: 0.8-56.4) in a cohort in French
Guiana [212]. In the Brazilian cohort [196], the proportion of any adverse congenital outcomes
among ZIKV infectedwomenwas high (41.9% [49/117]), comparedwith the uninfected group
(5.2% [3/57]). In a prospective case control study in Brazil, womenwith laboratory-confirmed
ZIKV had 55.5 (95% CI: 8.6-infinity) times the odds of having a baby with microcephaly
comparedwith womenwithout evidence of ZIKV infection [216]. A retrospective case control
study in Hawaii found an odds ratio of 11.0 (95% CI: 0.8-147.9) [206]. In the latter, however,
exposurewas assessed retrospectively using serology.
Exclusion of alternatives
We included 23 new studies in this version [40, 193, 196, 197, 199, 201, 205, 207, 208, 210–219,
221, 223, 224, 257]. Many studies included in this review that reportedonadverse outcomesof
congenitalZIKVexcludedTORCHinfections [40, 193, 196, 197, 199, 201, 205, 207, 208,210–219,
221, 223, 224, 257]; exposure to toxic chemicals [40, 197, 207, 208, 210] or genetic conditions
[197, 207, 208, 210, 213, 217, 223]. Maternal or foetal malnutrition, hypoxic-ischaemic lesions
andunderlyinggenetic conditionswerenotexcluded. Nosinglealternativeexplanation could
be given to explain the relation between ZIKV and adverse congenital outcomes.
Cessation
Wedid not find any new publications for this causality dimension. Evidence is still lacking on
the effect of intentional removal due to lack of vaccination or elimination ofmosquitoes on a
large scale.
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Dose-response
There is still no direct evidence about the association between Zika viral load and probability
of adverse congenital outcome in observational studies, or of an association between
symptomatic status and outcome. In a study in the United States, Honein et al. found
similar proportions of adverse congenital outcomes in symptomatic and asymptomatic
ZIKV-infectedmothers [204].
Animal experiments
This version of the review includes an additional 11 studies [227, 230, 258–266]. These studies
confirm a consistent relation between a range of contemporary ZIKV and adverse congenital
outcomes, including from Brazil [260], Puerto Rico [264] and Mexico [262, 265]. The body
of evidence coming from animal studies has grown; both in mice and macaques, congenital
anomalies such as intra-uterine growth restriction and signs of microcephaly were observed
after ZIKV infection [258, 260, 266].
Analogy
As for version 1, evidence for this dimension was not reviewed systematically because our
search strategy did not include terms for other infections or conditions. Studies included in
this versionof the reviewconfirmtheanalogybetweencongenital ZIKVandTORCH infections
[267]. Vertical transmission ofWNVandDENVwere summarised in version 1 of the review. In
version 2, we included a case series from El Salvador that reported CHIKV in 169 newborns of
women with symptomatic CHIKV infection; a minority had CNS infection, but microcephaly
was not reported [268]. For most analogous pathogens, infections earlier in the pregnancy
have a higher risk of adverse outcomes [267].
Specificity
We included one study [60], suggesting an expansion of evidence of a distinct congenital Zika
syndrome (CZS) [60]. In a review of 34 published reports, the authors suggest five congenital
abnormalities that, in conjunction, comprise a pattern that is unique to ZIKV: severe
microcephaly with overlapping cranial structures, subcortical location of brain calcifications,
macular scarring and retinal mottling, congenital contractures and early pyramidal and
extrapyramidal symptoms [60].
Consistency
The studies included in this version of the review confirm the pattern of consistency observed
in version 1. ZIKV infection in association with adverse congenital outcomes were reported
in a range of study designs from different regions (WHO situation report 05.01.2017),
although the proportion of affected infants varies over geographic region and time. ZIKV
exposure resulted in adverse congenital outcome in people living in ZIKV endemic areas
[40, 193–199, 201, 202, 204–208,210–214, 216, 218–220,223–225, 257, 269, 270] and in female
travellers who returned to non-endemic countries [193, 203, 209, 215, 217, 221, 271, 272].
Direct evidence from epidemiological studies comparing different lineages is lacking due to
circulation of a single strain.
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Conclusion
The evidence added in version 2 of the review confirms the conclusion of a causal association
between ZIKV and adverse congenital outcomes. New findings expand the evidence base
in the dimensions of biological plausibility, strength of association, animal experiments and
specificity. In vitro and in vivo studies elucidate pathways on how these outcomes likely occur.
Conclusive evidence on the strength of association is lacking. Studies provide crude overall
measures of association, not taking into account potential co-factors.
Question v1, n v2, n Summary
Temporality
1.1a 18 19 Confirmation. Sufficient information to conclude that
ZIKV infection precedes the development of congenital
abnormalities in individuals [194, 196–198, 201, 207–
209, 211–213, 215, 217, 218, 220, 221, 223–225].
1.1b 2 1 The peak of adverse congenital outcomes in Colombia
was 24 weeks after infection [224] (similar to Brazil, 34
and 30weeks [29]).
1.2 18 19 Confirmation. Most mothers of infants with adverse
outcomes were exposed to ZIKV during the first or
the second trimester of their pregnancy [193, 273].Third
trimester exposure can lead to brain malformations as
well [214].
Biological plausibility
2.1 1 6 Confirmation of the role of viral entry factors
(receptor-ligand interaction) [240, 243–245, 247, 249].
2.2 1 4 Substantial expansion of the evidence on which cells
express the receptors responsible for cell entry of ZIKV
[240, 244, 245, 249].
2.3 11 11 Expansion of evidence, sufficient information
to conclude that ZIKV particles can be found
in the umbilical cord blood and/or amniotic
fluid of previously or currently infected mothers
[40, 193, 195, 203, 204, 209, 210, 213, 217, 219, 221].
2.4 0 7 The evidence that ZIKV particles found in tissue of the
offspring are capable of replication was inconclusive in
the previous version. In this update we found that in
vitroevidencestrongly indicates theseZIKVparticlesare
capable of replication [231, 235, 245, 249, 250]. Ex vivo
experimentsdemonstrateZIKVcapableof replicationas
well [195, 217].
2.5 6 7 Expansion of evidence, sufficient information to
conclude that particles can be found in the brain and
other tissues of cases with congenital abnormalities
[40, 193, 195, 210, 218, 219, 233].
2.6 7 6 Confirmation. ZIKV particles found in the brain are
capable of replication [195, 228, 229, 232, 233, 239].
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2.7 9 22 Strong expansion of evidence; Expansion of the
understanding of how ZIKV causes congenital
anomalies [227, 228, 230, 232, 234–242, 246–248,
251–256].
Strength of association
3.1 2 5 Expansion of evidence on the strength of association at
an individual level [196, 199, 206, 212, 216]. However, the
estimation of the effect size remains imprecise.
3.2 1 0 At apopulation level, confirmation lackson the strength
of association. However, 29 countries reported a relative
increase inmicrocephalycasesduringtheZIKVoutbreak
(WHO situation report 05.01.2017).
Exclusion of alternatives
4.1 18 23 Confirmation. In many epidemiological studies TORCH
infections are assessed [40, 193, 196, 197, 199, 201, 205,
207, 208, 210–219, 221, 223, 224, 257].
4.2 4 5 Confirmation. Exposure to toxic chemicals has been
excluded [40, 197, 207, 208, 210].
4.3 0 0 No exclusion of alternative explanation:
maternal/foetalmalnutrition.
4.4 0 0 No exclusion of alternative explanation:
hypoxic-ischaemic lesions.
4.5 3 7 Confirmation of evidence where the role of genetic
conditions was excluded [197, 207, 208, 210, 213, 217,
223].
4.6 0 0 No exclusion of alternative explanation: radiation.
Cessation
5.1 0 0 No publication with evidence that intentional removal
of ZIKV infection in individuals leads to a reduction in
congenital abnormalities.
5.2 0 0 No publication with evidence that intentional removal
ofZIKV infectionatpopulation-level leads toa reduction
of cases of congenital anomalies
5.3 2 0 Natural removal (end of epidemic) leads to a reduction
in microcephaly cases in Brazil; Other countries have
shown a decrease in reportedmicrocephaly cases as the
cumulative ZIKV incidence plateaued
Dose-response
6.1 0 0 No publication with evidence that the risk of adverse
congenital outcomes is associated with the viral load in
themother.
6.2 0 0 No publication with evidence that the clinical severity
of the infection of the mother determines the severity
of the congenital anomalies. In one cohort study,
symptoms in themother did not influence the outcome
[204].
Animal experiments
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7.1 3 3 Expansion of the evidence that the inoculation of
pregnant female animals (mice and macaques) with
ZIKV causes congenital anomalies in the offspring
[258, 260, 266].
7.2 10 3 Confirmation of the evidence that the intracerebral
inoculation of newborn mice with ZIKV leads to ZIKV
replication in the CNS [259, 263, 265].
7.3 8 3 Expansion of the evidence that other routes of
inoculation of newborn animals with ZIKV leads to
ZIKV replication in the CNS (intravaginal infection of
adult mice, subcutaneous infection of newborn mice)
[262, 264, 266].
7.4 1 8 Expansion of the evidence that other experiments with
animals or animal-derived cells support the association
of ZIKV infection and congenital anomalies [227, 230,
258, 261–265].
Analogy
8.1 NA NA CHIKVwas shown tobevertically transmissible and lead
to adverse congenital outcomes [268].
8.2 NA NA Confirmation. Congenital ZIKV analogous to other
TORCH infections [267].
8.3 NA NA For most analogous pathogens, infections earlier in the
pregnancy have a higher risk of adverse outcomes.
Specificity
9.1 0 4 Expansion of evidence for distinct congenital Zika
syndrome. Unique pattern of five features suggested:
severe microcephaly with overlapping cranial
structures, subcortical location of brain calcifications,
macular scarring and retinal mottling, congenital
contractures and early pyramidal and extrapyramidal
symptoms [60].
Consistency
10.1 NA NA Confirmation. ZIKV-related adverse congenital
outcomes in different regions (South America, Central
America, and the Pacific region). The proportion of
cases varies over geographic regions/time.
10.2 NA NA Confirmation. ZIKV exposure and adverse congenital
outcome in different populations (people living in ZIKV
endemic areas and travellers.
10.3 NA NA No publication with evidence of consistency across
lineages due to circulation of single strain.
10.4 NA NA Confirmation. ZIKV exposure and adverse congenital
outcomes found in different study types.
Table 3.2: Summary of the evidence on the relation between ZIKV infection and adverse
congenital outcomes. Evidence is displayed per dimension of the causality framework and
per question. Zika virus (ZIKV); Dengue virus (DENV); West Nile virus (WNV); Chikungunya
virus (CHIKV); Toxoplasmosis, Other [Syphilis, Varicella-zoster, Parvovirus B19], Rubella,
Cytomegalovirus, andHerpes infections (TORCH); Central Nervous System (CNS).
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3.4.2 GBS/ITP
In the search period for version 2 of the review, an additional 155 cases of ZIKV-related GBS
[274–287] and 11 ZIKV-related cases of ITP [189–192] were described in 19 studies. Table 3.3
summarises the evidence for specific questions in each of 10 causality dimensions (detailed
overview in Supplementary Table 3).
Temporality
We found an additional 17 publications that confirmed that ZIKV infection preceded the GBS
or ITP at an individual level [189, 191, 192, 274–278, 280–283, 285, 287–289] or at a population
level [279, 283, 290, 291]. ZIKV infections seems to be followed by GBS on average between 5
and 10 days. In one case series fromColombia [283], the authors distinguished between rapid
onsetofGBSsymptomsafterZIKVsymptoms (para-infectious)andpost-infectiousonset,with
an asymptomatic period after ZIKV symptoms before the start of GBS symptoms.
Biological plausibility
Wedid not find any publications about the biological plausibility of ZIKV as a cause of GBS or
ITP.
Strength of association
We did not find any comparative observational studies during the search period for version
2. Several surveillance studies confirmed an increase in notified GBS cases during ZIKV
outbreaks at the population level [290]. Rate ratios were significantly higher for Brazil,
Colombia, the Dominican Republic, El Salvador, Honduras, Suriname and Venezuela when
comparing pre-ZIKV GBS incidence and the incidence during the outbreak [290]; this ratio
ranged from2.0 (95%CI: 1.6-2.6) to 9.8 (95%CI: 7.6-12.5).
Exclusion of alternatives
We included 12 publications [189, 190, 192, 275, 277, 280, 281, 283, 284, 286, 287, 290] that
expanded the list of alternative causes for autoimmune disease that were excluded, such as
infections, vaccines, other system illnesses and medication, drugs or other chemicals. Many
GBS cases in these publications had serological evidence of previous exposure to DENV, as
seen in version 1. It remains unclear how large thepotential role of co-factors such as antibody
dependent enhancement are.
Cessation
We did not identify any publications with evidence about the effect of intentional
removal/elimination/prevention of ZIKV on either GBS or ITP. An additional publication
confirmed evidence that the natural removal of ZIKV resulted in a decrease in GBS cases in
Brazil, Colombia, DominicanRepublic, El Salvador,Honduras, SurinameandVenezuela [290].
Dose-response
Wedid not identify any publications about this dimension for either GBS or ITP.
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Animal experiments
No additional evidence from animal experiments was identified that support the association
between ZIKV infection andGBS/ITP development.
Analogy
As for version 1, evidence for this dimension was not reviewed systematically because our
search strategy did not include terms for other infections or conditions. We did not identify
any new publications addressing this dimension for either GBS or ITP.
Specificity
Wedid not identify any new publications addressing this dimension for either GBS or ITP.
Consistency
Studies included in version 2 confirmed the consistency of the evidence for 3 of 4 questions
about the association between ZIKV and GBS. By geographical region, ZIKV transmission has
been associated with the occurrence of GBS in 2 of 4 regions; increased GBS incidence has
been reported in theWHO regions of the Americas and theWestern Pacific region, but not in
the African or Southeast Asian region, despite recent ZIKV circulation [292]. By study design,
the association between ZIKV infection andGBShas been found at individual and population
level andwithdifferent studydesigns. Bypopulation, ZIKV infectionhasbeen linked toGBS in
ZIKVendemic regions [189, 190, 192, 274–277, 279–281, 283, 286–291, 293] and travellers from
non-affected countries who were exposed in these endemic regions [191, 278, 282, 284, 285].
There was insufficient evidence to examine the consistency of evidence about ZIKV and ITP.
Conclusion
Thebodyof evidencehasgrownduring the searchperiod for version2butonly for dimensions
that were already populated in version 1 for GBS. There is still a limited understanding of the
biological pathways that potentially cause the occurrence of autoimmune disease following
ZIKV infection. Additionally, prospective comparative epidemiological studies are still
lacking. It remains unclear how co-factors such as age and previous exposure to flaviviruses
influences the risk of developingGBS. The evidence supports a temporal association between
ZIKV and ITP but there is an absence of evidence for other dimensions of causality.
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Question n v1 n v2 Conclusion
Temporality
1.1a 9 17 Expansion of the evidence. Additional case reports and
case series were identified that confirmed that ZIKV
infectionprecededadverseautoimmuneoutcomes [189,
191, 192, 274–278, 280–283, 285, 287–289].
1.1b 9 4 Expansion of the evidence that on the population level
ZIKV precedes GBS or ITP [279, 283, 290, 291].
1.2 7 14 Expansion of evidence that the interval between
exposure to ZIKV and occurrence of symptoms is typical
for para- or post-infectious autoimmune-mediated
disorders [189, 192, 274–278, 280–285, 287].
Biological plausibility
2.1 3 0 No additional evidence was identified that ZIKV
epitopesmimic host antigens (molecularmimicry).
2.2 1 0 No additional evidence was identified that ZIKV
infection leads to an increased in detectable
autoreactive immune cells or autoreactive antibodies.
2.3 0 0 There is no evidence on other biologically plausible
mechanisms of ZIKV infection leading to GBS/ITP.
Strength of association
3.1 1 0 No additional evidence was identified on the
association between Zika infection and GBS/ITP at
the individual level.
3.2 2 4 Expansion of evidence. GBS incidence increased
in several regions, during the same time ZIKV was
circulating [279, 283, 290, 291].
Exclusion of alternatives
4.1 7 9 Confirmation of the evidence where other infections
were assessed. However, often previous DENV infection
was reported, and not excluded [189, 190, 192, 277, 280,
281, 283, 287, 290].
4.2 0 1 Expansion on the evidence where vaccines were
excluded [189].
4.3 0 6 Expansion on the evidence where other systemic
illnesses were excluded [189, 190, 192, 275, 284, 286].
4.4 0 2 Expansion on the evidence where medication, drugs or
other chemicals was excluded [275, 284].
Cessation
5.1 0 0 No relevant studies identified that intentional removal
or prevention of ZIKV infection in individuals leads to a
reduction in cases with GBS/ITP.
5.2 0 0 No relevant studies identified that intentional removal
or prevention of ZIKV infection at population level leads
to a reduction in cases with GBS/ITP.
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5.3 6 2 Expansion. Additionally, in Venezuela and the
Dominican Republic, it was shown that GBS cases
decreased with a decrease in reported ZIKV cases
[283, 290].
Dose-response
6.1 0 0 No relevant studies identified that the risk and the
clinical severity of GBS/ITP are associated with viral
titres.
Animal experiments
7.1 0 0 No relevant studies identified where the inoculation
of animals with ZIKV leads to an autoimmune
reaction resulting in peripheral neuropathy or
thrombocytopenia.
7.2 0 0 No relevant studies identified that other animal
experiments support the association of ZIKV infection
andGBS/ITP.
Analogy
8.1 NA NA No additional studies identified that other flaviviruses
or arboviruses cause GBS/ITP.
8.2 NA NA No additional studies identified that other pathogens
cause GBS/ITP.
8.3 NA NA No additional studies identified that explain which
pathogen or host factors facilitate the development of
GBS/ITP.
Specificity
9.1 0 0 Norelevant studies identifiedthatpathologicalfindings
in cases with GBS/ITP are specific for ZIKV infection.
Consistency
10.1 NA NA Confirmation that the association between ZIKV cases
and caseswithGBS is consistently foundacrossdifferent
geographical regions.
10.2 NA NA Confirmation that the association between ZIKV cases
and caseswithGBS is consistently foundacrossdifferent
populations/subpopulations.
10.3 NA NA No additional studies identified that the association
between ZIKV cases and cases with GBS/ITP
is consistently found across different ZIKV
lineages/strains.
10.4 NA NA Confirmation that the association between ZIKV cases
and caseswithGBS is consistently foundacrossdifferent
study designs.
Table 3.3: Summary of the evidence on the relation between ZIKV infection and adverse
autoimmune outcomes. Evidence is displayed per dimension of the causality framework
and per question. Zika virus (ZIKV); Dengue virus (DENV); Guillain-Barré syndrome (GBS);
immune-mediated idiopathic thrombocytopaenia purpura (ITP).
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3.4.3 Search results from January 19, 2017 to January 05, 2018
Automated search and de-duplication processes identified 2,410 publications about any
aspect of ZIKV infection. The next update, v3, of this reviewwill address causality dimensions
in the realm of epidemiological studies; strength of association, dose-response relationship,
specificity and consistency.
3.5 Discussion
3.5.1 Statement of principal findings
This systematic review confirms evidence of a causal association between ZIKV and adverse
congenital outcomes and between ZIKV and GBS, although evidence about biological
plausibility is still lacking. We assessed evidence about an association between ZIKV and ITP
but found that this only addressed the dimension of temporality. The review is transitioning
from classic systematic reviewmethods to those of a living systematic review.
3.5.2 Strengths and limitations of the study
The strengths of this study are the systematic approach to the identification, selection
and extraction of data following a causality framework that provides a structure for the
consideration of heterogeneous sources of evidence and a large set of review questions.
Automation of the review output allows rapid updating of tables of results. We have also
developed methods to automate search and de-duplication of search results to make the
transition to a living systematic review that will allow continual updating of results. The
main limitation of the classic systematic review of such a complex topic is the high workload
and time required to maintain it. Another limitation, resulting from the large number of
review questions, is the time taken to resolve inter-reviewer differences in interpretation of
eligibility criteria. This could have resulted in subjectivity over decisions about inclusion in
the review. Although a second reviewer checked all extractions, changes in the review team
could introduce inconsistency. As in version 1, we used case definitions as authors described
them in individual publications. This potential source of information bias is likely to decrease
over time as standardised case definitions andprotocols are adopted [294]. As in the previous
version, we did not systematically apply quality assessment tools to individual studies.
Because much of the technical infrastructure was built as the evidence emerged, output was
delayed. As much of the LSRmethodology was novel, it took time to find a balance between
speed and efficiency.
3.5.3 Strengths and weaknesses in relation to other studies, discussing
particularly any differences in results
Our systematic reviewdiffers frommost standard reviewsbecauseof thenumberofquestions
within the dimensions of the causality framework and the number of outcomes. Other recent
examples of living systematic reviews only distinguish between two study types (RCT and
non-RCT) [139] and are guided by only a small set of review questions [295, 296]. Our review
conclusion, confirming evidence for a causal association between ZIKV and GBS differs
from that of a review [297] of the findings of four case reports [58, 280, 298, 299] and one
case-control study [176]. The authors found insufficient evidence to confirm the presence
of an acute motor axonal neuropathy variant of GBS. They did not, however, suggest an
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alternative explanation for the increase in incidence of GBS in the countries that experienced
ZIKV outbreaks. The two versions of our review included 64 publications about ZIKV andGBS
across ten dimensions of causality.
3.5.4 Meaning of the study: possible mechanisms and implications for
basic researchers, clinicians or policymakers
The conclusions on the causal relation between ZIKV and adverse congenital outcomes and
ZIKV and GBS did not change with this update. We found insufficient evidence about the
association between ZIKV and ITP to state with certainty that there is a causal association.
The total volume of evidence about the association between ZIKV and GBS is less than for
the association with adverse congenital outcomes. There is, in particular a lack of published
research to elucidate biological mechanisms for direct neuronal or autoimmune damage
in GBS [48]. The descriptive data about the numbers and types of different studies over
time illustrates how evidence about a new, or re-emerging, infection emerges over time.
The evidence from many regions that were affected by the ZIKV outbreak remains limited
to anecdotal evidence of adverse outcomes, in the form of case reports or case series. The
slowing of ZIKV transmission in 2017 means that fewer people are being affected by ZIKV
and its complications and fewer people are being enrolled into prospective studies. Further
progress in epidemiological research will rely more heavily on research consortia who are
contributing to joint analyses of data from existing studies.
3.5.5 Unansweredquestions and future research
As the volume and complexity of the evidence in different causality dimensions accumulates,
theneedforexpert inputand interpretationof thefindingsof this systematic review increases.
The focusof researchonZIKVandcausalassociationswithdifferent typesofadverseoutcomes
is also changing. For congenital abnormalities resulting from ZIKV vertical transmission,
epidemiological research should focus on the need for observational comparative studies of
CZS and to quantify the strength of association and clarify associations with gestational age,
symptomatology and viral load and potential co-factors such as previous dengue infection
and flavivirus vaccination. WHO standardised study protocols provide suggestions for
exclusion of alternative explanations and exploration of co-factors (Harmonization of ZIKV
Research Protocols). For GBS, epidemiological studies are needed to quantify the association
with ZIKV more precisely, but also to determine whether there are distinct phenotypes
resulting from autoimmune mechanisms or direct neuronal involvement. For ITP, additional
evidence across all causality dimensions is needed.
3.5.6 Plannedupdates of a living systematic review
Living systematic reviewmethodology and techniqueswill continue to develop. Since a chain
is only as strong as itsweakest link, any processing step has the potential to slowdown trough
put speed of a living systematic review. Clearly defined protocols that define not only update
frequencies but also agreed upon through put speed of different actors in the publishing
process is vital. The next update of the systematic reviews will use living systematic review
methods to assess the evidence for 2017 and early 2018 (version 3, Figure 3.2). The review
will, for the first time, separate evidence from epidemiological study designs from in vitro
and in vivo laboratory studies. Wewill narrowdown the inclusion criteria based on study type.
Epidemiological evidence will address the causality dimensions ‘strength of association’,
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‘dose-response’, ‘specificity’ and ‘consistency’. Several co-factors might play a role in the
strength of association. Thus, we will continue to collect information on previous DENV
infection, yellow fever vaccination status, socioeconomic status, gestational age and others
factors thatmight play a role in the severity of the outcome. Wewill amend the protocol with
amore focused search strategy and inclusion criteria (Supplementary File 3).
Systematic reviews of questions addressed by laboratory studies are less frequent than those
addressing epidemiological research questions. There is still need to update understanding
of the causality dimensions ‘biological plausibility’ and ‘animal experiments’, particularly to
increase our understanding of biological pathways for ZIKV effects on the peripheral nervous
system and the immune system. We encourage and welcome collaboration from scientists
with expertise in these fields to update systematic reviews for these causality dimensions.
3.5.7 Conclusion
This systematic review confirms previous conclusions that ZIKV is a cause of congenital
abnormalities, including microcephaly and is a trigger of GBS. Evidence suggests an
association with idiopathic thrombocytopaenia purpura but is not conclusive. The transition
to living systematic review techniques and methodology provides a proof of concept for the
use of these methods to synthesise evidence about an emerging pathogen such as ZIKV,
ultimately leading to integration in thewhole public health information cycle [300]. With the
infrastructure for living systematic review methods and open source access to the software
and outputs, we aim to enhance outbreak preparedness and the study of emerging and
re-emerging pathogens.
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4.1 Abstract
Background: The Zika virus (ZIKV) caused a large outbreak in the Americas leading to the
declaration of a Public Health Emergency of International Concern in February 2016. A
causal relation between infection and adverse congenital outcomes such as microcephaly
was declared by the World Health Organization (WHO) informed by a systematic review
structured according to a framework of ten dimensions of causality, based on the work of
BradfordHill. Subsequently, theevidencehas continued toaccumulate,whichwe incorporate
in regular updates of the original work, rendering it a living systematic review.
Methods:Wepresentanupdateofour livingsystematic reviewonthecausal relationbetween
ZIKV infection and adverse congenital outcomes and between ZIKV and Guillain-Barré
syndrome (GBS) for four dimensions of causality: strength of association, dose-response,
specificity, and consistency. We assess the evidence published between January 18, 2017 and
July 1, 2019.
Results: We found that the strength of association between ZIKV infection and adverse
outcomes fromcase-control studies differs according towhether exposure toZIKV is assessed
in the mother (OR 3.8, 95% CI: 1.7-8.7, I2=19.8%) or the foetus/infant (OR 37.4, 95% CI:
11.0-127.1, I2=0%). In cohort studies, the risk of congenital abnormalitieswas 3.5 times higher
after ZIKV infection (95% CI: 0.9-13.5, I2=0%). The strength of association between ZIKV
infection andGBSwashigher in studies that enrolled controls fromhospital (OR: 55.8, 95%CI:
17.2-181.7, I2=0%) than in studies that enrolled controls at random from the same community
orhousehold (OR: 2.0, 95%CI: 0.8-5.4, I2=74.6%). In case-control studies, selectionof controls
fromhospitals could have biased the results.
Conclusions: The conclusions that ZIKV infection causes adverse congenital outcomes and
GBS are reinforcedwith the evidence published between January 18, 2017 and July 1, 2019.
4.2 Introduction
The Zika virus (ZIKV), a mosquito-borne flavivirus, caused a large outbreak of infection in
humans in the Americas between 2015-2017 (WHO Zika -Epidemiological Update). Since
then, the circulation of ZIKV has decreased substantially in the Americas [301] but ZIKV
transmissionwill likely continue at a lower level . Smaller outbreaks have been reported from
countries in Africa and Asia, including Angola and India [302], and Singapore [303]. Regions
with endemic circulation, such as Thailand [304], have the potential for new ZIKV outbreaks
with adverse outcomes [36].
The World Health Organization (WHO) declared ZIKV as a cause of adverse congenital
outcomes and Guillain-Barré syndrome (GBS) as early as September 2016 [305], informed by
a systematic review of evidence structured according to a framework of ten dimensions of
causality, basedonBradfordHill (Table 4.1) [29]. Theaccumulationof evidenceon theadverse
clinical outcomes of ZIKV has barely slowed down since theWHOdeclared the Public Health
Emergency of International Concern (PHEIC) on February 1st, 2016, with approximately 250
research publications on ZIKV appearing every month (see Zika Open Access Project). We
updated the systematic review to January 18, 2017 as a living systematic reviewby introducing
automated searchmethods to produce a high quality, up to date, online summary of research
[136] about ZIKV and its clinical consequences, for all the causality dimensions [306].
Since 2017, understanding about the pathogenesis of how ZIKV causes congenital
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abnormalities has evolved [307, 308]. The quality of diagnostic methods, especially for
acute ZIKV infection, has also improved [309–311]. More importantly, understanding of
the limitations of diagnostic testing, and the need for interpretation in the context of
other flavivirus infections, has developed. Important epidemiological questions about the
associations between ZIKV infection and adverse congenital outcomes and GBS remain
unanswered, however. Much of the early epidemiological evidence, which relied on
surveillance data, was limited in use because of issues with the quality of the reporting
and case definitions. The reported strength of association between ZIKV and adverse
outcomes has varied in studies of different designs and in different settings. Evidence for a
dose-response relationship with higher levels of exposure to ZIKV resulting in more severe
outcomes, of clinical findings that are specific to ZIKV infection, or of adverse outcomes
caused by different lineages of ZIKVwas not found in the earlier systematic reviews.
The objectives of this study are to update epidemiological evidence about associations
betweenZIKV infection andadverse congenital outcomes andbetweenZIKVandGBS for four
dimensions of causality: strength of association, dose-response, specificity, and consistency.
4.3 Methods
We performed a living systematic review, which we have described previously [306]. This
review updates the findings of the previous reviews [29, 306] and will be maintained up to
date, in accordance with the methods described below. Reporting of the results follows the
Preferred Reporting Items of Systematic reviews and Meta-Analyses (PRISMA) statement
(Supplementary File 1) [134].
4.3.1 Focus on epidemiological aspects of causality
This review and subsequent updates focuses on four dimensions of causality that are
examined in epidemiological study designs: strength of association, dose-response
relationship and specificity of effects and consistency of association (Table 4.1, Extended data
- Supplementary File 2). Evidence for domains of causality that are typically investigated in
in vitro and in vivo laboratory studies (Table 4.1) was not sought. In the absence of licensed
vaccines or treatments for ZIKV infection, we did not search for evidence on the effects of
experimental removal of ZIKV.
4.3.2 Eligibility criteria
We considered epidemiological studies that reported original data and assessed ZIKV as the
exposure and congenital abnormalities or GBS as the outcomes. We based the exposure and
outcome assessment on the definitions used in the publications. We applied the following
specific inclusion criteria (Extended data, Supplementary File 2):
Strength of association: at the individual level, we selected studies that included participants
both with and without exposure to ZIKV (Figure 4.1), such as cohort studies and case-control
studies. At the population level, we included studies that assessed the outcome during
the ZIKV outbreak and provided a comparison with pre or post-outbreak incidence of the
outcome.
Dose-response relationship: we included studies that assessed the relation between the level
of the viral titre or the presence or severity of the symptoms and the occurrence or severity of
the outcome.
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Review Baseline [8] Update 1 [10] Update 2 [this review]
Period <May 30, 2016 May 30, 2016-January 18, 2017 >January 18, 2017 -July 01,
2019
Search strategy “ZIKV” or “Zika” “ZIKV” or “Zika” Focussed search strategy
(Supplementary File 2)
Study design Epidemiological studies; in vivo/in vitro studies; surveillance
reports
Epidemiological studies
Dimensions of the causality framework
based on BradfordHill*
Temporality (cause precedes effect)
Biological plausibility of proposed biologicalmechanisms
Strength of association Strength of association
Exclusion of alternative explanations
Cessation (reversal of an effect by experimental removal of,
or observed a decline in, the exposure)
Dose-response relationship Dose-response relationship
Experimental evidence from animal studies
Analogous cause-and-effect relationships found in other
diseases
Specificity of the effect Specificity of the effect
Consistency of findings across different study types,
populations and times
Consistency of findings
across different study types,
populations and times
Table 4.1: Comparison of the search strategy included study designs and causality dimensions
addressed in the different review periods. *The causality framework is described elsewhere in
detail [177].
Specificity of the outcome for ZIKV exposure: we included studies that assessed whether the
pathological findings in cases with the outcome are specific for ZIKV infection.
Consistency: we looked at eligible studies to determine the consistency of the relationship
between ZIKV exposure and the outcomes across populations, study designs, regions or
strains.
ZIKV infected No ZIKV infectionPregnant women 
Foetus ZIKV+ ZIKV‐
Pregnancy outcomes
Congenital outcomes
Diagnostic uncertainty
Exposure assessment (foetus)
Outcome assessment
Pregnancy outcomes
Congenital outcomes
Exposure assessment (mother)
Figure 4.1: For congenital abnormalities due to ZIKV, exposure assessment in mother-infant
pairs can be performed in themother or the foetus or infant.
4.3.3 Search and information sources
We searched PubMed, Embase, LILACS and databases and websites of defined health
agencies (Extended data, Supplementary File 2). We included search terms for the exposure,
the outcome and specific study designs. We also performed searches of the reference lists of
included publications. A detailed search strategy is presented in Supplementary File 2. For
this review, the search covered the period from January 19, 2017 to July 1, 2019.
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4.3.4 Study selection and extraction
One reviewer screened titles and abstracts of retrieved publications. If retained, the same
reviewer screened the full text for inclusion. A second reviewer verified decisions. One
reviewer extracted data from included publications into piloted extraction forms in REDCap
(version 8.1.8 LTS, Research Electronic Data Capture) [312]. A second reviewer verified data
entry. Conflicts were resolved by consulting a third reviewer.
4.3.5 Synthesis of evidence
First, we summarised findings for each dimension of causality and for each outcome
descriptively. Where available, we calculated unadjusted odds ratios (OR) or risk ratios (RR)
and their 95% confidence interval (CI) from published data for unmatched study designs. For
matched study designs, we used the effectmeasure and 95%CI presented by the authors. For
publications that presented results for multiple measures of exposure and/or outcome, we
compared these results. We applied the standard continuity correction of 0.5 for zero values
in any cell in the two-by-two table [313]. We used the I2 statistic to describe the percentage
of variation across studies that is due to heterogeneity for reasons other than chance [147].
Quantitative synthesis was performed using R 3.5.1 [314]. We conducted random effects
meta-analyses using the R package metafor (version 2.0-0) [313]. Finally, we compared
descriptive and quantitative findings from this review period with previous versions of the
review [29, 306].
4.3.6 Searching and screening frequency
Daily searches of PubMed, Embase and LILACS are automated and monthly searches are
performed manually for other information sources in the first week of the month (Extended
data, Supplementary File 2), with screening of all retrieved publications on the same day.
The search strategy consisted of a combination of free terms andMESH terms that identified
the exposure and outcomes (Extended data, Supplementary File 2). Searches frommultiple
sources were combined and automatically deduplicated by an algorithm that was tested
against manual deduplication. Unique records enter a central database, and reviewers are
notified of new content.
4.3.7 Frequency of results update
The tables and figures presented in this paper will be updated every six months as a
new version of this publication. As soon as new studies are included, their basic study
characteristics are extracted andprovidedonlinehttps://zika.ispm.unibe.ch/assets/data/pub/
causalityMap/.
4.3.8 Duration ofmaintenance of the living systematic review
We will keep the living systematic review up to date for as long as new relevant data are
published and at least until October 31, 2021, the end date of the project funding.
4.3.9 Risk of bias/certainty of evidence assessment
To assess the risk of bias of cohort studies and case-control studies, we compiled a
list of questions in the domains of selection bias, information bias, and confounding,
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Figure 4.2: Map of the epidemiological studies that report on adverse congenital outcomes
(blue) or Guillain-Barré syndrome (red) associated with Zika virus exposure. The size of the
points correspondwith thenumberof exposed individualswith theadverseoutcome, according
to the definitions used in the publications.
based on the quality appraisal checklist of the United Kingdom National Institute for
Health and Care Excellence (NICE) [https://www.nice.org.uk/process/pmg4/chapter/
-g-quality-appraisal-checklist-quantitative-studies-reporting-correlations-and] and
literature [315]. Twoindependent reviewersconductedthequalityassessment. Disagreements
were resolved by a third reviewer.
4.4 Results
4.4.1 Search results from January 19, 2017 to July 1, 2019 (Update 2)
From January 19, 2017 to July 1, 2019 we screened 1941 publications, of which we included 638
basedontitleandabstract. After reviewing the full text, 249publicationswere included (Table
2, Figure 4.2 Of these publications, 195 reported on congenital abnormalities linked to ZIKV
[50, 171, 316–507] and 59 on GBS [63, 303, 339, 360, 392, 414, 442, 508–559]. Five outbreak
reports, described both outcomes [339, 360, 392, 414, 442].
4.4.2 Adverse congenital outcomes
We included 39 case reports [323, 330, 332, 345, 351, 357, 376, 378, 379, 385, 393, 395, 396, 401,
404, 405, 410, 420, 440–442, 446, 447, 449, 452, 461, 462, 464, 465, 468, 482, 488, 489, 494,
499, 501, 503, 507], 62 case series [50, 316, 320–322, 324–326, 329, 335, 339, 340, 342–344,
346, 348, 352, 353, 355, 356, 359, 362, 363, 367, 368, 371, 387, 390, 399, 400, 403, 409, 412, 415,
416, 424, 427, 429, 431, 435–437, 443–445, 455, 457, 458, 460, 466, 467, 469, 473, 475, 486, 491,
492, 496–498, 502], 10 case-control studies [354, 398, 402, 421, 422, 430, 459, 481, 490, 504],
35 cohort studies [317, 318, 327, 333, 334, 336, 337, 347, 350, 364, 366, 374, 375, 380, 386, 394,
411, 423, 426, 433, 434, 438, 448, 451, 453, 454, 456, 463, 474, 480, 485, 487, 493, 500, 506], 19
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Table 4.2: Included publications in the baseline review, update 1 and update 2 (this version), by
outcome and epidemiological study design.
Outcome Adverse congenital outcomes,
number of publications
GBS, number of publications
Review period/version Baseline* Update1† Update2 Baseline* Update1† Update2
Study design
Case report 9 13 39 9 5 17
Case series 22 12 62 5 11 22
Case-control study 0 2 10 1 1 7
Cohort study 1 8 35 0 0 0
Cross-sectional study 2 1 19 0 1 3
Controlled trials 0 0 0 0 0 0
Ecological study/outbreak
report
5 4 27 19 7 9
Modelling study 2 0 3 0 0 1
Total: 41 40 195 34 25 59
* Baseline review, earliest date of each information source to May 30, 2016 [29]; † Update 1,
May 30, 2016 to January 18, 2017 [306].
Records identified through 
database searching
(n = 3428)
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Additional records identified 
through other sources
(n = 0)
Records after duplicates removed
(n = 1941)
Records screened
(n = 1941)
Full‐text articles 
assessed for eligibility
(n = 638)
Studies included in 
qualitative synthesis
(n = 249)
Studies included in 
quantitative synthesis 
(n = 11)
Full‐text articles excluded, with reasons
(n = 389)
Unrelated to ZIKV: 1
Remotely related to ZIKV/causality: 160
No original information: 209
Insufficient information available: 19
Figure 4.3: PRISMA flow-chart publications retrieved, screened and included between January
18, 2017 and July 1, 2019. Adapted from: Moher et al. (2009) [134].
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cross-sectional studies [171, 319, 341, 349, 358, 370, 372, 377, 383, 391, 397, 408, 417–419, 428,
432, 471, 505], seven ecological studies [331, 338, 389, 407, 476, 477, 495], three modelling
studies [328, 382, 384] and 20 outbreak reports [360, 361, 365, 369, 373, 381, 388, 392, 406, 413,
414, 425, 439, 450, 470, 472, 478, 479, 483, 484] that report on congenital abnormalities linked
to ZIKV.
Causality dimensions
Strength of association
Individual level: In this review period, five case-control studies reported on strength of
association, four in Brazil (n=670 participants) [354, 398, 421, 459] and one in French Polynesia
(n=123 participants) [481]. The studies assess adverse pregnancy outcomes including infants
bornwithmicrocephaly, according toexposure toZIKV for cases. Of these, all studiesmatched
controls, based on gestational age and/or region. During the review period up to January
18, 2017, we included one case-control study [199], which we replaced with a publication
reporting the final results of the study [354]. The meta-analyses incorporate estimates from
studies identified in all review periods. Assessment of exposure status varied between the
studies (Extended data, Supplementary File 3). In five case-control studies, exposure to ZIKV
was assessed in the mother, based on clinical symptoms of ‘suspected Zika virus infection’
[459], or presence ofmaternal antibodiesmeasured by IgM (Kumar et al. (2016) [206]), PRNT
(de Araujo et al. (2018) [354], Subissi et al. (2018) [481]), or both PRNT and IgG (Moreira-Soto
et al. (2018)) maternal antibody [422]. In meta-analysis, we found that the odds of adverse
congenital outcomes (microcephaly or congenital abnormalities) were 3.8 times higher in
ZIKV-infected mothers (95% CI: 1.7-8.7, tau2=0.18, I2=19.8%, Figure 4.4). Moreira-Soto et al.
(2018) found that inBahia, Brazil, Chikungunya infectionwasalsoassociatedwithbeingacase
[422]. In twomatched case-control studies, exposure to ZIKV was assessed in infants; Araujo
et al. found a 73.1 (95% CI 13·0–Inf) times higher odds was reported for microcephaly when
ZIKV infection was assessed by reverse transcription polymerase chain reaction (RT-PCR) in
the neonate [354]. Krow-Lucal et al. (2018) found an OR of 21.9 (95% CI: 7.0-109.3) based on
evidence of recent Zika infection assessed using IgM followed by PRNT in infants in Paraiba,
Brazil [398]. When exposure was assessed at the infant-level, the combined odds of adverse
congenital outcomeswas 37.4 times higher (95%CI: 11.0-127.1, tau2=0, I2=0%, Figure 4.4).
In this review period, one cohort study reported on strength of association, in 610 pregnant
women returning from ZIKV-affected areas in Central and South America to the USA [318].
Maternal ZIKV exposure was measured using RT-PCR or IgM followed by plaque reduction
neutralisation test (PRNT). Among the 28 infants born to ZIKV-infected mothers, none
were diagnosed with microcephaly and, one was born with a major malformation. In the
ZIKV-unexposed group, eight out of 306 had major malformations. A complete overview of
different outcomes assessed is presented in the extended data, Supplementary File 3. During
the review period up to January 18, 2017, we included two cohort studies, one in womenwith
rash and fever (Brasil et al. (2016)) and one in unselected pregnant women (Pomar et al.
(2017)) [196, 212]. Inmeta-analysis of all three studies, we found that the risk ofmicrocephaly
was 3.5 times higher in ZIKV-infected mothers of babies (95% CI: 0.90-13.51, tau2=0, I2=0%,
Figure 4.5).
Population level: At a population level, data from Mexico collected at different altitudes
during the ZIKV outbreak, showed that the risk of microcephaly was increased in regions
at altitudes below 2200m, in which ZIKV can circulate [384]. Hay et al. (2018) reanalysed
surveillance data from Colombia and northeast Brazil and concluded that time-dependent
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Figure 4.4: Forest plot and meta-analysis of case-control studies reporting on ZIKV infection
assessed in mothers (A) and in infants (B) and adverse congenital outcomes (microcephaly,
congenital malformations, central nervous system abnormalities). The odds ratio from the
five case-control studies that assess exposure in mothers combined is 3.8 (95% CI: 1.7-8.7,
tau2=2.37, I2=19.8%); the odds ratio for the studies that assess exposure in infants is 37.4 (95%
CI: 11.0-127.1, tau2=0, I2=0%). The odds ratios are plotted on the log scale. Abbreviations: CSF,
cerebrospinal fluid, PRNT, plaque reduction neutralisation test; RE, random effects; RT-PCR,
reverse transcription polymerase chain reaction.
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Figure 4.5: Forest plot and meta-analysis of cohort studies reporting on ZIKV infection and
adverse congenital outcomes. The risk ratio from the random effects model is 3.5 (95%
CI: 0.9-13.5, tau2=0, I2=0%). The risk ratios are provided on the log scale. Abbreviations:
PRNT, plaque reduction neutralisation test; RE, random effects; RT-PCR, Reverse transcription
polymerase chain reaction.
reportingchangesmighthavecausedapparent inconsistencies in theproportionofcongenital
abnormalities as a result ofmaternal ZIKV infection [382].
Dose response
Halai et al. (2017) [118] examined the severity of congenital outcomes according tomeasures
of the severity of maternal ZIKV infection in a subset of mothers in the cohort presented
by Brasil et al. (2016) [196]. They evaluated ZIKV load, assessed by RT-PCR using the cycle
threshold (CT) as a measure of number of RNA copies, and a severity score of symptoms
in 131 pregnant women. They concluded that neither higher viral load nor more severe
symptoms was associated with more severe congenital abnormalities [380]. Moreira-Soto
et al. found higher maternal antibody titers in microcephaly cases compared with controls
[422]. In previous review periods, Honein et al. (2016) compared outcomes in neonates born
to symptomatic and asymptomatic infected pregnant women returning to the USA with
possible ZIKV infection and found no differences [204].
Specificity
Although some outcomes, such as lingual phenotype [372] or neurogenic bladder [560],
have been hypothesised as a specific phenotype for congenital ZIKV infection, no additional
evidence was identified that certain congenital adverse findings are specific for congenital
ZIKV infection.
Consistency
Geographical region: All four WHO geographic regions (the Africa region [AFRO], the
American region [AMRO], theSouth-EastAsian region [SEARO]andtheWesternPacific region
[WPRO]) with past or active ZIKV transmission have now reported congenital abnormalities
due to ZIKV infection. During this review period, the first congenital abnormality due to
infection with the Asian lineage of the virus on the African mainland occurred in a traveller
returning from Angola [464]. Possible cases of congenital abnormalities have occurred in
Guinea-Bissau [457]. In themost recentWHO situation report fromMarch 2017, two cases of
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microcephaly are documented in Thailand and one in Vietnam, which were also described
in detail in other works [420, 498, 499]. We identified another publication on congenital
abnormalities due to endemic ZIKV in Cambodia [346]. The occurrence of congenital adverse
outcomes in AFRO, SEARO, and WPRO seems sporadic, despite the endemic circulation
of ZIKV. As noted above, the observed complication rate varied strongly between regions.
Extended data, Supplementary File 3 provides a full overview of the published studies on
congenital abnormalities per region and country.
Traveller/non-traveller populations: In this update, we found further evidence that
congenital abnormalities occurred in infants born to women travellers returning from
ZIKV-affected areas and women remaining in those areas. In total, 25 publications report
on 272 congenital abnormalities due to ZIKV infection in travellers [323, 329, 334, 366, 378,
387, 395, 400, 404, 405, 416, 424, 446, 448, 451–453, 465, 468, 469, 471, 482, 497, 501, 503],
with 109 publications reporting congenital abnormalities due to ZIKV in 2652 non travellers
[50, 171, 316, 320, 321, 324–327, 330, 332, 333, 335–337, 339, 340, 342–346, 348, 349, 351–357,
362, 363, 367, 368, 370–372, 374–377, 386, 391, 393, 394, 398, 399, 402, 403, 408–411, 415, 418,
420–423, 426–430, 433–438, 440–442, 444, 445, 447, 454, 456–459, 461–464, 466, 467, 473,
475, 481, 485, 487–494, 496, 499, 500, 502, 504–507]
In this review period, evidence emerged that transmission through sexual contact with
infected travellers also resulted in foetal infection [396, 501].
Study designs: The association between ZIKV infection and congenital abnormalities was
consistent across different study designs (Table 2).
Lineages: We found no new evidence of consistency across different lineages from
observational studies. The currently observed adverse congenital outcomes are linked
to the ZIKV of the Asian lineage.
Risk of bias assessment
In all case-control studies, uncertainty about the exposure status due to imperfect tests could
result in a bias towards the null. Some studies might suffer from recall bias where exposure
wasassessedby retrospectively askingabout symptoms [459, 481]. For the cohort studies [196,
318], theenrolment criteriawerebasedonsymptomatology. Asa result, even in theabsenceof
evidenceof ZIKV, theunexposedgroupsmighthavehad conditions thatwereunfavourable to
their pregnancy. We expect this to bias the results towards the null or underestimate the true
effect. Owing to imperfect diagnostic techniques, both false positives (IgM, cross reactivity)
and false negatives (due to the limited detectionwindow for RT-PCR)might occur, potentially
resulting inbias; thedirectionof this biaswouldoftenbe towards thenull. Noneof the studies
controlled for potential confounding. Extended data, Supplementary File 4 provides the full
risk of bias assessment of the studies included in themeta-analysis.
4.4.3 GBS
During this review period, we included 17 case reports [442, 512, 518, 524, 528, 529, 531, 532,
535, 537, 540, 542, 545, 548, 551, 557, 558], 22caseseries [339, 508–511, 513, 514, 516, 519, 521, 522,
525, 526, 536, 539, 541, 543, 546, 549, 553, 556, 559], seven case-control studies [303, 523, 527,
533, 544, 547, 550], one ecological study [530], one modelling study [63] and eight outbreak
reports [360, 392, 414, 515, 534, 552, 554, 555] that reported on ZIKV infection andGBS.
63
CHAPTER 4. ZIKA VIRUS AS A CAUSE: A LIVING SYSTEMATIC REVIEWPART 2
4
0.1 1 10 100 500
Odds Ratio
Simon, 2018 [Neutralising Ab (PRNT)] 
Cao−Lormeau, 2016 [IgM]*
GeurtsvanKessel, 2018 [IgG and VNT]*
Dirlikov, 2017 [IgM and/or RT−PCR]*
Salinas, 2017 [IgM]*
Styczynski, 2017 [Recent flavivirus infection] 
30.00 [2.66, 338.18]
59.70 [9.38, 379.94]
 2.23 [0.52,   9.48]
36.00 [4.99, 259.48]
 1.70 [0.47,   6.16]
 1.27 [0.38,   4.30]
 6.99 [1.70,  28.76]RE Model for All Studies (Q = 21.30, df = 5, p = 0.00; I2 = 78.3%)
Hospital controls
Community controls
Author(s), Year [exposure assessment] Odds Ratio [95% CI]
55.83 [17.15, 181.73]
2.03 [0.94, 4.38]RE Model for Subgroup (Q = 11.08, df = 3, p = 0.01; I2 = 74.6%)
RE Model for Subgroup (Q = 0.16, df = 1, p = 0.69; I2 = 0.0%)
Figure 4.6: Forest plot of six included case-control studies and their exposure assessment.
Odds ratios (ORs) are shown on the log-scale. The meta-analysis is stratified by the selection
of controls: Hospital controls, or community/household controls. Most similar exposure
assessment measures are compared (IgM [176, 527, 544, 547], recent flavivirus infection [550],
or IgM and/or RT-PCR [523]). OR: 7.0 [95% CI: 1.7-28.8, tau2=2.78, I2=78.3%]. ORs from studies
markedwith an asterisk (*) arematchedORs, unmarked studies provided crudeORs.
Causality dimensions
Strength of association
Individual level. The number of studies reporting on the strength of association between
ZIKV infection and GBS at an individual level increased substantially. We identified five
case-control studies [523, 527, 544, 547, 550] published since the previous update, which
included one case-control study from French Polynesia [176]. All studies were matched
for age and place of residence. In the studies from Brazil, Colombia, Puerto Rico and New
Caledonia, temporal clustering of cases in association with ZIKV circulation was documented
[523, 544, 547, 550]. In Bangladesh, ZIKV transmission was endemic [527]. Exposure
assessment was based on serology [544, 550] or a combination of RT-PCR and serology
[523, 527, 547]. Extended data, Supplementary File 3 shows the variability in ORs according to
criteria for ZIKV exposure assessment, based on unmatched crude data extracted from each
case-control study. Figure 4.6 shows the association between GBS and ZIKV infection, using
the diagnostic criteria that weremost similar across studies. Heterogeneity was considerable
(I2=78.3%), but was reduced slightly after stratification based on the method of selection of
controls. The summary OR was higher in studies that enrolled controls from hospital (OR:
55.8, 95% CI: 17.2-181.7, tau2=0, I2=0%) [176, 547] than in studies that enrolled controls at
random from within the same community [523, 544, 550] or from the same household [527]
(OR: 2.0, 95% CI: 0.8-5.4, tau2=0.46, I2=74.6%). Amongst studies with community controls,
ORs were lower when enrolment and assessment took place several months after onset of
symptoms [544, 550] than in studies with contemporaneous enrolment [523, 527]. To further
illustrate the heterogeneity in exposure assessment between and within the studies, we
provide additional aggregations of the data in Extended data, Supplementary File 3.
Population level. At a population level, Mier-Y-Teran-Romero et al. (2018) showed that
the estimated incidence of GBS ranged between 1.4 (0.4–2.5) and 2.2 (0.8–5.0) per 10,000
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ZIKV infections comparing surveillance/reported cases from Brazil, Colombia, Dominican
Republic, El Salvador, French, Honduras, Puerto Rico, Suriname, Venezuela, and Micronesia.
The across-location minimum and maximum estimates were used to estimate an average
risk of having GBS and being reported after ZIKV infection across locations of approximately
2.0GBS cases per 10,000 infections (95%credible interval 0.5–4.5 per 10,000ZIKV infections)
[63].
Dose response
In a case-control study, Lynch et al. (2018) found higher titres of neutralising antibodies in
ZIKV-infected GBS cases than in patients with symptomatic ZIKV infection but without GBS
[533].
Specificity
Dirlikov et al. (2018) compared Puerto Rican GBS cases reported through public health
surveillance that were preceded by ZIKV and cases that were not preceded by ZIKV infection
[522]. Clinical features involvingcranialnerveswereobservedmore frequently inZIKV-related
cases and, at a six-month follow-up visit, residual cranial neuropathywas notedmore often in
this group. However, clinical symptoms did not allow a distinction to bemade between ZIKV
and non-ZIKV related GBS.
Consistency
Geographical region:During this reviewperiod,GBS likelydue toZIKV infectionwas reported
in Asia; including Thailand, Bangladesh, Singapore and India [303, 332, 511, 527]. Publication
in theWHORegionof theAmericas followedthepatternasobservedbeforeandnoGBS linked
to ZIKV infection was reported in Africa. Extended data, Supplementary File 3 provides a full
overview of the published studies on congenital abnormalities by region and country. In a
reanalysis of surveillance data from the Region of the Americas, Ikejezie et al. (2016) found
consistent time trends between GBS incidence and ZIKV incidence [530].
Traveller/non-traveller populations: In studies included in this update, we found additional
evidence of GBS in both travellers and non-travellers with ZIKV infection. Ten publications
report on 11 travellers [512, 514, 528, 531, 532, 537, 542, 551, 557, 558], while 34 publications
report GBS or ITP due to ZIKV in 402 non travellers [303, 339, 442, 508, 513, 516–527, 529, 533,
535, 539–541, 543–550, 553, 556, 559].
Study designs: Across the different study designs, the relation between GBS and ZIKV is
consistently shown. Table 2 and Extended data, Supplementary File 3 provide an overview of
the included study designs.
Lineages: We still lack evidence on the consistency of the relation between GBS and ZIKV
across different lineages from observational studies. The observed cases of GBS were linked
to ZIKV of the Asian lineage.
4.4.4 Risk of bias assessment
Potential selection bias in case-control studies was introduced by the selection of controls
from hospitals rather than from the communities in which the cases arose [176, 547].
Uncertainty about the exposure status due to imperfect tests would tend to result in a bias
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towards the null. Two case-control studies did not conduct a matched analysis although
controls were matched, and no study controlled for potential confounding by factors other
than those used for matching. Exclusion criteria and participation rate, especially of the
controls, were poorly reported. Extended data, Supplementary File 4 provides the full risk of
bias assessment of the studies included in themeta-analysis.
4.5 Discussion
In this living systematic review, we summarised the evidence from 231 observational studies
in humans on four dimensions of the causal relationship between ZIKV infection and adverse
congenital outcomes andGBS, published between January 18, 2017 and July 1, 2019.
4.5.1 Strengths and limitations
The strengths of this living systematic review are that, first, we automated much of the
workflow [306]; we search both international and regional databases daily and we screen
papers for eligibility as they become available, so publication bias is unlikely. Second,
we have quantified the strength of association between ZIKV infection and congenital
abnormalities andGBS and investigated heterogeneity of outcome and exposure assessment
within and between studies. Third, for congenital outcomes, we included studies with both
microcephaly and other possible adverse outcomes, which acknowledges the spectrum of
congenital adverse outcomes caused by ZIKV. This work also has several limitations. First, we
have not assessed the dimensions of the causality framework that involve laboratory studies,
so we have not updated the pathobiology of ZIKV complications, which was addressed in
the baseline review [29] and the first update to January 2017 [306]. Limiting the review to
epidemiological domains has allowed more detailed analyses of these studies and we hope
that scientists with expertise in laboratory science will continue to review advances in these
domains. Second, the rate of publications onZIKV remains high so, despite the reduced scope
and automation, maintenance of the review is time-consuming and data extraction cannot
be automated. Third, this review could suffer from continuity bias, which is important for
the conduct and interpretation of living systematic reviews and results from changes in the
author team. Careful adherence to the protocol will reduce this risk.
4.5.2 Interpretation of thefindings
ZIKV and congenital abnormalities: Since the earlier versions of the review [29, 306],
evidence on the causal relationship between ZIKV infection and congenital abnormalities
has expanded. Unfortunately, the total number of cases investigated in the published
cohort or case-control studies remains small. In case-control studies in which infants with
microcephaly or other congenital abnormalities are compared with unaffected infants, the
strength of association differs according to whether exposure to ZIKV is assessed in in the
mother (OR 3.8, 95% CI: 1.7-8.7, tau2=0.18, I2=19.8%) or the foetus/infant (OR 37.4, 95% CI:
11.0-127.1, tau2=0, I2=0%). This large difference in effect size can be explained by the fact
that not all maternal ZIKV infections result in foetal infection. In cohort studies, the risk of
congenital abnormalities was 3.5 times higher (95% CI: 0.9-13.5, I2=0%, tau2=0) in mothers
withevidenceofZIKV infection thanwithout,which is similar to theOR formaternal exposure
to ZIKV estimated from case-control studies. Further research is needed to understand the
drivers of mother to child transmission. Higher maternal antibody titres were correlated
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with a higher incidence of adverse congenital outcomes in one case-control study [422].
But, amongst ZIKV-infected mothers followed prospectively, severity of ZIKV infection was
not associated with more severe congenital abnormalities [380]. Convincing evidence on a
dose-response relation is therefore still lacking.
ZIKV andGBS: Evidence about the causal relation betweenZIKV infection andGBShas grown
since our last review [306]. The body of evidence is still smaller than that for congenital
abnormalities, possibly because GBS is a rare complication, estimated to occur in 0.24 per
1000 ZIKV infections [176]. In this review, the strength of association between GBS and ZIKV
infection, estimated in case-control studies, tended to be lower than observed in the first
case-control study reported by Cao-Lormeau (2016) in French Polynesia [176]. It is possible
that finding by Cao-Lormeau et al. was a ‘random high’, a chance finding [561]. Simon et
al., however, found a similarly strong association in a case-control study in New Caledonia
[547]; in both these studies, controls were patients in the same hospital. Although matched
for place of residence, it is possible that they were less likely to have been exposed to ZIKV
than the cases, resulting in an overestimation of the OR. In case-control studies in which
controls were enrolled from the same communities as the cases, estimated ORs were lower,
presumably because exposure to ZIKV amongst community-enrolled controls is less biased
than amongst hospital controls [562]. Under-ascertainment of ZIKV infection in case-control
studies in which enrolment occurred several months after the onset of symptoms [544, 550]
is also likely to have reduced the observed strength of association. There is also possible
evidence of a dose-response relationship, with higher levels of neutralising antibodies to
both ZIKV and dengue in people with GBS [533]. However, the level of antibody titre might
not be an appropriate measure of viral titre, and merely a reflection of the intensity of the
immune response. Taking into account the entire body of evidence, inference to the best
explanation [563] supports the conclusion that ZIKV is a cause of GBS. The prospect of more
precise and robust estimates of the strength of association between ZIKV and GBS is low
because outbreaks need to be sufficiently large to enrol enough peoplewith GBS. In the large
populations that were exposed during the 2015-2017 outbreak, herd immunity will limit
future ZIKV outbreaks.
4.5.3 Implications for future research
The sample sizes of studies published to date are smaller than those recommended by
WHO to obtain precise estimates of associations between ZIKV and adverse outcomes
[Harmonization of ZIKV Research Protocols to Address Key Public Health]. Given the absence
of large new outbreaks of ZIKV infection in 2017-2019, there is a need for consortia of
researchers to analyse their data in meta-analyses based on individual participant data
[Individual Participant Data Meta-analysis of Zika-virus related cohorts of pregnant women
(ZIKV IPD-MA)]. Future collaborative efforts will help to quantify the absolute risks of
different adverse congenital outcomes and allow investigation of heterogeneity between
studies [204, 380, 386].
This review highlights additional research gaps. First, we did not assess the complication
rates within the infected group in studies without an unexposed comparison group; the
adverse outcomes are not pathognomonic for ZIKV infection, making an appropriate
comparison group necessary. Even though there are no individual features of ZIKV infection
that are completely specific, the growing number of publications on ZIKV will allow better
ascertainment of the features of a congenital Zika syndrome [60]. In this review, we did
not take into account the performance of the diagnostic tests in assessing the strength
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of association. Future research should include robust validation studies, and improved
understanding of contextual factors in the performance of diagnostic tests, i.e. the influence
of previous circulation of other flaviviruses, the prevalence of ZIKV and the test used.
This living systematic review will continue to follow studies of adverse outcomes originating
from ZIKV circulation in the Americas, but research in regions with endemic circulation of
ZIKV is expected to increase. Such studies will clarify whether ZIKV circulation in Africa and
Asia also results in adverse outcomes, as suggested by the case-control study of GBS from
Bangladesh [527]. Increased awareness might improve the evidence-base in these regions,
wheremisperceptionsabout thepotential risksofZIKV-associateddiseasewithdifferentvirus
lineages has been reported [564]. An important outstanding question remains whether the
absenceof reported cases of congenital abnormalities orGBS in these regions represent a true
absence of complications or is this due to weaker surveillance systems or reporting [565]. The
conclusions that ZIKV infection causes adverse congenital outcomes and GBS are reinforced
with the evidence published between January 18, 2017 and July 1, 2019.
4.6 SupplementaryMaterial
4.6.1 Underlying data
All dataunderlying the results are available aspart of thearticle andnoadditional sourcedata
are required.
4.6.2 Extendeddata
Extended data can be found online at the Harvard dataverse: Living systematic review
on adverse outcomes of Zika - Supplementary Material. 10.7910/DVN/S7USUI and Living
systematic review on adverse outcomes of Zika - Figures and Table. 10.7910/DVN/DLP5AN.
Supplementary material is available online in the published version of the manuscript
http://doi.org/10.12688/f1000research.19918.1.
This project contains the following extended data:
• SupplementaryFile1Prisma.docx (PRISMA checklist)
• SupplementaryFile2Methods.docx (Supplementary file 2, additional information to
theMethods)
• SupplementaryFile3Results.docx (Supplementary file 3, additional information to the
Results)
• SupplementaryFile4ROB.tab (Risk of bias assessment)
• Fig1.pdf (Most recent version of Figure 1)
• Fig2.pdf (Most recent version of Figure 3, PRISMAflowchart)
• Fig3A.pdf (Most recent version of Figure 4A)
• Fig3B.pdf (Most recent version of Figure 4B)
• Fig4.pdf (Most recent version of Figure 5)
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• Fig5.pdf (Most recent version of Figure 6)
• Table2.pdf (Most recent version of Table 2)
4.6.3 Reporting guidelines
PRISMA checklist and flow diagram for ‘Zika virus infection as a cause of congenital brain
abnormalities andGuillain-Barré syndrome: A living systematic review’, 10.7910/DVN/S7USUI
and Figure 4.3.
4.6.4 Grant information
This work was supported by the Swiss National Science Foundation [320030_170069], end
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5.1 Abstract
Background:Health authorities in theUnited States andEurope report an increasingnumber
of travel-associated cases of sexual transmission of Zika virus (ZIKV) following the 2016 ZIKV
outbreak. This, and other scientific evidence, suggests for the first time that ZIKV is sexually
transmissible inaddition to itsprimarymosquito-borne route. Theobjectiveof this systematic
review and evidence synthesis was to help develop amore lucid epidemiology of ZIKV.
Methods and Findings: We performed a living (i.e., continually updated) systematic review
of evidence published up to 15 April 2018 about sexual transmission of ZIKV and other
arthropod-borne flaviviruses in humans and other animals. We defined seven key elements
of ZIKV sexual transmission for which we extracted data: 1) rectal and vaginal susceptibility
to infection, 2) incubation period following sexual transmission, 3) serial interval between
the onset of symptoms in a primary and secondary case, 4) duration of infectiousness, 5)
reproduction number, 6) probability of transmission per sex act, and 7) transmission rate.
We identified 1217 unique publications and included 128, of which 77 presented data on
humans and 51 presented data on animals. Laboratory experiments confirm that rectal and
vaginal mucosae are susceptible to infection with ZIKV and that the testis serves as reservoir
for the virus in animal models. Sexual transmission was reported in 36 human couples, of
which 34/36 underwent male to female sexual transmission. The median serial symptom
onset interval in 15 couples was 12 days (interquartile range: 10-14.5); the maximum was 44
days. We found evidence from two prospective cohorts that ZIKV RNA is present in human
semen with a median duration of 34 days (95% CI: 28-41 days) and 35 days (no CI given) (low
certainty of evidence, according to GRADE). Aggregated data about detection of ZIKV RNA
from 37 case reports and case series indicate a median duration of 40 days (95% CI: 30-49
days) andmaximumduration of 370 days in semen. In human vaginal fluid,median duration
was 14 days (95% CI: 7-20 days) and maximum duration was 37 days (very low certainty).
Infectious virus in human semen was detected for a median duration of 12 days (95% CI: 1-21
days) and maximum of 69 days. Modelling studies indicate that the reproduction number
is below one (very low certainty). Evidence was lacking to estimate the incubation period or
the transmission rate. Evidence on sexual transmission of other flaviviruses was scarce. The
certainty of the evidence is limited because of uncontrolled residual bias.
Conclusion: The living systematic review and sexual transmission framework allowed us to
assess evidence about the risk of sexual transmission of ZIKV. ZIKV ismore likely transmitted
from men to women than from women to men. For other flaviviruses evidence of sexual
transmissibility is still absent. Taking into account all available data about the duration
of detection of ZIKV in culture and from the serial interval, our findings suggest that the
infectious period for sexual transmission of ZIKV is shorter than estimates from the earliest
post-outbreak studies, whichwere based on RT-PCR alone.
5.2 Author summary
WhyWas This StudyDone?
• Sexual transmission of Zika virus (ZIKV) is now documented but the risks of
transmission are not well understood.
• It is not known whether other flaviviruses can be transmitted through sexual
intercourse.
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WhatDid theResearchersDo and Find?
• Wedevelopeda sexual transmission framework forZIKV infection that identifiedseven
keyelements related toZIKVsexual transmission, andweconducteda livingsystematic
review through April 15th 2018 of available evidence about each element.
• Wefoundthat, inknowncases, sexual transmissionofZIKVismuchmorecommonfrom
men towomen than fromwomen tomen. For sexual transmission of ZIKV, themedian
serial interval—the timebetweenonset of symptomsbetween two sexual partners—is
12 days.
• Themedian duration of ZIKV RNA persistence in semen is longer (34 days) than in the
female genital tract (12 days). ZIKV can be detected for longer periods using reverse
transcription polymerase chain reaction compared to viral culture.
• We found no evidence of sexual transmission for any other arthropod-borne
flaviviruses.
WhatDoThese FindingsMean?
• Studies about the duration of detection of ZIKV in bodily fluids and the serial interval
suggest that theperiodZIKVcan transmit throughsexual contactmightbeshorter than
was anticipated from the earliest studies in 2016.
5.3 Introduction
Zika virus (ZIKV) can be transmitted between humans through sexual contact, although it is
most commonly transmitted by infectedAedes spp. mosquitoes [566]. Sexual transmission of
ZIKVhas important implications forpublichealth, forpeople living inendemic regionsand for
sexualpartnersof travellers returning tonon-endemic regions fromendemic regions, because
ZIKVinfectionduringpregnancycancausecongenital infectionof thefoetusandbecauseZIKV
infection can trigger the immune-mediated neurological condition Guillain-Barré syndrome.
ZIKV is an RNA flavivirus. Flaviviruses are a genus of viruses from the Flaviviridae family of
which themajority are transmitted to vertebrates by infectedmosquito or tick vectors [567].
Scientistsworking in Senegal in 2008were thefirst to report presumed sexual transmissionof
ZIKV ina case report thatdocumented their ownsymptomsand serological findings [44]. One
scientist developed symptoms after returning to the USA and his wife, who had not travelled
outside the USA, became unwell four days later. The large ZIKV outbreak (2015-2017) in the
Americas resulted in additional reports of travel-associated ZIKV sexual transmission in the
United States and Europe, which Moreira and colleagues synthesised in a narrative review
of the literature up to December 2016 [568]. In vivo and in vitro experimental studies have
provided evidence of the biological plausibility of this route of infection.
While possible sexual transmission has been established, there are many unanswered
questions about the transmissibility of ZIKV through sexual intercourse. Formosquito-borne
ZIKV infection, the incubation period and duration of viral shedding in serum have been
estimated, allowing implications for blood donation to be assessed [55]. Additional
information about parameters related toperson-to-person transmissionof ZIKVhas not been
systematically collatedor quantified, although several narrative reviewshavebeenpublished
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[43, 569]. Evidence about sexual transmission of other arthropod-borne flaviviruses in
humans, including West Nile virus (WNV), Yellow fever virus (YFV), Japanese encephalitis
virus (JEV), and Dengue virus (DENV) [570], has not been synthesised but WNV and YFV
has been detected in human semen [571, 572]. The primary objective of this review was to
systematically review evidence about defined aspects of the sexual transmission of ZIKV.
Secondaryobjectiveswere to systematically reviewevidenceabout the sexual transmissibility
of other arthropod borne flaviviruses; and to establish these reviews using a living systematic
review approach [136].
5.4 Methods
5.4.1 Sexual transmission framework
In March 2017, we developed a sexual transmission framework for ZIKV [47], based on
standard concepts about person-to-person transmission of infection [573]. The framework
includes key events in the course of an infection in an individual and transmission to a
sexual partner, some of which can be measured and others that can only be determined
indirectly or throughmodelling. Figure 5.1 shows these events and the relationships between
the following elements: 1) susceptibility to infection, 2) incubation period after sexual
transmission, 3) serial interval, 4) duration of infectiousness, 5) reproductive number, 6)
probability of transmission per sex act, and 7) transmission rate. The framework does
not include transmission from and to mosquitoes, which would be needed to estimate
the proportion of all ZIKV infections due to sexual transmission. The sexual transmission
framework defined the outcomes and informed the structure of the review.
5.4.2 Living systematic review
We performed this review as a living systematic review [136] because research into many
aspects of ZIKV is a new and fast moving field. Several studies are ongoing [574] and
have published interim results [49] and updated results could affect public health
decisions. The protocol for this review was registered on May 19, 2017 in the database
PROSPERO (CRD42017060338) [573]. We summarise the details that make the review
a living systematic review in S2 Text. Future updates will be reported quarterly online
(http://zika.ispm.unibe.ch/stf/) and in the online comments section of this publication.
Reporting is in accordance to the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) (S1 PRISMAChecklist).
Search strategy
The search included the electronic databases: Pubmed, Embase, BioRxiv, Arxiv, PeerJ, Lilacs
andonline repositories fromtheUnitedStatesCenters forDiseaseControl andPrevention, the
European Centre for Disease Prevention and Control, the Pan AmericanHealth Organization,
and the World Health Organization from the earliest date of each database and without
language restrictions. The searches includedmedical subject headings (MeSH) and keywords
for ZIKV and flaviviruses together with viral persistence and sexual transmission (S2 Text).
An automated search is run every day, with results deduplicated and imported into REDCap
(Research Electronic Data Capture, Vanderbilt University, OK). We checked reference lists of
included studies to identify additional relevant studies. For this report, we identified studies
published before and up to April 15, 2018.
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Figure5.1:Aschematic representationof thesexual transmissionofZIKVand itskeyparameters.
Numbered circles show the seven key elements. Dark blue circles are elements for which
evidence is based on empirical research. Light blue circles denote parameters derived from
mathematical modelling studies and in vivo studies. Panel A shows the transmission between
two individuals. The blue horizontal arrows show the time course of the disease for the primary
infected individual who is infected and the secondary individual who starts as susceptible
(element 1). The vertical solid red arrow represents a ZIKV transmission event, afterwhich there
is an incubation period (element 2) before symptoms develop. Element 3 is the serial interval,
theperiodbetween the start of symptoms in theprimaryand the secondary individual. Element
4 is the duration of infectiousness. After the infection, individuals can become immune. Panel B
shows the relationbetweendifferent parameters at population level. The reproductionnumber
(element 5) is the result of the contact rate, the probability of transmission per act (element 6)
and thedurationof infectiousness (4). The transmission rate (element 7) canbeestimatedusing
the reproduction number (5) and the serial interval (3).
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Outcomes Eligible study designs Detailed eligibility criteria
Primary outcomes:
2. Incubationperiod following sexual
transmission
Observational epidemiological
studies in humans (case report,
case series, cohort studies,
surveillance/outbreak reports).
Observational studies that report incubation
period due to sexual transmission.
3. Serial interval Observational studies that describe sexual
transmission inhumanswhere serial interval
(time between onset of symptoms between
sexual partners) is reported.
4. Duration of infectiousness Observational studies that report duration
of detection of virus in semen, cervical and
vaginal secretions and saliva; diagnostic
methods included reverse transcription
polymerase chain reaction (RT-PCR) or viral
culture.
Secondary outcomes:
1. Susceptibility In vivo/in vitro studies In vivo/in vitro studies that report on the
female genital tract, the male genital
tract, presence of virus in saliva or sexual
transmission of virus
5. Reproduction number due to
sexual transmission
Mathematicalmodelling studies Modelling studies that report on the
parameters of interest
6. Probability of transmission per sex
act
7. Transmission rate
Table 5.1: Eligibility criteria for each outcome.
Eligibility criteria
We included observational studies, in vitro and in vivo studies and mathematical modelling
studies that directly addressed any of the elements of the sexual transmission framework
in either humans and animals for ZIKV or other arthropod-borne flavivirus. We included
observational studies that reported one or more cases of sexual transmission, one or more
measurements of presence of virus in bodily fluids, or both. As bodily fluids we included
semen, cervical and vaginal secretions and saliva; diagnostic methods included reverse
transcription polymerase chain reaction (RT-PCR) or viral culture. We did not include reviews,
editorials or commentaries that did not report original data. Table 5.1 provides an overview
of the eligibility criteria for each outcome. Primary outcomes can be directly estimated
from observational studies and secondary outcomes are calculated or inferred from indirect
evidence.
Study selection anddata extraction
One reviewer screened titles and abstracts of retrieved papers. If retained in the first step, we
screened the full text of the paper. One reviewer extracted data into piloted extraction forms
in REDCap [312]. A second reviewer verified exclusion decisions and data entry.
Synthesis of the evidence
We provide descriptive summaries of findings about the elements of the ZIKV sexual
transmission framework forbasic research studies (element 1), observational epidemiological
studies (elements 2-4) and mathematical modelling studies (elements 5-7). In addition,
we used data from included studies to calculate estimates for the serial interval, the period
between the start of symptoms in the primary and the secondary individual, and the duration
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of the detection of ZIKV. We report the median serial interval and its interquartile range. To
estimate the duration of detection of ZIKV positivity, we conducted interval censored survival
analysis and fitted Weibull distributions using the ’straweib’ package [575, 576] in R (version
3.4.1), based on previous studies [49, 575, 576]. We assumed that all infected patients were
RT-PCR or viral culture positive at symptom onset. We report median estimated durations
and corresponding 95% confidence intervals. Additional information about the methods
is provided in S3 Text. For other flaviviruses we summarise findings from all study types
descriptively.
Certainty assessment of the evidence
Weassessed themethodologyof includedstudiesusingspecific checklists foreachstudy type.
For observational studies we used National Institutes of Health (NIH) Quality Assessment
Tool for Case Series Studies [577] and United Kingdom National Institute of Health and
Clinical Excellence (NICE) checklists for case-control studies and cohort studies [578]. For in
vivo studies we used the SYstematic Review Center for Laboratory animal Experimentation’s
(SYRCLE) risk of bias tool for animal studies [579] and formathematicalmodelling studies the
International Society forPharmacoeconomicsandOutcomesResearch (ISPOR)Questionnaire
to Assess Relevance and Credibility ofModeling Studies [580]. We performed the assessment
by a consensus-driven approach among multiple reviewers. We appraised the certainty of
the key parameters according to the Grading of Research Assessment Development and
Evaluation (GRADE) tool [581–583] (S6 Table). In accordance with GRADE, assessments of
the overall certainty of evidence from observational studies started at low certainty. We
downgraded the level of certainty for small sample size and evidence from case reports or
case series. We assessed outcomes ofmathematical modelling studies as high, medium, low
or very low certainty.
5.5 Results
We identified 1227 unique citations and excluded 901 by title and abstract screening (Figure
5.2). Of the remaining326potential eligible citationswith relevant abstracts, 128publications
were eligible for inclusion. Table 5.2 summarises characteristics of the included studies.
5.5.1 Basic research studies
Weincluded41 in vivoand in vitro studies of ZIKV [266, 584–616] (Table 5.2)Of these41 studies,
sixwere invitro studiesand35werestudies in invivoanimalmodels; 12 innon-humanprimates
(NHP) suchasCynomolgusmacaques (Macaca fascicularis), Rhesusmacaques (Macacamulatta)
andCommonmarmosets (Callithrix jacchus) and23 inmice. In one study, both guineapigs and
NHPwere used [589]. These studies provide insight in the underlying biologicalmechanisms
of susceptibility toZIKV infection through sexual transmissionandsubstantiate thebiological
plausibility of this transmission route.
Susceptibility (1)
In mouse and NHP models the vaginal and rectal mucosae were shown to be susceptible to
infectionwith ZIKV [266, 592, 595, 598, 602, 614]. When ZIKV infectedmalemiceweremated
with uninfected femalemice the femalemice became infected [591, 592, 615]. Female tomale
transmission of ZIKV inmice was unsuccessful [592]. In Rhesusmacaques, systemic infection
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Figure 5.2: Flow diagram of reviewed studies. Numbers of studies screened, assessed for
eligibility, and included in the review, with reasons for exclusions at each stage.
Category Publications onZIKV Publications on other
Flaviviruses
Epidemiological studies
Case reports 44 7
Case series 18 1
Cohort studies 4 -
Outbreak or surveillance reports 1 -
Mathematicalmodelling studies 2 -
Basic research studies
In vivo studies 35 7
In vitro studies 6 1
Review studies - 2
Total publications: 110 18
Reporting on sexual transmission between
two partners
24a 1
Publications used for quantitative analysis 51 -
Reporting serial interval 12a -
Reporting at least one measurement in
bodily fluids of interest using RT-PCR or viral
culture
48a -
Table 5.2: Overview of study designs of included studies. aOverlap in publications; one
publication can report onmultiple outcomes (e.g. reportingon serial interval and/or persistence
and/or sexual transmission).
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through oropharyngeal mucosal inoculation with ZIKV was only successful after inoculation
with a very high dose of virus, suggesting a very low risk of oral mucosal transmission [604].
Four Rhesusmacaques became viraemic after intranasal or intragastric inoculationwith ZIKV
[589]. Inguineapigs, direct transmissionbetweenanimals infected subcutaneouslywithZIKV
and co-housed uninfected animals was seen [589].
In human prostate cells, testicular cells and mature spermatozoa are susceptible in vitro to
ZIKV infection [585, 610, 612]. Human Sertoli cells can support high levels of ZIKV replication
and persistence [617]. In multiple mouse models, using different strains of ZIKV, the testes
seem to be a preferred site for viral replication, able to sustain high viral loads for a longer
duration than other organs [592, 594, 597, 600, 602, 603, 607, 614]. In some of these models,
ZIKV caused inflammation of the testes [592, 593, 601, 614], reduced testicular size and
decreased levels of testosterone [609, 611, 614, 618]. The testes of experimentally infected
NHP harboured high levels of ZIKV [599, 605]. High titres of ZIKV RNA were detectable
in semen until day 28 in Rhesus and Cynomolgus macaques [605]. However, one group of
Rhesus macaques had only low levels of viral RNA in the testes and no detectable virus in
the prostate or epididymis. In common marmosets, ZIKV RNA in semen was sporadically
detected [587].
The female genital tract of macaques was able to sustain ZIKV replication for shorter
durations and with lower viral loads than the male genital tract [584, 590, 605]. Although
cervical and endometrial cells were susceptible in vitro , virus was not detected in the female
genital tract inmice or NHP for longer than 7 days after infection [584, 590]; in one study, the
ovary sustained higher titres up to 14 days post infection. Intravaginal infection ofmice led to
systemic infection [266, 592, 596, 598, 608, 611, 613, 619] and to adverse congenital outcomes
[592]. In pregnant female mice, sexual transmission led to more ZIKV dissemination to the
female reproductive tract, compared to subcutaneous or intravaginal inoculation [619]. In
NHP the incubation time following infection was longer for intravaginal infection compared
with subcutaneous infection [586]. In mice, viral titres were lower in the salivary glands
than the testes and ovaries. In NHP, viral RNA was detected in saliva up to 28-42 days
[586, 588, 590, 599, 605] and ZIKV could be cultured at day 7 and day 14 [587, 605].
Risk of bias in in vivo studies
Most studies did not describe in detail the methods used to avoid bias. Detailed certainty
assessment of the in vivo studies is provided in S6 Table.
5.5.2 Observational studies
ZIKV transmission between sexual partners
As of April 15, 2018, the US Centers for Disease Control and Prevention (CDC) reported
that, of 5,672 cases of ZIKV infection, 52 were acquired through sexual transmission in
the United States [45]. The European Centre for Disease Prevention and Control (ECDC)
reported, as of 13 March 2017, 20 out of 1,737 cases of sexual transmission amongst those for
which the route of transmission was known [46]. We included 67 reports about ZIKV sexual
transmission, measurement of ZIKV infection status using RT-PCR or viral culture in samples
of semen, vaginal fluid or saliva, or both [44, 49, 77, 514, 619–676]. Twenty-four of these
studies reported on 36 couples in which a primary partner with ZIKV infection, who returned
from a ZIKV endemic area, is suspected to have transmitted ZIKV to a secondary partner
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[44, 514, 620, 621, 628, 629, 631, 632, 634–636, 638, 639, 643–645, 647, 667, 671, 672, 674]
(Table 5.3). Thirty-four of 36 episodes of transmission were from man to woman (94%), one
(3%)was fromwoman toman [632] and one (3%)was fromman toman [634]. Penile-vaginal
intercourse was reported as themost likely mode of transmission betweenmen andwomen,
but oral andanal intercoursewerementionedas possible transmission routes in some reports
[44, 621, 629, 631, 632, 634, 638, 639, 647, 671, 672]. One study reported transmission of ZIKV
from a vasectomised man to his female sexual partner [621]. Amongst primary infected
individuals, 27/36 (75%) were symptomatic, 2/36 (6%) were asymptomatic and no symptom
status was not reported for the remaining 7/36 (19%). ZIKVwas detected by RT-PCR in blood,
urine, saliva or semen in 14/36 (39%) of the primary partners and in 18/36 (50%) secondary
partners. Nodiagnosticmethodwas stated for 29/72 (40%) individuals. In 5/36 (14%) couples,
the secondary partner had a history of travel to an endemic region [621, 635, 636, 639, 671].
Incubation period (2) and serial interval (3) We were not able to extract information
on the incubation period following sexual exposure to ZIKV, since dates of exposure of
the primary partner and dates of sexual intercourse with the secondary partner were
rarely reported. Thirteen reports about 15 couples reported on dates of symptom onset for
both partners. The median serial interval was 12 days (interquartile range: 10-14.5 days)
[44, 621, 631, 632, 634–636, 638, 643, 645, 647, 671, 672] and themaximumwas 44 days [671].
Duration of infectiousness (4) Duration of infectiousness was not measured directly in
any included study. Observational studies measured the duration of detection of ZIKV in
bodily fluids in case reports, case series and prospective cohort studies. S3 Text provides
additional information. Case reports and case series We included 48 publications describing
180 individuals who underwent diagnostic testing by RT-PCR or viral culture on semen,
vaginal fluid or saliva at one or more time points [77, 621–627, 629–631, 633–643, 645, 646,
648–656, 659–671, 673, 675]. In semen (data available from 37 case reports and case series
from 119 individuals, Figure 5.3, S3 Text)[77, 621–623, 625, 626, 629–631, 633–636, 638–643,
645, 646, 648, 649, 651, 653–656, 661–663, 666–668, 670, 671, 675], the median duration of
RT-PCR positivity was 39.6 days (95% CI: 29.9-49.0 days) and the maximum was 370 days
[625]. The median duration based on viral culture was 9.5 days (95% CI: 1.2-20.3 days) (data
from 22 men in 11 reports) and a maximum of 69 days [621]. The median duration of ZIKV
positivity in anyfluid from the female genital tractwas 13.9 days (95%CI: 7.2-19.6 days) based
on RT-PCR (data from 15 women in 7 reports) and a maximum of 37 days [668]. The median
durationof ZIKVpositivity of salivawas 7.3 days (95%CI: 4.2-10.8 days) basedonRT-PCR (data
from76 individuals in 23 reports) andamaximumof 91 days [661]. Therewere too fewdata for
analysis of viral culture specimens in female genital tract fluids and saliva. Prospective cohort
studies: one cohort study enrolled 150 women and men with symptomatic ZIKV infection in
PuertoRico. ZIKVwasdetectedbyRT-PCR in 31/55men,with amediandurationof persistence
of 34 days (95% CI: 28-41 days). ZIKV RNA was only detected in a few participants in saliva
or vaginal fluids [49]. A second cohort study, amongst people returning from ZIKV endemic
areas or infected in the United States, detected ZIKA RNA in semen of 60/184 symptomatic
men [619]. The mean time to ZIKV RNA clearance was 54 days (95% CI: 53-55 days). The
median durationwas not reported, but plotted at approximately 35 days. Only three out of 19
of the semen samples provided within 30 days after symptom onset could be cultured; none
of the 59 samples provided after 30 days could be cultured.
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Characteristics n (%) References
Direction of transmission
Male-female 34 (94%) [44, 514, 620, 621, 628, 629,
631, 635, 636, 638, 639, 643–
645, 647, 667, 671, 672, 674]
Female-male 1 (3%) [632]
Male-male 1 (3%) [634]
Symptomatic status
Symptomatic 27 (75%) [44, 620, 621, 628, 631, 632,
634–636, 638, 643, 645, 647,
667, 671, 672]
Asymptomatic 2 (6%) [629, 639]
Not reported 7 (19%) [514, 644, 674]
Secondary infected individual has travelled to endemic area
Yes 5 (14%) [621, 635, 636, 639, 671]
No 31 (86%) [44, 514, 620, 628, 629, 631,
632, 634, 638, 643–645, 647,
667, 672, 674]
Serial interval reported
Yes 15 (42%) [44, 621, 631, 632, 634–636,
638, 643, 645, 647, 671, 672]
No 21 (58%) [514, 620, 628, 629, 639, 644,
667, 674]
Diagnostic certainty primary infected individual
Confirmedwith RT-PCR 14 (39%) [621, 628, 631, 632, 634–636,
638, 639, 643, 645, 671]
Confirmedwith serology 4 (11%) [44, 647, 672]
Suspected 3 (8%) [629, 647]
Not reported 15 (42%) [514, 620, 644, 667, 674]
Diagnostic certainty secondary infected individual
Confirmedwith RT-PCR 18 (50%) [621, 628, 629, 631, 632, 634–
636, 638, 639, 643, 645, 647,
671]
Confirmedwith serology 4 (11%) [44, 647, 672]
Suspected 0 (0%) –
Not reported 14 (39%) [514, 620, 644, 667, 674]
Table 5.3: Key characteristics of the couples (n=36) for which sexual transmission of ZIKV was
suspected.
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Figure 5.3: ZIKVdetection in semenbyRT-PCR. TheX-axis indicates time in days from symptom
onset. The labels on the Y-axis represent the date of publication of the studies and the date
of analysis for the last line, in ascending order. Green lines represent the duration of RT-PCR
positivity in individuals from case reports and case series (n=119), extending to the last positive
RT-PCR measurement. Green dots at day 0 represent an assumption of RT-PCR positivity for
patients with no sample taken at symptom onset. Blue lines represent the interval between
the last positive measurement and the first subsequent negative measure (red dot). The black
dotted line represents thepublicationof theWHOinterimguidelinesandtheadvisedsuggested
duration of protected sexual intercourse (6months, black triangle). The black dots andwhisker
bars represent median aggregated values and 95% confidence intervals for [a] a prospective
cohort (n=55 men) [49], and [b] the aggregation of all available case reports and case series.
Maximum values in these data sets are shownwith a red diamond or a red greater than symbol
for values outside the range of the image. Lines for which the date is not provided are from the
same date as the line above. ZIKV, Zika virus; RT-PCR, reverse transcriptase PCR.
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Risk of bias in observational studies
Studies varied widely in risk of bias and completeness of reporting (S6 Table). Many studies
reporting on transmission events did not use reliable diagnostic methods in both partners,
potentially leading to misclassification bias. The median duration of ZIKV persistence was
higher in case reports and case series than in the prospective cohort study
Mathematicalmodelling studies
Reproductionnumber (5), transmissionprobability (6), transmission rate (7) We included
twomathematicalmodelling studies, both of which used a deterministic structure [168, 169].
Gao et al. used surveillance data from Brazil, Colombia and El Salvador [168], Towers et al.
useddata fromColombia [169]. Both studiesderived the reproductionnumber forZIKVsexual
transmission: 0.136 (95% CI: 0.009-0.521) [168] and ‘likely below one’ [169]. The two studies
calculated theproportionofZIKV infections resulting fromsexual transmissionas3.04%(95%
CI: 0.12-45.73%) [168] and23%(95%CI: 1-47%) [169]. Neither studyprovidesnew information
about the transmissionprobability per sex act or the transmission rate for sexual transmission
of ZIKV.
Risk of bias ofmathematicalmodelling studies
For both modelling studies, the data used to populate the model was not suitable to derive
the outcome. Surveillance data on which these studies base their results, did not distinguish
between vector transmitted ZIKV and sexually transmitted ZIKV. The results of these studies
did not provide information about the size of the risk of sexual transmission. External
validation for bothmodels is lacking. Detailed certainty assessment is shown in S6 Table.
5.5.3 Sexual transmission framework parameters
Table 5.4 summarisesfindings for theoutcomesof the sexual transmission frameworkand the
GRADE assessment of the certainty of the evidence. S6 Table provides the GRADE evidence
profile.
5.5.4 Otherflaviviruses
Weincluded18studies reportingonthesexual transmissionpotentialofotherarthropod-borne
flaviviruses [52, 571,677–691]. Tenof 18studies (56%)were invitroexperimentsorobservations
in animals and eight studies (44%) were case reports or case series. JEV was demonstrated
to be transmissible from male to female pigs via semen [52, 677, 682, 683]. Persistence of
virus was demonstrated for at least 17 days in boars [683]. JEV can be cultured from the
seminal fluids of pigs [686]. In humans, we found one case report of male to female sexual
transmission of WNV, although the secondary partner also lived in a mosquito-endemic
area [685]. WNV was found post-mortem in the prostate and testis of a 43-year-old man on
immunosuppressive therapy following a kidney transplant [678]. Intravaginal inoculation
of WNV in mice led to local acute inflammation followed by systemic illness in a proportion
of the animals [679]. The testes of six Japanese macaques (Macaca fuscata) showed low
dengue virus (DENV) neutralizing antibodies titres [680]. Experimentally DENV infected
pigtail macaques (Macaca nemestrina) showed dissemination of virus in the prostate gland
and seminal vesicles [688]. DENV RNA could be detected in experimentally infected mice
three days after infection [689]. Four case reports describe the presence of DENV in saliva
83
CHAPTER 5. ZIKA VIRUS AS A SEXUALLY TRANSMITTED INFECTION
5
Parameter Value Sample
size
References GRADE
1. Susceptibility Summary: based on animal models, rectal
and vaginal mucosae are susceptible to
infection. The testes form a reservoir for
virus. Male-female transmission is more
common than female-male transmission.
- [266, 592, 594, 595, 597, 598,
600, 602, 603, 607, 614]
NA
2. Incubationperiod following sexual
transmission
Could not be calculated - NA
3. Serial interval Median: 12 days (interquartile range: 10-14.5
days)
15 couples [44, 621, 631, 632, 634–636,
638, 643, 645, 647, 671, 672]
very low1
4. Duration of infectiousness
Male genital tract RT-PCR (cohorts): median: 34 days (95%CI: 28-41 days) n=55 [49] low2
median: 35 days, mean: 54 days (95% CI:
53-55 days)
n=184 [619]
Male genital tract RT-PCR (case
reports and case series):
median: 39.6 days (95%CI: 29.9-49.0 days) n=119 very low2,3
Male genital tract viral culture: median: 9.5 days (95%CI: 1.2-20.3 days) n=22 [77, 621, 622, 631, 640, 641,
651, 654, 661–663]
very
low1,2,3
Female genital tract RT-PCR: median: 13.9 days (95%CI: 7.2-19.6 days) n=15 [659, 660, 664, 665, 668, 673] very
low1,2,3
Saliva RT-PCR: median: 6.8days (95%CI: 4.3-9.6 days) n=76 [623–625, 627, 631, 634, 637,
638, 640, 643, 649–652, 659–
661, 663, 666, 668, 669, 675]
very
low1,2,3
5. Reproduction number due to
sexual transmission
< 1 - [168, 169] very low4
6. Probability of transmission per sex
act
Could not be calculated - NA
7. Transmission rate (assumed) - NA
Proportion of cases due to sexual
transmission
3.0% (95% CI: 0.1-45.7%); 23% (95% CI:
1-47%)
- [168, 169] very low4
Table 5.4: Summary of the evidence on sexual transmission of Zika virus as assessed using
the sexual transmission framework. Estimates of the outcomes and publications that provide
evidence for these different parameters of the sexual transmission framework are listed per
outcome. Additionally, the certainty assessment using GRADE methodology is provided. NA,
not applicable; RT-PCR, reverse transcriptase polymerase chain reaction. 1Small sample size or
small number of studies. 2Indirect measure of duration of infectiousness 3Risk of selection bias
or selective reporting. 4Serious indirectness and imprecision.
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diagnosed by either RT-PCR or viral culture, for up to 7 days [687, 690, 691]. DENV RNA was
demonstrated in the vaginal secretion of one patient up to 18 days after onset of symptoms
[684]. Female mice that weremated to Tick-borne encephalitis virus infectedmale mice had
worse reproductive outcomes than the ones mated to a group of non-infected males; in one
femalemouse the virus was detected [681]. YFVwas demonstrated in the urine and semen of
a patient using RT-PCR 21 days after onset of symptoms [571].
5.6 Discussion
This systematic review summarises publisheddata related to sexual transmissionof ZIKVand
other arthropod-borne flaviviruses published on or before 15 April 2018. In animals, vaginal
and rectal mucosa are susceptible to ZIKV, with the testis as a preferred site of replication.
Male to female transmission wasmore frequent than female tomale transmission in animal
models and in humans. In humans, we estimated the serial interval for sexually transmitted
infection to be 12 (interquartile range: 10-14.5) days. ZIKV was detectable in semen for a
median of 34 (95%CI: 28-41) days by RT-PCR and 9.5 (95%CI: 1.2-20.3) days by viral culture. In
mathematical modelling studies, the reproduction number for sexual transmission of ZIKV
was below one. The overall certainty of the evidence was low. We found no evidence that
other arthropod-borne flaviviruses can be sexually transmitted.
5.6.1 What the study adds to existing research
TheZIKV sexual transmission framework allowedus to synthesise evidence fromboth animal
and human studies in a structured way, taking into account the risks of bias in the included
studies. Susceptibility of tissues to ZIKV could only be assessed in animalmodels. Therewere
consistent findings in animal models that help to explain the overrepresentation of reported
cases ofhumanmale to female transmission, even thoughmicearenot anatural host forZIKV
and in vivo studies often use immunocompromised animals. First, vaginal mucosa are more
susceptible thanurethralmucosa to infection [266, 592, 595, 598,602,614]. Second,high levels
of ZIKV replication in the testes in mice and sustained detection of viral RNA and of virus in
tissue culture in mice and NHPmodels is consistent with the longer duration of detection in
men thanwomen. Rectal mucosa is also susceptible to ZIKV so, although only observed once
[634], unprotectedanal intercourse isalsoa likely routeofZIKVtransmission. Theriskofbiasof
the included in vivo studies as assessed with the SYRCLE tool, was high. Most of these studies
explored the suitability of animal models or investigated pathophysiological pathways and
source of bias were rarely reported.
Our analysis shows that, when assessed from case reports and case series, the duration of
detection of ZIKV in semen by RT-PCR is overestimated; all reports are of people with ZIKV
detected and a small number of outliers influence the estimate. A prospective cohort study
that enrolled people with symptomatic ZIKV infection consecutively estimated a shorter
duration of persistence, but also showed that only half of themen and only one of 50 women
had ZIKV detected in genital fluids [49]. Case reports and case series are early sources of
information about a new disease but, by their nature, researchers report novel and unusual
findings. Parameters andeffect sizes estimated fromaggregatingdata fromthese sources are
likely to be overestimates, the so-called ‘random high’; extreme values in a distribution that
are observed by chance and are more likely to be reported because of they are noteworthy.
As evidence accumulates in well-designed studies, the estimates decrease in size. Notably,
the prospective cohort study in Puerto Rico found ZIKV in semen in only half of men with
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symptomatic infection and only vaginal fluid in only one of 50 women. Similarly, ZIKV was
found in semen in only 60/183 (33%)ZIKV infectedmen in theUnited States [619]. Persistence
of viral RNA in body fluids is often used as a proxy for the duration of ZIKV infectiousness,
although it remains unclear whether the presence of viral RNA corresponds with infectious
virus. ZIKV RNA positivity persists for longer than detection of ZIKV in viral culture in both
mice [592] and human semen samples. However, viral cultures might underestimate the
duration of infectiousness if low pH or other specimen-dependent factors produce false
negative results [627, 692]. The estimated serial intervalwas based onobservations fromonly
15 couples, but was consistent with that of several respiratory infectious diseases [693]. The
serial interval for sexual transmission was towards the lower end of estimates for mosquito
borne transmission (10-23 days) [694].
Someelementsof the infectionprocess, suchas the incubationperiod, transmissibilityofZIKV
per sex act, and transmission rate could not be observed. Inmathematical models published
so far [168, 169, 695], the estimates were based on assumptions about transmissibility of
mosquito-borne infection. Estimates from our review might provide more reliable data for
use in future modelling studies. The potential for sustained sexual transmission of ZIKV
appears low, based on the reproduction number estimated in mathematical modelling
studies. The estimated reproduction number was higher for mosquito-borne transmission,
1.96 (95% CI: 0.45–6.23), than for sexual transmission [168], although this number is highly
dependent on the geographical location [161]. This review did not find evidence supporting
sexual transmission of other arthropod borne flaviviruses. The continual updating of the
literature search identified a finding of YFV in urine and semen [571]. However, it remains
to be clarified for many viruses if detection in semen means that there is a risk of sexual
transmission [572].
5.6.2 Strengths andweaknesses of the study
The strengths of our living systematic review are the high coverage of the body of published
literature, the structured overview and the re-analysis of individual patient data on
persistence of ZIKV. The automation of search and deduplication processes makes it feasible
to keep the review updated as new information becomes available. Updated analyses of the
data from case reports show regression to the mean of the median estimate of the duration
of RNAdetection in semen (https://zika.ispm.unibe.ch/stf/). Future updates of this reviewwill
alsoallowfor incorporationof techniques to synthesisemathematicalmodelling studies, such
as multi-model ensembles. This study also has limitations. Screening and data extraction
were not done by two independent reviewers because of time constraints but we believe
that we reduced errors by having a second reviewer to check decisions and data extracted.
The statistical methods used to estimate the duration of persistence of ZIKV in bodily fluids
assume that all samples are positive for ZIKV at time zero [49], which might not be the
case. Additionally, the sexual transmission framework might not include all factors that are
required to investigate the risks of sexual transmission of ZIKV. The certainty of this body of
evidence was assessed as being of low or very low because of bias in the observational study
designs, and indirectness of evidence fromanimal studies. The certainty of the evidence base
could increase if the design and reporting of both animal and human studies improve and if
their findings are consistent with, and increase the precision of the evidence presented here.
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5.6.3 Implicationsandnextstepsforresearchers, cliniciansandpolicymakers
The risk of sexual transmission of ZIKV is particularly relevant for women who are pregnant
or planning a pregnancy, and people with high levels of sexual partner change such as some
groups ofmenwho have sexwithmen andwomen at high risk. An expert group has used the
ZIKV sexual transmission framework to stimulate discussion about research priorities [47].
One important limitation to the generalisability of findings from our review is that the data
that we analysed about sexual transmission of ZIKV in humans relied largely on information
from travellers returning from endemic areas with symptomatic ZIKV infection and their
sexual partners. This group probably differs from people in endemic regions in ways that
could affect sexual transmission of ZIKV, such as previous exposure to other flaviviruses [696].
Additional studies in ZIKV endemic settings could enrol travellers who work in areas with
mosquito-borne ZIKV transmission and who return to families living in areas, e.g. at high
altitude, where the vector does not survive [47]. There are unanswered questions about the
potential for sexual transmission of asymptomatic ZIKV infection, even though ZIKV is often
asymptomatic [24, 697, 698], about clinical differences between ZIKV infections acquired
through sexual and mosquito-borne routes, and about the long term consequences of ZIKV
in the genital tract, such as its effects on the testis and onmale infertility. Research about the
potential for sexual transmission of other flaviviruses is needed, although these viruses often
display different symptomatology or affinity for different species.
Cliniciansandpolicymakersneed informationthathelps toadvisebothopposite sexandsame
sex couples how to reduce the risk of sexual transmission of ZIKV. The relationship between
detectable RNA in semen and infectiousness therefore needs to be further investigated in
both laboratory and epidemiological studies. Current guidelines for travellers returning
from endemic areas advise six months of protected intercourse [566]. As more information
becomes available a revision of the duration of protectionmight be indicated.
5.6.4 Conclusions
This living systematic review gives an up to date synthesis of information about the sexual
transmission of ZIKVwith a structured framework. Planned regular updates will allow timely
updating of relevant data from a rapidly expanding evidence base. We did not quantify the
absolute risk of sexual transmission of ZIKV but appears small based on information about
theproportionofpeoplewith symptomaticZIKVwhohaveZIKVdetected ingenital secretions
and the short median duration of detection of ZIKV in semen and vaginal fluid. Taking into
account all available data about the duration of detection of ZIKV in culture and from the
serial interval, our findings suggest that the infectious period for sexual transmission of ZIKV
is shorter thanestimates fromtheearliestpost-outbreakstudies,whichwerebasedonRT-PCR
alone.
5.7 Supplementarymaterial
Supplementary material is available online in the published version of the manuscript http:
//doi.org/10.1371/journal.pmed.1002611.
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6.1 Abstract
The 2015–2017 epidemics of Zika virus (ZIKV) in the Americas caused widespread infection,
followed by protective immunity. The timing and burden of the next Zika virus outbreak
remains unclear. We used an agent-based model to simulate the dynamics of age-specific
immunity to ZIKV, and predict the future age-specific risk using data from Managua,
Nicaragua. We also investigated the potential impact of a ZIKV vaccine. Assuming lifelong
immunity, the risk of a ZIKV outbreak will remain low until 2035 and rise above 50% in 2047.
The imbalance in age-specific immunity implies that people in the 15–29 age rangewill be at
highest risk of infection during the next ZIKV outbreak, increasing the expected number of
congenital abnormalities. ZIKV vaccine development and licensure are urgent to attain the
maximum benefit in reducing the population-level risk of infection and the risk of adverse
congenital outcomes. This urgency increases if immunity is not lifelong.
6.2 Author summary
Zika virus (ZIKV) caused a major outbreak in the Americas between 2015–2017. It remains
unclear if immunity after infection offers life-long protection at an individual level and
how long herd immunity can protect a population against a new ZIKV outbreak. Data from
Managua,Nicaragua showedan imbalance inprotective immunity after ZIKV infection across
different age-strata. We used this data to parameterize an individual based mathematical
model to predict the future risk of a new ZIKV outbreak and to evaluate the effect of loss of
immunity and the introduction of vaccination. We found that the 15–29 age range will be at
highest risk of infection during the next ZIKV outbreak, increasing the expected number of
congenital abnormalities. We show that vaccination could curb the risk of infection and could
extend to herd immunity, but introduction within the next decade is crucial to provide the
most benefit.
6.3 Introduction
Zika virus (ZIKV) is a flavivirus, which is transmitted primarily by mosquitoes of the genus
Aedes. Before 2007, circulation of the virus only occurred sporadically in African and Asian
countries [699, 700]. Between 2007 and 2013, ZIKV caused large-scale epidemics in the
populations of Micronesia [24], French Polynesia [701] and other Pacific islands [699].
ZIKV probably became established in Aedes aegypti mosquitoes in the Americas between
2013-2014, [167, 702] and then spread rapidly across the continent. In 2015, doctors in Brazil
started reporting clusters of infants bornwithmicrocephaly, a severe congenital abnormality,
and of adults with Guillain-Barré syndrome, a paralyzing neurological condition, resulting in
the declaration by the World Health Organization (WHO) of a Public Health Emergency of
International Concern (PHEIC) [94]. WHO stated, in September 2016, that ZIKV in pregnancy
was the most likely cause of the clusters of microcephaly, and other adverse congenital
outcomes [29, 177]. The risk of an affected pregnancy appears highest during the first
trimester, with estimates between 1.0 and 4.5% [186, 703]. By the beginning of 2018, over
220,000 confirmed cases of ZIKV infection had been reported from Latin America and the
Caribbean [1], which is estimated to be only 1.02% (± 0.93%) of the total number of cases,
based onmathematicalmodelling studies [167].
Protective immunity conferred by infection, combined with high attack rates and herd
immunity, can explain the ending of epidemics and the lack of early recurrence [156], as has
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been seen with ZIKV [173]. The duration of protective immunity induced by ZIKV infection
remains uncertain, since immunity to ZIKV infection was not studied extensively before the
2013 outbreaks. Evidence from seroprevalence studies in French Polynesia and Fiji found that
levels of ZIKV neutralizing antibodies decrease with time [68]. If the fall in antibody levels
means that people become susceptible to infection again, population level ZIKV immunity
might be declining already. Even if protective immunity is lifelong, the risk of a new ZIKV
outbreak will rise as susceptible newborns replace older individuals, lowering the overall
proportion of the population that is immune. Amodelling study, based ondata from the 2013
epidemic in French Polynesia, estimated that ZIKV outbreaks are unlikely to occur for 12 to 20
years, assuming lifelong immunity [164].
A direct consequence of population renewal will be an unequal distribution of immunity
by age group, with younger age groups at higher risk from a new epidemic than older
people [173]. That effect will be amplified if ZIKV attack rates are lower in children than
adults. Assessing the risk of ZIKV infection in women of reproductive age is essential
because ZIKV infection in pregnancy, leading to adverse congenital outcomes, has such
important implications for individuals, for public health and for investment in surveillance
and mitigation strategies, including vector control, early warning systems, and vaccines
[704, 705]. However, no vaccine is currently available against ZIKV. Phase I clinical trials
of ZIKV candidate vaccines have shown levels of neutralizing antibody titers that were
considered protective against reinfection [86, 87]. Some vaccines have already entered phase
II trials [88], but some companies have stopped vaccine development [706].
Researchers inManagua, Nicaraguawere the first to report the age-stratified seroprevalence
of ZIKV antibodies in population-based surveys [182]. The first cases of autochthonous
ZIKV infection in Nicaragua were reported in January, 2016, and an epidemic was observed
between July and December of that year. Through case-based surveillance, the public health
authorities of Nicaragua reported a total of 2,795 people with ZIKV detected by reverse
transcriptase (RT) PCR over this period [1]. The number of symptomatic infections is likely
much higher, owing to under-reporting. Furthermore, ZIKV infection is asymptomatic in 33 to
87%of cases [23], which are generally not identified by surveillance systems. Shortly after the
end of the 2016 epidemic, Zambrana et al. analyzed sera from two large population-based
surveys in Managua to measure the prevalence of IgG antibodies against ZIKV in 2- to
14-year olds (N=3,740) and 15- to 80-year olds (N=2,147) [182]. The authors reported ZIKV
seroprevalence of 36.1% (95% confidence interval, CI: 34.5; 37.8%) among the 2-14 year
age group and 56.4% (95% CI: 53.1; 59.6%) among the 15-80 year age group [182, 707]. The
observed post-outbreak seroprevalence in adults is in line with findings from seroprevalence
studies from French Polynesia, Brazil, and Bolivia [171, 697, 708].
In this study,weusedpublisheddata fromthe2016ZIKVepidemic inManaguaanddeveloped
an agent-basedmodel (ABM) to predict the evolution of age-specific protective immunity to
ZIKV infection in the population of Managua, Nicaragua during the period 2017–2097. We
assessed: 1) the risk of a future ZIKV outbreak; 2) the consequences of a future ZIKV outbreak
onwomenof reproductive age; 3) the influence of loss of immunity on future attack rates; and
4) how vaccination could prevent future ZIKV outbreaks.
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6.4 Materials andmethods
6.4.1 Modelling strategy
We assessed the consequences of future outbreaks of ZIKV infection in Managua, Nicaragua
using a stochastic ABM. The model follows a basic susceptible-infected-recovered (SIR)
framework and integrates processes related to ZIKV transmission, immunity, demography,
adverse congenital outcomes and vaccination (Table 6.1). We parameterized the model
based on published estimates or inferences from data about the 2016 ZIKV epidemic (Table
6.1, Supporting information S1). We considered different scenarios about the duration of
immunity, the timing and scale of ZIKV reintroductions in the population, and the timing and
scale of a hypothetical vaccination program targeted towards 15 year old girls.
Table 6.1: Parameterization of the agent-basedmodel.
Parameter Comment Source
ZIKVepidemic parameters
Transmission ratea Inferred from the 2016 epidemicb [182]
Recovery rate Inferred from the 2016 epidemicb [182]
ZIKV immunity
Initial immunitya Inferred from the 2016 epidemicb [182]
Duration of immunity Lifelong or decayingwith time 5 scenariosc
Demography
Initial age distribution – [709]
Birth rate – [709]
Death ratea – [710]
Ageing Linear ageing at each time-step –
ZIKV reintroduction
Delay until reintroduction 1 to 80 years 80 scenariosc
Cases reintroduced 1, 5 or 10 cases 3 scenariosc
Risk of adverse congenital event
Exposure Proportion of women in the first
semester of pregnancy
[709]
Risk ofmicrocephaly Upon infection during exposure time (3
levels of risk)
[186, 703]
Targeted vaccination
Date of implementation In 2021, 2025 or 2031 3 scenariosc
Effective coverage Proportion of 15 year old girls vaccinated
(0% to 80%)
5 scenariosc
aage-dependent parameters; binferred from the 2016 epidemic by fitting a compartmental
SIRmodel to these data, see Supporting information S1; cthe different scenarios are
discussed in the text in detail under the headings corresponding to the headings of this table.
6.4.2 Model structure
We simulated a population of 10,000 individuals for 80 years (2017–2097). We assigned
agents’ age and ZIKV infection status (susceptible S, infected I or immune R). Initial
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conditions reflected the situation in Managua, Nicaragua in 2017, when there was no
documentation of active transmission. In the outbreak-free period, we only considered
demographic and immunity processes: births, deaths, ageing and, if applicable, loss of
immunity and vaccination. Given the scarcity of these events at the individual level, we
selected a long time-step of seven days and stochastically applied the transition probabilities
at each time step for each agent. After a given time, ZIKV-infected cases were reintroduced in
thepopulation. Upon reintroduction, the time stepwas reduced to0.1 days, andweevaluated
the epidemic-related transition probabilities: Susceptible agents may become infected at a
rate βaI/N , where βa is the age-dependent transmission rate and N the total population
size. Infected individuals may recover with a rate γ. We ignored the influence of the vector
population and assumed that the force of infection is directly proportional to the overall
proportion of infected individuals. We allowed six months for the outbreak to finish after
introduction. Simulations were conducted independently for each combination of scenarios
and repeated 1,000 times. In the baseline scenario, we assumed no vaccination, no loss of
immunity and a reintroduction of 10 infected individuals.
We implemented the model in ‘Stan’ version 2.18 [711] and we conducted analyses with R
version 3.5.1 [314]. The Bayesian inference framework Stan permits the use of probability
distributions over parameters instead of single values, allowing for the direct propagation of
uncertainty. Stan models are compiled in C++, which improves the efficiency of simulations.
The algorithm in Supporting information S1 describes the ABM in pseudo code. The model
code and data are available fromhttp://github.com/ZikaProject/SeroProject.
6.4.3 Parameterization
ZIKVepidemic parameters
We inferred the probability distributions for the age-specific transmission rate βa and the
recovery rate γ from data on the 2016 ZIKV epidemic in Managua, Nicaragua. We used
surveillance data [182], which give weekly numbers of incident ZIKV infections, confirmed
by RT-PCR (dataset A, n=1,165), and survey data on age-stratified ZIKV seroprevalence,
measured among participants of pediatric and household cohort studies in Managua during
weeks 5–32 of 2017 (datasetB, n=3,740 children and 1,074 adults) [182].
We conducted statistical inference using a deterministic, ordinary differential equation
(ODE)-based version of the ABMwith three compartments (S, I andR) and two age classes
(a ∈ {1, 2} corresponding to ages 0–14 and≥15):
dSa
dt
= −βaSa
∑
Ia
N
(6.1)
dIa
dt
= βaSa
∑
Ia
N
− γIa (6.2)
dRa
dt
= γIa (6.3)
We ignored demography in this model because it covers a short time span. We recorded the
overall cumulative incidence of ZIKV cases using a dummy compartment:
dC
dt
=
∑
a
βaSa
∑
Ia
N
(6.4)
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in order to compute theweekly incidence onweek t:
Dt = C(t)− C(t− 1) (6.5)
Wefitted themodel toweekly incidence dataA using a normal likelihood after a square-root
variance-stabilizing transformation [712]:
Pr(A|βa, γ, ρ, σ) =
∏
t
N (
√
A|
√
ρD, σ) (6.6)
whereρ is a reporting rate parameter andσ an error parameter. In addition, we also fitted the
model to the number of individuals with anti-ZIKV antibodies at the end of the epidemic by
age groupBa using a binomial likelihood:
Pr(B|βa, γ) =
∏
a
B(Ba|na, pa) (6.7)
whereBa the number of individuals with antibodies,na is the sample size in each age group,
and pa = Ra(tend)/Na(tend) the proportion of immune at the end of the epidemic. The
full likelihoodwas obtained bymultiplying Eq. 6.6 and Eq. 6.7. We chose weakly-informative
priors for all parameters and fitted themodel in Stan (Table 6.2). We describe the calculation
of the basic reproduction numberR0 in Supporting information S1. We used one thousand
posterior samples for βa and γ obtained by Hamiltonian Monte Carlo in the ABM model,
ensuring the propagation of uncertainty of these parameters. In Supporting information S1
we provide a schematic representation of the models and the information flow. Parameter
values can translate from deterministic to agent-based versions of an epidemic model if the
time step is small [713], whichwas the reason for using a time step of 0.1 days.
Table 6.2: Parameter estimates inferred from incidence and sero-prevalence data on the 2016
ZIKV epidemic inManagua, Nicaragua.
Parameter Interpretation Prior Posterior (median and 95%CrI)
β1 Transmission for age group 0-14 Expon(0.1) 0.19 (0.16; 0.22)
β2 Transmission for age group≥15 Expon(0.1) 0.32 (0.30; 0.36)
1/γ Duration of infectious period Gamma(1, 0.1) 4.8 (4.3; 5.4)
ρ Reporting rate Beta(1, 1) 0.24% (0.21; 0.26)
I(0) Initial number of infectious Expon(0.1) 74 (40; 134)
R0 Basic reproduction number – 1.58 (1.56; 1.59)
CrI: Credible interval.
ZIKV immunity
We used the deterministic model, described in the previous section, to infer the proportion
of people with protective immunity within each age group at the end of the 2016 epidemic
p˜a. We used one thousand posterior samples of p˜a in the ABM to allow the propagation of
uncertainty. Protective immunity to ZIKV after infection was lifelong in our first scenario, so
the reduction of the overall proportion of immune individuals in the population decreased
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only because of population renewal. Given the absence of evidence about the duration of
immunity toZIKV,weconsidered four scenariosassumingexponentiallydistributeddurations
of immunitywithmeansof 15, 30, 60, 90, or 150years. Thesevalues correspond toaproportion
of initially immune agents that loses immunity after 10 years of 55%, 28%, 15%, 11% or 6%,
respectively (Supporting information S1).
Demography
We based the initial age distribution of the population on data from the World Bank [714].
We used age-dependent death rates for 2016 from the World Health Organization [710].
For births, we computed a rate based on an average birth rate in Nicaragua of 2.2 births per
woman, which was uniformly distributed over the female reproductive lifespan [709]. We
defined the period of reproductive age between 15 and 49 years. The ageing process was
linear, increasing the age of each agent by 7 days at each 7-day time step.
ZIKV reintroduction
We reintroduced ZIKV in the population after a delay of d = {1, · · · , 80} years in
independent simulations. We chose this approach rather than continuous reintroductions to
remove some of the stochasticity and assess more clearly the association between immunity
decay and risk of an outbreak. As the probability of an extinction of the outbreak depends
on the number of ZIKV cases reintroduced in the population, we considered three different
values for the seed (1, 5 or 10 cases) and compared the results (Supporting information S1).
Simulations using continuous reintroductions each year are presented in the Supporting
information S1.
Risk of adverse congenital outcomes
The estimated number of microcephaly cases resulting from the reintroduction of ZIKV
depended on the exposure, i.e. the number of pregnant women infected by ZIKV during their
first trimester, towhichweapplied threedifferent levels of risk, basedonpublishedestimates
[186, 703]. We obtained the number of ZIKV infections among women aged 15–49 years
from ABM simulations. As gender was not explicitly considered in the model, we assumed
that women represented 50% of the population. We assumed a uniform distribution of
births during the reproductive period, and considered that the first trimester constituted a
third of ongoing pregnancies at a given time. We explored three different levels of risk of
microcephaly in births to pregnant woman with ZIKV infection during the first trimester, as
reported by Zhang et al. (2017), based on data from French Polynesia (0.95%, called low risk)
and Brazil (2.19% and 4.52%, called intermediate and high risk, respectively) [167, 186, 703].
Vaccination
We examined the effects of a potential ZIKV vaccine, given to 15-year-old-girls. This
vaccination strategy was used for rubella virus, which also causes congenital abnormalities,
before the vaccine was included in the measles, mumps and rubella vaccine given in early
childhood [715]. The main objective of vaccination would be the prevention of adverse
congenital outcomes, including microcephaly. We simulated this intervention in the ABM,
assuming vaccine implementation starting in 2021, 2025 or 2031. From that date, half of the
agents reaching age 15, representing females, could transition to immune statusR regardless
of their initial status, with an effective vaccination coverage ranging from20% to 80%.
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6.4.4 Outcomeanalysis
From the simulations, we collected 1) the evolution of the age-specific ZIKV immunity in the
population; 2) the attack rate resulting from the reintroduction of ZIKV at year d; 3) the age
of newly infected individuals. We fitted a binary Gaussian mixture model to dichotomize
the observed attack rates into either outbreaks or non-outbreaks. We defined the outbreak
threshold as the 97.5% upper bound of the lower distribution. This corresponded to a
threshold of 1%, so that attack rates≥1%were considered as outbreaks. The age structure of
newly infected individuals was used to compute relative risks of infection by age group.
6.4.5 Sensitivity analysis
We explored the effect of seasonality, of changes in vector density, of migration, and of an
endemic circulation of ZIKV on our predictions regarding the attack rate and the proportion
of introductions that result in anoutbreak. Different scenarios,methods andassumptions are
provided in Supporting information S2.
6.5 Results
6.5.1 2016 ZIKVepidemic
The fitted model (Fig. 6.1), resulted in a reporting rate of 0.24% (95% credible interval, CrI:
0.21; 0.26). The transmission rate in the 0-–14 age groupwas 42% (95%CrI: 35; 48) lower than
in the≥15 age group. This corresponded to an overall basic reproduction numberR0 of 1.58
(95%CrI: 1.56; 1.59). The predicted percentage of immune at the endof the epidemicwas 36%
(95%CrI: 34; 38) for the 0–14 age group and 53% (95%CrI: 50; 57) for the≥15 age group.
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Figure6.1:Modelfit for the2016ZIKVepidemic.Modelfit for (A)weekly incidencedata and (B)
post-epidemic sero-prevalencedata fromthe2016ZIKVepidemic inManagua,Nicaragua. Data
points are in red and the correspondingmodel fit (posteriormedian and 95% credible interval)
is in blue.
6.5.2 Immunity andpopulation
In our forward simulations, the expected population size increased by 42% between 2017
and 2097. Under the assumption that ZIKV infection results in lifelong protective immunity,
population renewal will create an imbalance in the proportion immune in different age
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groups. We expect the overall proportion of the populationwith protective immunity to have
halved (from 48% to 24%) by 2051 and to be concentrated among the older age classes (Fig.
6.2A). The 0–14 year old age group will become entirely susceptible by 2031 and the 15–29
year old age group by 2046.
6.5.3 Future risk of ZIKVoutbreak
Reintroductions of ZIKV in the population of Managua are unlikely to develop into sizeable
outbreaks before 2035, 24 years after the 2016 epidemic, assuming lifelong immunity for
individuals infected in 2016 (Fig. 6.2B). After this point, attack rates resulting from ZIKV
reintroductionwill rise steeply. By 2047, we predict that ZIKV reintroductionswill have a 50%
probability of resulting in outbreaks with attack rates greater than 1% (Fig. 6.2C). In 2047 the
median attack rate of successful introductions is 3.6% (IQR: 2.0–6.2).
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Figure 6.2: Future risk of ZIKV outbreaks. (A) The evolution of the immunity status per
age group in a population of 10,000 agents for the next 80 years based on the demographic
structure of Nicaragua. (B) Heat map of the distribution of the attack rates resulting from the
reintroduction of ZIKV in the population at each year (1000 simulations for each year). (C) The
evolution of the proportion of reintroductions resulting in outbreaks (with a threshold of 1%)
with time (green), proportion of susceptible (orange), and effective reproduction numberRe
(purple).
6.5.4 Risk of infection andmicrocephaly births in women of reproductive
age
The differences between age groups in both immunity and transmission will result in a
disproportionate burden of infection in the 15–29 year age class. The relative risk of infection
in this age group ranges from 1.2 to 1.6, comparedwith the general population if an outbreak
occurs during the period 2032–2075 (Fig. 6.3A). As most pregnancies occur in this age group,
these women are also the most likely to experience a pregnancy with an adverse outcome.
The increased risk of infection in this group implies that the number of adverse congenital
outcomes resulting from a ZIKV outbreak during this period is likely to be higher than
expected with a homogeneous distribution of immunity across ages. Assuming different
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values for the added risk of microcephaly after a ZIKV infection during the first trimester, we
expect the mean number of additional microcephaly cases due to ZIKV infection resulting
from the reintroduction of the virus in Managua, Nicaragua to reach 1 to 5 cases per 100,000
population in 2060 (Fig. 6.3B).
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Figure 6.3: Risk of infection and microcephaly births in women of reproductive age. (A)
Relative risk of ZIKV infection during a ZIKV outbreak per age group compared to the
general population by year (median, interquartile range). (B) Expected number of additional
microcephaly events associated with ZIKV infection during pregnancy per 100,000 total
population according to three different risk scenarios.
6.5.5 Loss of immunity
If protective immunity to ZIKV is not lifelong, the time window before observing a rise in
the attack rates resulting from ZIKV reintroduction will shorten (Fig. 6.4A). For instance,
if 15% of the those who were infected in 2016 lose their immunity after 10 years (a mean
duration of immunity of 60 years), the time until the risk of outbreak upon reintroduction
reaches 50%would be 14 years earlier (2033) thanwith lifelong immunity (2047). If 55% lose
their immunity after 10 years (a mean duration of immunity of 15 years), in 2024, 50% of the
introductions result in an outbreak, and the attack rate in 2047 is 47%. Loss of immunity over
timewould reduce the relative risk in the 15–29 year old age group (Fig. 6.4B).
6.5.6 Targeted vaccination
The implementation of a vaccination program targeted towards 15 year old girls between
2021 and 2031 would reduce the risk of infection in women aged 15-29 years and would
also indirectly reduce the overall risk of a ZIKV outbreak in the population (Fig. 6.5). If
effective vaccine coverage is 60–80% amongst 15 year old girls, the prolongation of herd
immunity could effectivelymitigate the overall risk of a ZIKV outbreak in the population. The
reduction in the number of microcephaly cases would then exceed what would be expected
by considering only the direct protection granted by a vaccine to future mothers. A later
implementation of the intervention would be less effective, as it becomes more difficult to
maintain the herd immunity (Fig. 6.5B).
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Figure 6.4: Loss of immunity. Consequences of alternative scenarios regarding the mean
duration of protective immunity (15, 30, 60 and 150 years), compared with lifelong immunity
(thick black line): (A) median attack rate of ZIKV among reintroductions resulting in outbreaks
(with a threshold of 1%) and (B) relative risk of ZIKV infection during an outbreak in the 15–29
year age group comparedwith the general population.
6.5.7 Sensitivity analysis
We considered additional model features that may impact our predictions in a sensitivity
analysis (Table 6.3 and Supporting information S2). Accounting for seasonality or for a
future increase in vector abundance would result in higher transmission rates. This would
lead to a shorter time window until a rise in the risk of ZIKV outbreak, and higher overall
attack rates. A future diminution of vector abundance would have the opposite effects.
Humanmigration from rural areas toManagua, Nicaraguawould lead to a sharper decline of
protective immunity in the population, also lowering the time window before the next ZIKV
outbreak. Finally, a continuous endemic circulation of ZIKV in the region would increase the
probability of an outbreak early on and lead tomore stochasticity.
Table 6.3: Summary of the impact of features considered in the sensitivity analysis.
Scenario Consequence on themodel Years until 50% of
reintroductions result in an
outbreak (Year)
Attack rate in 2047 (IQR)
Baseline – 31 years (2047) 3.6% (2.0–6.2)
Seasonality Increased transmission rate (+12%) 21 years (2037) 15.3% (11.2–18.4)
Increased vector abundance Increased transmission rate (+12%) 21 years (2037) 15.3% (11.2–18.4)
Decreased vector abundance Decreased transmission rate (–12%) 44 years (2050) 1.6% (1.3–2.5)
Migration Influx of susceptible individuals 23 years (2039) 12.7% (8.7–16.2)
Endemicity Continuous reintroductions 23 years (2039) 2.5% (1.7–4.1)
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Figure 6.5: Targeted vaccination. Consequences of implementing a targeted vaccination
programamong 15-year-old-girls from2021 onwardswith various levels of effective vaccination
coverage (from 20 to 80%) compared with no vaccination (thick black line). (A) relative risk
of ZIKV infection during an outbreak in the 15–29 year age group compared with the general
population and (B) attack rate of ZIKV among reintroductions resulting in outbreaks (median,
interquartile range, with a threshold of 1%), when vaccination is introduced from 2021, 2031,
2041, 2051 or 2061 onwards (red vertical line).
6.6 Discussion
In thismathematicalmodelling study,we show that a newZIKVoutbreak inNicaraguawould
affect proportionallymorewomen in the young reproductive age range (15–29 years) than the
general population, owing to the age-dependent infection pattern and population renewal.
TheriskofanewZIKVoutbreak inNicaragua, after reintroduction,will remain lowbefore2035
because of herd immunity, then rise to 50% in 2047. If protective immunity to ZIKV decays
with time, ZIKV recurrence could occur sooner. Timely introduction of targeted vaccination,
focusing on females aged 15 yearswould both reduce the risk of adverse congenital outcomes
and extend herd immunity, mitigating the overall risk of an outbreak and resulting in lower
attack rates if an outbreak occurs.
6.6.1 Strengths and limitations of the study
A strength of our approach is that it allows for the propagation of uncertainty from the initial
data into the risk assessment, by transferring the posterior distributions of the parameters
from the deterministic model fitted to surveillance and seroprevalence data on the 2016
epidemic into the ABM used for simulations. Roche et al. showed that, when a sufficiently
small time step was chosen, stochastic and deterministic models using the same parameter
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values led to similar results [716]. Additionally, we benefited from the availability of high
quality data frompopulation-based surveys that included participants from age 2 to 80 years
in Managua, Nicaragua. The age-stratified seroprevalence data allowed us to investigate
the risk in different age groups and better assess the evolution of the age-specific immunity,
which is crucial when studying adverse congenital events caused by ZIKV infection during
pregnancy.
We chose a simple approach based on an SIR structure, similar to the model used by Netto
et al. (2017), to focus on the dynamics of infection and immunity in the human population
[171]. We did not model vector populations and behavior explicitly, as in some other studies
[163, 164, 173]. This simplification limits the mechanistic interpretation of the epidemic
parameters, but provides a phenomenological description of the transmission dynamics. We
believe that this approach is appropriate because our main objective was to determine the
risk of an outbreak after reintroduction of ZIKV, which is mostly influenced by the level of
protective immunity in thehumanpopulation.Weacknowledge that the futureoccurrenceof
ZIKV in the area also depends on the presence of a competent vector. Our choice is supported
by sensitivity analyses that show that more complex model structures (delayed SIR and
Ross-MacDonald-type models) were not superior to a simple SIR structure in describing
the 2016 ZIKV epidemic of Managua (Supporting information S1). Similarly, Pandey et al.
(2013) showed that additionalmodel complexity does not result in a better description of the
dynamics of transmissionof dengue virus (anotherAedes-borne virus) in ahumanpopulation
compared with a SIR model [162]. In our model, the transmission rate (βa) captures both
human-mosquito and mosquito-human transmission; we assumed a constant transmission
rate, as observed in the 2016 outbreak.
Despite having modeled the effect of migration on our predictions, uncertainty remains;
factors such as the political instability in Nicaragua could drive migration and influence
disease transmission, as we currently observe in Venezuela and bordering countries [717].
6.6.2 Interpretation in comparisonwith other studies
This study shows that the lower attack rate of ZIKV in children than in adults will hasten the
emergence of a population that will be fully susceptible to infection, especially if immunity
is not lifelong. The advantage of our approach is that we used the age-specific attack rates
to model the processes of ageing in relation to protective immunity to ZIKV explicitly. Even
with lifelong immunity, ourmodel predicts that childrenaged0–14 yearswill becomeentirely
susceptible by 2031 and 15–29 year olds by 2046. In future outbreaks, the attack ratewill then
be highest amongst 15–29 year olds, including womenwhowill be at risk of ZIKV infection in
pregnancy. If immunity wanes, the time until the next ZIKV outbreak will be reduced and, in
that case, the distribution of infection risk would be more equal across age groups (Fig. 6.4).
Several authors have studied the time to a next ZIKV outbreak, but none studied the effect of
the lossof immunityover time inrelationtoage. Assuming lifelong immunity, ourestimatesof
the timeuntil the risk increases are similar to the 12–20 years before re-emergence estimated
for French Polynesia [164]. Netto et al. (2017) used an SEIR model to show that in Salvador,
Brazil, the effective reproduction number was insufficient to cause a new outbreak during
the “subsequent years” [171]. Lourenço et al. (2017) showed the same for the whole of Brazil:
herd immunity should protect the population from a new outbreak in the coming years [172].
Ferguson et al. (2016) concluded that the age distribution of future ZIKV outbreaks will likely
differ and that a new large epidemic will be delayed for “at least a decade” [173].
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Other ZIKV vaccination studies confirm our findings. However, they do not show the effect
in risk groups nor assume herd immunity from previous outbreaks as we did; Durham et al.
(2018) showed that immunizing females aged 9 to 49 years with a 75% effective vaccine and
a coverage of 90%, would reduce the incidence of prenatal infections by at least 94% [718].
Similarly, Bartsch et al. (2018) showed thatwomenof childbearing age or young adultswould
be an ideal target group for vaccination [719]. Valega-Mackenzie et al. (2018) formulated a
vaccination model for ZIKV transmission that included mosquito and sexual transmission
[720]. They found that vaccination works if high coverage is achieved, both when sexual
transmission or vector-borne transmission ismost important.
6.6.3 Implications and future research
Our finding that people in the 15–29 year age range are more at risk of infection implies that
we expect a higher number of congenital abnormalities due to ZIKV infection. Thus, vaccine
development efforts should be increased. Our conclusions are drawn based on data from
Managua, Nicaragua, but should be relevant tomany regions in the Americas and the Pacific
that have documented high post-epidemic levels of seropositivity [171, 697, 708]. In regions
where ZIKV has not yet caused an epidemic but competent vectors are present, vaccination
would be in place as well. Further age-stratified seroprevalence studies, using sensitive and
specific tests and with longitudinal follow-up, are needed to improve our understanding of
ZIKV antibody distribution in populations and to quantify the duration of immunity. This
information will provide important information to improve mathematical modeling of ZIKV
risk.
ZIKV vaccine development faces considerable hurdles. First, the evaluation of vaccine
efficacy has stalled because the reduced circulation of ZIKV has reduced the visibility of
ZIKV-associated disease [706]. Second, it remains unclear if neutralizing antibodies induced
by vaccination are sufficient to protect women against vertical transmission and congenital
abnormalities [90]. Third, it is not clear whether or how vaccine-induced antibodies against
ZIKVwill cross-react with other flaviviruses. Tomove vaccine development forward, we need
to find regions where disease will occur to be able to conduct trials. This requires identifying
populations that are at risk, and implementing surveillance there. These caneither be regions
whereZIKV is endemic, orwhereZIKVoutbreaks are likely to occur; throughout theAmericas,
there might be regions that did not experience an outbreak, but do have suitable conditions
such as competent vectors. Conducting vaccine trials in disease outbreaks is complex, but
there are tools to facilitate planning [721]. ZIKV in an endemic setting, such as in Africa and
Asia, could prove a suitable setting as well. However, ZIKV circulation in endemic setting is
notwell described and the occurrence of adverse outcomes in this context is less documented
[177]. Further research in understanding the transmission of the virus in an endemic context
is therefore needed. Similarly, we need to increase the understanding of changes over time
in vector abundance and population composition, since these influence the risk of new
outbreaks.
6.6.4 Conclusion
Preparedness is vital; the time until the next outbreak gives us the opportunity to be
prepared. The next sizeable ZIKV outbreak in Nicaragua will likely not occur before 2035
but the probability of outbreaks will increase. Young women of reproductive age will be at
highest risk of infectionduring thenextZIKVoutbreak. Vaccination targeted to youngwomen
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could curb the risk of a large outbreak and extend herd immunity. ZIKV vaccine development
and licensure are urgent to attain the maximum benefit in reducing the population-level
risk of infection and the risk of adverse congenital outcomes. The urgency of ZIKV vaccine
development increases if immunity is not lifelong.
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S1.1 Model workflow 17
Figure 1 provides a workflow of the parameterization using an ODE model and subsection predictions 18
using an ABM model. 19
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Figure 1: Graphic description of the model.
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S1.2 Comparison of SIR model with SEIR model and the 20
Pandey model. 21
We chose a simple SIR structure to model the transmission of ZIKV (Fig. 2). Other common choices 22
include SEIR structures, including an incubation period, and a Pandey-type structure explicitly modelling 23
the vector population as implemented in Champagne et al. (2016) [1]. We support this choice by 24
conducting model selection using leave-one-out cross-validation (LOO-CV) [2]. The objective of LOO-CV 25
is to estimate the leave-one-out information criterion (LOOIC), a measure of the pointwise out-of-sample 26
prediction accuracy from a fitted Bayesian model. The estimation of the LOOIC relies on Pareto smoothed 27
importance sampling (PSIS), a procedure for regularizing importance weights. 28
SIR model
S I R
βI γ
SEIR model
S E I R
βI η γ
Pandey model
HS HE HI HR
VI VE VS
βHVI η γ
βVHIτ
Figure 2: Description of the three compared models. These diagrams ignore the stratification in two age
groups: 0-14 and ≥15.
We compared the fits of the SIR, SEIR and Pandey model to incidence and seroprevalence data from 29
Managua, Nicaragua. The LOOIC for the SEIR model (93.9) was slightly lower than for the SIR model 30
(95.2) but the the estimated pointwise difference in LOOIC (∆LOOIC) of -1.3 was small compared to 31
its standard error, indicating no evidence in support of a better fit. The ∆LOOIC between the SIR and 32
Pandey models was also small and in favour of the SIR model. Overall, this model selection approach 33
supported our choice of the SIR model. 34
Table 1: Model comparison
Model LOOIC (SE) ∆LOOIC (SE)
SIR 95.2 (8.7) Ref.
SEIR 93.9 (8.9) -1.3 (1.6)
Pandey 99.5 (8.3) +4.3 (3.6)
S1.3 Prior predictive check 35
The choice of prior distribution is a crucial aspect of analyses conducted in a Bayesian framework. Prior 36
predictive checks can be used to assess the adequacy of the choice of prior distributions [3]. The principle 37
is to use the model to simulate artificial data from the chosen set of prior distribution. If the chosen set 38
of priors can lead to any dataset that could plausibly be observed, then the priors can be qualified as 39
“non-informative”. Figure 3 shows that this is indeed the case here, as our choice of priors for β1, β2, γ, ρ 40
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and I(0) lead to a wide variety of possible epidemic data, from 0 to 4,000 cases reported weekly and from 41
0 to 100% post-epidemic seroprevalence. 42
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Figure 3: Prior predictive check for the model. (A) Weekly number of reported cases of Zika virus infection
in Managua, Nicaragua (grey area shows the 95% range in the artificial data simulated from the prior
distributions, red dots show actual data). (B) Post-epidemic seroprevalence (grey bar shows the 95%
range in the artificial data, red dots are actual data).
S1.4 Comparison of “square root normal”, “negative bino- 43
mial” and “Poisson” approaches 44
Several approaches can be used to fit an ODE model to incidence data. The objective is to obtain the 45
joint posterior distribution of the parameters β1, β2 and γ by considering the likelihood of the incidence 46
data A. A straightforward choice for modelling count data is to use a Poisson distribution to link the 47
output of the ODE system at time t Dt to weekly incidence data At: 48
Pr(A|β1, β2, γ) =
∏
t
Poisson(At|Ct) (1)
A common problem using Poisson distributions is the presence of overdispersion. A direct solution is to 49
use instead a negative binomial distribution, with an additional overdispersion parameter φ: 50
Pr(A|β1, β2, γ) =
∏
t
Neg-Bin(At|Ct, φ) (2)
However, the classical negative binomial distribution can struggle when data varies from 0 to large values, 51
as it results in variance estimates that do not scale properly. A solution is to use a modified negative 52
binomial distribution where the overdispersion parameter is scaled by the mean, so that: 53
Pr(A|β1, β2, γ) =
∏
t
Neg-Bin(At|Ct, Ct × φ) (3)
An alternative is to use a normal distribution after a square-root transformation aimed at stabilizing the 54
variance, as described in [4]: 55
Pr(A|β1, β2, γ) =
∏
t
N (
√
At|
√
Ct, σ) (4)
We decided to use this last solution in our model, but provide here a comparison of the model fit 56
(Figure 4) and parameter estimates (Table 2) obtained with the other approaches. We show that all the 57
approaches lead to very similar fits and parameter estimates, although the Poisson approaches leads to 58
narrower credible intervals. 59
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Figure 4: Comparison of fit with Sqrt (A), Poisson (B), and Modified negative binomial (C).
Table 2: Comparison of parameter estimates with Sqrt, negative binomial, and Poisson.
Approach Square root normal Poisson Modified negative binomial
β1 0.17 (0.15–0.20) 0.16 (0.14–0.18) 0.17 (0.15–0.19)
β2 0.31 (0.28–0.34) 0.30 (0.27–0.32) 0.31 (0.29–0.33)
1/γ 5.24 (4.69–5.86) 5.58 (4.98–6.21) 5.35 (4.85–5.84)
S1.5 R0 calculation 60
We used the next generation matrix method described by Diekmann et al. (2010) to calculate R0 (eq. 5 61
- 7) [5]. β1 is the transmission rate for the 0–14 age group; β2 for the >15 group and γ is the common 62
recovery rate. 63
We start by expressing the model with the infection matrix F and the migration matrix V : 64
F =
(
β1 β1
β2 β2
)
(5)
V =
(−γ 0
0 −γ
)
(6)
R0 is defined as the square root of the largest eigenvalue of FV −1: 65
R0 =
√
β1 + β2
γ
(7)
S1.6 Loss of immunity scenarios 66
We explored plausible scenarios of loss of immunity with mean durations of 15, 30, 60, 90, and 150 years 67
(Fig. 5). 68
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Figure 5: Different scenarios considered regarding the loss of immunity.
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S1.7 ABM algorithm 69
Here, we provide pseudo code of the ABM (Algorithm 1). 70
Algorithm 1 ABM
1: procedure Initialization . Add initial conditions S/R and sex per n individual
2: for n← 1, popMax do
3: R[n]← select random 1 or 0 with probability(age[n])
4: S[n]← 1−R[n]
5: I[n]← 0
6: sex[n]← select random 1 or 0 with probability 0.5
7: end for
8: end procedure
9: procedure Simulation . Simulation over wkMax weeks
10: for wk ← 1, wkMax do
11: for n← 1, popMax do . Loop over popMax individuals
12: if individual is alive then
13: procedure Population dynamics . Pre-outbreak
14: Birth,Death,Ageing
15: end procedure
16: procedure Loss of Immunity . Loss of immunity
17: [R→ S] with probability RateToProb(ξ)
18: end procedure
19: procedure Vaccination . Vaccination
20: [S → R] with probability vaccinationProb, at age[n]
21: end procedure
22: procedure Infection, Recovery . During outbreak
23: [S → I] with probability RateToProb(β, age[n])
24: [I → R] with probability RateToProb(γ)
25: end procedure
26: end if
27: end for
28: procedure Start outbreak . Introduction of infection
29: if wk = introductionWk then
30: Change timestep: 7 days to 0.1 days
31: Collect summary statistics pre-outbreak
32: Introduce introductionN infections
33: end if
34: end procedure
35: total number alive . Collect summary of week wk:
36: total number infected
37: end for
38: end procedure
6
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S1.8 The number of infections introduced does influence the 71
probability of an outbreak, but not the attack rate of suc- 72
cessful outbreaks 73
The proportion of outbreaks (1% threshold) after introduction depends on the number of infections 74
introduced; the attack rate of the successful outbreaks does not depend on the number of infections 75
introduced (Fig. 6). 76
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Figure 6: Attack rate over time for the introduction of (A) n=1, (B) n=5, (C) n=10 infections.
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S2.1 Introduction 14
The results regarding the future risk of ZIKV outbreak in Managua, Nicaragua presented in the main 15
analysis rely upon several hypotheses and modelling choices. The potential effects of two main points of 16
uncertainty, the rate of immunity loss and the introduction of targeted vaccination, were evaluated in the 17
main text. Here, we assess the potential effects on our results of several additional features that were not 18
considered in the main analysis. 19
S2.2 Seasonality 20
Variations in vector abundance according to the season may result in a variation in the transmission rate 21
according to yearly cycles. We explored the effect of seasonality using the approached proposed by Netto 22
et al. (2017) [1], that is based on a forcing cosine function f with a frequency of 52 weeks (equation 1). 23
The amplitude α and the shift κ of the cosine function are estimated from data: 24
f(t, α, κ) = 1 + α× cos
(
6.283(t− κ)
52
)
(1)
All things being equal, introducing seasonality will lead to an increase of the estimated transmission 25
rate at certain times of the year, as in this case the decrease in incidence towards the end of the epidemic 26
is not only caused by a lack of susceptibles, but also by the seasonal decrease in transmission. In forward 27
simulations, this may lead to an earlier increase of the risk of outbreak if introductions happen at a 28
favourable time. However, as the shift of the seasonal cycle κ is estimated from data, this model assumes 29
that disease introduction in the population took place on the most optimal time. This could lead to an 30
underestimation of the transmission rate if disease introduction occurred at a less optimal time in the 31
season. 32
We compare our baseline model ignoring seasonality (“No seasonality”, Fig. 1A-D) with a model 33
including seasonal forcing with α and κ informed by data (“Flexible seasonal forcing”, Fig. 1E-H) and 34
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Figure 1: Model implemented without seasonality (A-D). Model implemented with flexible seasonal forcing:
κ and α are estimated from data (E-H). Model implemented with full seasonal forcing: κ is estimated
from data and α is fixed at 1 (I-L).
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a model including seasonal forcing with α fixed to 1 (“Full seasonal forcing”, Fig. 1I-L). Compared to 35
no seasonality, including a flexible seasonal forcing leads to a peak estimate of R0 higher by 6%, and 36
including full seasonal forcing higher by 12%. 37
We considered the impact of an augmentation of the transmission rate by 12% on the model predictions 38
(Fig. 3, scenario n◦2). Such an increase would result in a reduction of the time window before observing a 39
rise in the risk of ZIKV outbreak (21 years until 50% of reintroductions result in outbreaks, compared with 40
31 years in the baseline model) and an increase of the attack rate at year 2047 to 15.3% (IQR: 11.2–18.4), 41
compared with 3.6% (IQR: 2.0–6.2) in the baseline model. 42
S2.3 Varying vector densities 43
Changes in vector density may result in an increase or a decrease of the transmission rate. Vector densities 44
may change over time according to human population densities and climate [2]. The complex interactions 45
between climate, human demography and vector abundance make long term predictions of future vector 46
abundance difficult. Therefore, we considered the impact of both an increase and a decrease of the 47
transmission rate on our estimate of the future risk of ZIKV outbreak. 48
As reported in the previous section, an increase of the transmission rate by 12% would result in an 49
earlier increase of the risk of outbreak and higher average attack rates (Fig. 3, scenario n◦2). Conversely, 50
a decrease of the transmission rate by 12% would extend the time window before observing a rise in the 51
risk of outbreak (44 years until 50% of the simulated introductions result in outbreaks, Fig. 3, scenario 52
n◦3). The average attack rate in 2047 would be 1.6% (IQR: 1.3–2.5). 53
S2.4 Migration 54
Human migration may impact the future evolution of the proportion of susceptible individuals in Managua, 55
Nicaragua. We considered the effect of urbanization, or an influx of rural inhabitants, which is a 56
plausible scenario in this particular context [3]. Evidence suggests that rural populations have lower 57
seroprevalence [4]. Urbanization might thus result in a quicker decline of protective immunity in the 58
population than expected. 59
The International Institute for Applied Systems Analysis (IIASA) produces predictions of population 60
and urbanization according to different Shared Socioeconomic Pathways (SSP) storylines. SSP storylines 61
are different narrative scenarios of how trends change over time [5]. We considered a scenario where 62
the projected urbanization in Nicaragua follows the SSP2 or “middle of the road” storyline [6]. This 63
implies that the proportion of urbanization in Nicaragua will rise from 60 to 79% between 2015 and 2100 64
(Fig. 2). We considered an extreme situation where urbanization consists of an influx of fully susceptible 65
individuals with a median age of 30. Under these conditions, the time until 50% of reintroductions result 66
in an outbreak would decrease from 31 to 23 years and the attack rate in 2047 is 12.7% (IQR: 8.7–16.2) 67
(Fig. 3, scenario n◦1). 68
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Figure 2: Proportion and rate of urbanization in Nicaragua according to the SSP2 scenario [6].
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Figure 3: Comparison of the predicted evolution of protective immunity (A); the distribution (B) and the
average (C) of the attack rates resulting from the reintroduction of ZIKV in the population each year;
and the proportion of reintroductions resulting in an outbreak with attack rate ¿1% across four modelling
scenarios: baseline scenario used in the main analysis (n◦0), scenario including migration from rural areas
(n◦1), scenario corresponding to a transmission rate increased by 12% (n◦2) or decreased by 12% (n◦3).
S2.5 Endemic transmission 69
In the main analysis, we considered that ZIKV entirely disappeared from Managua, Nicaragua after the 70
epidemic waves of 2015-2017. This assumption is coherent with the sharp decline in reported cases of 71
ZIKV on the continent after 2017 and the limited evidence on ZIKV infection of new world monkeys 72
(limiting the establishment of sylvatic endemic circulation cycles [7]). If low level circulation exists and 73
ZIKV becomes endemic in the Americas, repeated reintroductions in Managua, Nicaragua would occur 74
which would have implications on our projections. 75
We considered this scenario by modifying the rate of reintroduction of ZIKV in our simulations. In 76
the main model, we consider a single introduction per simulation, corresponding to an epidemic setting 77
where ZIKV does not circulate and has to be reintroduced from outside. To mimic endemic circulation, 78
we consider continuous reintroductions of ZIKV into our population with a monthly probability of 1/12 79
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(on average one introduction per year), in the presence and absence of seasonality (Fig. 5). 80
With these conditions, the time until 50% of the simulations result in an outbreak where at least 1% 81
of the population is affected would be 23 years in absence of seasonality, and 22 years when seasonality 82
was considered (Fig. 4). The median attack rate in 2047 would be 2.5% (IQR: 1.7–4.1) in the absence of 83
seasonality and 5.1% (IQR: 2.3–13.9) when seasonality is considered. Continuous reintroductions would 84
also result in a lot more variability due to stochasticity. 85
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Figure 4: Comparison of the different ABM simulation scenarios taking into different levels of endemicity
and seasonality and the effect on the proportion of outbreaks. Baseline scenario with one reintroduction
per simulation (0), continuous reintroductions without seasonality (1), continuous reintroductions with
seasonality (2).
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Figure 5: Comparison of the different ABM simulation scenarios taking into different levels of endemicity
and seasonality. Red arrows represent ZIKV reintroductions. (A) A single reintroduction per simula-
tion with no seasonal fluctuation of the transmission rate, baseline scenario. (B) Random continuous
reintroductions each year without seasonality. (C) Random continuous reintroductions each year with
seasonality. The thick white line in panel B and C, represent the median attack rate of the baseline model
(A) for comparison.
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Chapter 7
Discussion
“Epidemiology is somethingmorethanthetotalof itsestablishedfacts. It includestheir
orderly arrangement into chains of inference which extends more or less beyond the
bounds of direct observation.”
–WadeHampton Frost (March 3, 1880 –May 1, 1938)
CHAPTER 7. DISCUSSION
7
In this thesis I described different epidemiological aspect of the Zika virus outbreak. In
this chapter I will discuss the methods, findings and their implications. This discussion
goes beyond the points raised in the discussions in the previous chapters. In the first
section, I provide a summary of the findings. In the second, I discuss the interpretation and
implications of the findings. In the third section, I discuss the strengths and limitations of
the work presented, and in the fourth section, the lessons learnt in the context of outbreak
response. In the last section, I present an outlook on future research. I finish this chapter with
the overall conclusions of this PhD thesis.
7.1 Summary of thefindings
In Chapter 2, I provided insight in how evidence accumulates during an outbreak and more
in general during new causal questions. Case reports and case series were the first studies to
appear, followedbybasic research (invivoand invitro studies). It tookmorethanayearafter the
onset of the ZIKV outbreak for robust epidemiological studies to be published. Establishing
early public health guidance thus requires a broad approach taking into account all evidence
available. We have to make do with the low quality evidence. To minimize further delays,
evidence should be accessible as soon as it becomes available through rapid and open access
dissemination.
In Chapter 3, I extended a systematic review thatwas conducted earlier [29] and turned it into
a living systematic review. I introduced the concept and implementation of living systematic
reviews in the context of an emerging disease. We assessed the evidence on the causal
relation between ZIKV infection and adverse congenital and auto-immune neurological
outcomes, published between May 30, 2016 and January 18, 2017, using a framework based
on the causality dimensions of Bradford Hill. During this period, we saw an expansion of the
evidence that ZIKV was indeed a cause of congenital abnormalities and GBS. We provided
a proof of concept for the use of living systematic reviews to synthesize evidence about an
emerging pathogen such as ZIKV. In Chapter 4, I assessed the evidence published between
January 18, 2017 and July 1, 2019. We quantified the strength of association of the relation
between maternal ZIKV infection and congenital adverse outcomes and between ZIKV
infection and GBS. We found that the strength of association between ZIKV infection and
adverse outcomes from case-control studies differs according to whether exposure to ZIKV is
assessed in themother (odds ratio (OR) 3.8, 95%CI: 1.7–8.7, I2=19.8%)or the foetus/infant (OR
37.4, 95% CI: 11.0–127.1, I2=0%). In cohort studies, the risk of congenital abnormalities was
3.5 times higher after ZIKV infection (95% CI: 0.9–13.5, I2=0%). The strength of association
between ZIKV infection and GBS was higher in studies that enrolled controls from hospital
(OR: 55.8, 95% CI: 17.2–181.7, I2=0%) than in studies that enrolled controls at random from
the same community or household (OR: 2.0, 95% CI: 0.8–5.4, I2=74.6%). The heterogeneity
between the studies could be partly explained by the heterogeneity inmethods and sampled
populations. Studies suffered frombias and uncontrolled residual confounding.
In Chapter 5, I presented a framework to systematically assess the evidence for ZIKV as a
sexually transmitted disease. We reviewed all available literature and concluded that the risk
of sexual transmission of ZIKV is likely small, but relevant for certain risk groups. We found
that in semen viral RNA could bedetected for amedianperiod of 34days (95%CI: 28–41 days)
and 35 days (no CI given) based on two cohort studies. Aggregated data about detection of
ZIKV RNA from 37 case reports and case series indicate a median duration of 40 days (95%
CI: 30–49 days) and a maximum duration of 370 days in semen. In human vaginal fluid, the
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median duration was 14 days (95% CI: 7–20 days) and the maximum duration was 37 days.
Infectious virus in human semenwas detected for amedian duration of 12 days (95% CI: 1–21
days) and a maximum of 69 days. We highlighted the poor quality of the evidence and the
need for systematic observational studies that evaluate the risk of sexual transmission of
ZIKV.
In Chapter 6, I presented predictions on the future risk of ZIKV, based on data fromManagua,
Nicaragua, using mathematical modelling. We concluded that the risk of a new outbreak in
thenextdecades is lowdue toherd immunity. However, anextoutbreakwill disproportionally
hit people in the young reproductive age hardest (age 15–29 years). Vaccination could curb
this risk: Early introduction of vaccination in 15-year-old girls has the capacity to extend the
herd immunity and be of benefit to the whole population. Introduction of a vaccine needs to
happen within a decade after the 2016 outbreak to achieve this protection. The duration of
immunity following ZIKV infection has impact on the speed at which outbreaks will reoccur.
7.2 Implications and interpretation of thefindings
Disease outbreaks have always been part of human history and will remain a challenge in
the future. Every new outbreak allows us to learn lessons from it and expand our knowledge.
Here I put the results in the wider context of the public health response to ZIKV and
disease outbreaks in general. I discuss the implications of the findings in three themes: The
accumulation of evidence and causal inference during disease outbreaks, the estimation of
the risk of sexual transmission, and the future risk of ZIKV.
7.2.1 The implication and interpretation of the findings on the delay
in evidence accumulation and causal inference during disease
outbreaks
I showed in Chapter 2-4 that early in disease outbreaks a lot of questions are unanswered,
many of which are of a causal nature. During disease outbreaks we want to know what
caused the outbreak, what interventions will be of benefit, or if the disease causes a certain
adverse outcome. These questions are not only relevant to advance science, they often
serve important public health purposes when the answers are translated into action through
guidelines. Rapidestablishmentof evidence-basedpublichealthguidance is vital for aproper
outbreak response. In Chapter 2, I concluded that in the ZIKV outbreak the quality of the
evidence was limited. This pattern is likely similar in other outbreaks of emerging diseases
and emerging causal questions in general. Early in an outbreak, we often only have access
to surveillance data, case reports and case series. These studies are well suited for discovery
and explanation of new phenomena [133]. Fundamental research can provide insight into
the biology and pathogenesis of the disease. However, robust epidemiological studies, that
provide evidence for guidance, would often not be available. This was confirmed with the
findings presented in Chapter 2. At least in the first year after the ZIKV outbreak, no robust
epidemiological studies were available yet. This means that we have to make do with the
available evidence and look at the full body of evidence. We need to draw causal conclusions
from imperfect data.
In Chapter 3, I used a framework that considers the totality of evidence on the causal
relation between ZIKV infection and adverse outcomes. The framework and the continuous
incorporation of evidence tries to tackle the shortcomings of the evidence illustrated in
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Chapter 2. With a living systematic review we manage to integrate new evidence as it
becomes available. In Chapter 4, I extend these findings with meta-analyses of the strength
of association. The strong heterogeneity observed between the studies might imply that we
miss information on important co-factors to fully explain this variation. The heterogeneity
could also be a result of a lack of standardized methods and protocols early in an outbreak.
By using a living systematic review format, we observed an extension of the evidence and
the conclusions that ZIKV caused congenital abnormalities and adverse auto-immune
neurological outcomeswere reinforced.
Every publication on a suspected causal association contributes a piece of evidence, but none
of these pieces of evidence by itself might be enough to answer causal questions. Early in
an outbreak evidence helps to discover and explain new phenomena [133]. Here, anecdotal
evidence is of great value to initiate other studies and generate hypotheses. Looking at all
available evidence during an outbreak, regardless of the study design, helps to understand
causal relations [125]. In theabsenceofplausiblealternativeexplanationsonemight conclude
that themost likely conclusion is that of causality. We saw this in the ZIKV outbreak using the
Bradford Hill dimensions [29] and Chapter 3 and Chapter 4. It took three years after the start
of the PHEIC for the firstmeta-analysis of the strength of association between ZIKV infection
and adverse outcomes to be presented (Chapter 4). Quantifying the strength of association
and the risk of adverse outcomes due to ZIKV infection is important for resource planning and
prioritizing the disease: there are many competing public health challenges and resources
are limited. A quantification of the risk can be extended to the assessment of the burden and
helps to informpolicy-makers. Fromdiscoveryof a causal association to theaggregationof the
available evidence, we need to take into account the risk of bias and confounding. The value
of a piece of evidence is often dependent on the purpose for which it is used [722].
An implication of the findings is that we have to be aware that during disease outbreaks
evidence is imperfect. In a setting of emerging evidence, causal inference is performed using
imperfect evidence. Emphasizing and communicating the limited quality of early evidence
is vital, and guidance based on this evidence should be updated as soon as more robust
evidence becomes available.
7.2.2 The implication and interpretation of the findings on the risk of
sexual transmission
The sexual transmission framework presented in Chapter 5 can serve as a blueprint for
the systematic investigation of disease transmission. We applied it to break down the
complicated concept of transmission into smaller quantifiable parameters. It illustrates the
use and limitations of observational data. Not all parameters can be directly measured or
inferred from the data. Mathematical modelling and basic research studies can help fill in
the gaps. The framework served to identify research gaps during aWHOmeeting where the
research on sexual transmission of ZIKVwas discussed (Chapter 8.2) [47].
Different diagnostic techniques represent the duration of persistence of ZIKV in the genital
tract differently; this resulted in the conclusion that the duration of infectiousness is likely
underestimated if it is based on the viral culture of genital tract fluids, detection of viral
RNA likely overestimates it (Chapter 5). This implies that we need to take into account
these patterns for interpreting the findings. We presented all data in a concise format
together with the emphasis on the limitations; this helped an expert committee to formulate
recommendations. The results presented in Chapter 5 were used as evidence in the WHO
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guideline on the sexual transmission of ZIKV (Chapter 8.1). The recommended duration of
protected sexual intercourse after possible ZIKV infection was reduced from six months to
threemonths formen, and twomonths for women.
Case reports and disease surveillance have allowed the discovery of sexual transmission
and viral persistence in semen, but larger systematic longitudinal studies provided ‘better’
evidence for guidance. Aswith the causal research, taking into account indirect evidence from
animal studies and mathematical models, helped to make sense of the observational data.
Weobserved that the anecdotal nature of the data fromobservations in case reports and case
series resulted in a bias. Here, the more extreme results are typically reported; for example:
a longer duration of viral persistence in the genital tract. Following the evidence over time,
we observed a regression to themean duration of persistence from the case reports and case
series, similar to the values presented in recent cohort studies [49, 619]. Thus, early evidence
overestimated thedurationof persistence,whichwas reflected in the initial recommendation
by several health agencies to practice six months of abstinence or condom-protected sexual
intercourse.
7.2.3 The implication and interpretation of the work on estimating the
future risk of Zika virus inManagua,Nicaragua
InChapter 6, I showed thatpeopleof young reproductive age (15–29 year) aremore likely tobe
affected by a next ZIKV outbreak, because of an uneven distribution of protective antibodies
across the different ages, which has important public health implications. In this age group
most births occur and thus the risk of adverse congenital outcomes is highest. An extension
of the herd immunity by vaccination could potentially reduce the risk of future outbreaks and
thus prevent adverse congenital outcomes. The later vaccination is introduced, the less effect
on herd immunity it has.
An implication of the finding that in the next decade a new large outbreak is unlikely is that
it allows time to prepare for it. Vaccination should be introduced within the next ten years to
prevent losing the benefit vaccine-induced immunity has on extending the herd immunity.
Our model can be refined and applied in other contexts. The conclusion that herd immunity
protects people from a next outbreak in the near future, seems to hold true in the Pacific,
where large outbreaks after the 2013 outbreaks have not been observed [61]. If acquired
immunity against reinfection with ZIKV is not lifelong, the risk of new outbreaks will rise
quicker than anticipated. Understanding whether immunity wears off and at which speed is
crucial formore accurate risk prediction and public health planning.
7.3 Strengths and limitations of thework presented
7.3.1 Strengths
One of the overall strengths of this thesis is the application of a variety of epidemiological
methods to combine imperfect data into coherent narratives, from which we distil relevant
public health messages. Similar to how Wade Hampton Frost described the purpose of
epidemiology over a century ago, as quoted at the beginning of this Chapter [723]. I combine
data with systematic review methodology in conceptual frameworks and mathematical
modelling, allowing inference frommany lines of evidence [125].
We are the first to formally provide insight into how evidence on a causal question
accumulates in an outbreak context (Chapter 2). Meta-research, the study of research
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itself, is a young field [724] especially in the context of disease outbreaks. Meta-research has
established its value andplace in science by its contribution to investigating problems such as
the replication crisis [725]. We are also the first to transform a systematic review into a living
systematic review in this context. I highlight the benefits and provide a solution to systematic
reviews in rapidly emerging fields that become out-datedwithinmonths.
I managed to capture and describe the uncertainty in the data throughout the different
chapters. In the quantification of the strength of the association between ZIKV and adverse
outcomes (Chapter 4), I take into account and describe the heterogeneity and some of its
potential sources. In theworkon thesexual transmissionofZIKV I comprehensively compared
the evidence on the duration of infectiousness and its uncertainty of which its conclusions
directly contributed to inform guidelines (Chapter 8.1). In the prediction of the future risk of
ZIKV outbreaks (Chapter 6), I considered the uncertainty around parameters and propagate
the uncertainty throughout the simulations. The findings have an important public health
message and call to action. There, I ensured reproducibility by sharing themodel code.
7.3.2 Limitations
Concluding causality from observational data, poses the risk of incorrect conclusions due
to uncontrolled unidentified confounding [726]. Conclusions here were reached by group
consensus, which might not be the appropriate since groups of people can be biased
by pre-existing beliefs [727]. People tend to prefer information that is consistent with a
hypothesis rather than information which opposes it [728]. Much research was designed to
corroborate the hypothesis that ZIKV was indeed a cause of adverse outcomes increasing
the risk of confirmation and publication bias. I did not quantify the publication bias. Where
one could argue that research is about challenging hypotheses, or falsifiability and not
verifiability [729]. ZIKV as a cause of adverse outcomes is neither sufficient nor necessary
[103]. ZIKV is a component cause for adverse outcomes and the effects are not unique to the
cause. Wemerely skimmed the surface of logical reasoning and its application to causality.
Despite the elegance of the living systematic review, if one is conducted in a vacuum and not
for public health guidance, the effort remains purely academic, detached from public health
needs. Updatesof the living reviewon the sexual transmissionareunlikely to causeupdatesof
the guidance, where ideally this should be the case [136]. I defined stopping criteria based on
the period of funding, where an endpoint based on the results or certainty of resultsmight be
more appropriate. The speed of the living systematic reviews during the first year of conduct
was low, becausewestartedwithadelayofover a year. It tooknearly twoyears to catchupwith
the evidence. The dissemination of evidence was also delayed due to lags within the author
team and external factors such as institutional clearance procedures.
In the studies presented in this thesis, we could not formally quantify several uncertainties.
DiagnosingZIKV is challenginganddiagnostic uncertainty is currently inherent to thedisease
[730]. In the different studies, we did not incorporate this uncertainty in our analysis, but only
discussed its effect on our conclusions. A formal assessment of the effect of the diagnostic
uncertainty would increase the reliability of the results and increase the confidence intervals
around the estimates to properly reflect the overall uncertainty. Similarly, not all uncertainty
could be quantified in the work on the sexual transmission of ZIKV. We conclude that the
risk of sexual transmission is ‘likely a small risk’. Furthermore, the duration of infectiousness
could not be measured directly, and we had to rely on data that suffers from bias. This
uncertainty is also propagated in the guidelines on the prevention of sexual transmission
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of ZIKV (Chapter 8.1), there is a discrepancy between the strength of evidence and the
strength of recommendation. The GRADE score of the evidence is low to very low, where
some recommendations are strong. Due to the nature of the evidence as illustrate above,
these situations are common in guideline development of emerging outbreaks [731]. A
last important source of uncertainty is around the generalizability of the modelling results
(Chapter 6). It is unclear how well the conclusions translate to other regions, since there
is strong heterogeneity in the distribution of vectors in the real world [732]. Updating our
estimatesas soonasmoredatabecomesavailablewill improve riskestimatesandpredictions.
7.4 Perspective and follow-upquestions
By conducting theworkpresented in this thesis, I have identified several gaps inZIKV research
and disease outbreak research in general. Some of these questions have been previously
identified in the WHO agenda on ZIKV research, but have remained unanswered [95]. The
points below originate from the weaknesses identified in the work presented in this thesis or
built upon ideas that arosewhile conducting thework.
7.4.1 Delay in accumulation of evidence and causal research
Where in this thesis I only explored the accumulation of evidence during the ZIKV outbreak,
the conclusions need to be validated using other emerging causal questions. We need to
increase theunderstandingofwhat causes the variation in the timebetween the introduction
of ZIKV and the publication of reports on adverse outcomes. By identifying these barriers, we
might be able to overcome these in future outbreaks or in emerging causal questions, and
thereby accelerate the speed at which evidence becomes available.
By distinguishing different stages in emerging questions, we can improve the understanding
of the role of evidence available at each point in time. Early on in an outbreak, we set out to
discover and hypothesize new associations. Here case reports and case series play a pivotal
role [132]. We then continue to look for explanations and try to refute the hypothesis. As
time passes and evidence from a wide variety of sources and study designs accumulates,
hypotheses become theory and evidence can be implemented into guidance. At this stage,
properly conducted cohort studies or case-control studies are a valuable source of evidence
to inform guidance and help understand causal relations [726]. Having infrastructure in
place, such as dormant cohorts that can be activated and rapidly start collecting data once an
outbreak occurs. However, these cohorts need to be funded andmaintained for outbreaks of
whichwedonot knowwhere andwhether theywill occur in the future. Modelling studies can
help identify regions at risk and guide planning.
We need to be able to quantify and communicate the uncertainty resulting from conclusions
drawn from imperfect data. Quantifying and signalling uncertainty could be performed
using semi-quantitative terminology such as used by the GRADE community (very low, low,
medium, high certainty). In pharmacovigilance, standardized language on the certainty
of the causal relation between a drug and adverse outcomes is used; the causal relation is
described as unlikely, possible, probable or definite. However, this quantification is largely
subjective and issueswith reproducibility remain [733]. Standardized objectivemethodology
would be of great value, but of great difficulty as well. In the context of living systematic
reviews, these might serve as a stopping criterion; we would conduct and maintain a living
systematic review until our research question has been answered with a pre-specified
certainty.
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The evidence presented in Chapter 3 and 4 has not answered the role of co-factors or
confounders on the causal relation between ZIKV infection and adverse outcomes. The
distribution of these factors might partially explain the observed heterogeneity between
the different observational studies. Several factors have been hypothesized to play a role in
the risk of ZIKV exposure and the subsequent risk of adverse outcomes, such as differences
in genetic makeup of individuals in a population [734], cross-reactivity because of previous
exposure to arboviruses [73] and variation in vector competence [735]. However, many of
these factors have not beenmeasured in a reliable and systematic way.
Living reviews and living guidelines form an opportunity for fields where evidence is
emerging. However, many challenges need to be solved. Conducting andmaintaining living
systematic reviews requires resources. A solution couldbe that living systematic reviews form
part of the outbreak response and are maintained by a community to guarantee continuity
and feasibility. Conducting living systematic reviews in the public domain and sharing data,
protocols and results increases transparency. An implementation of living systematic reviews
within the guideline development pipeline seems a logical next step [136]. However, these
efforts might be costly and time-consuming. It can also be difficult to communicate and
disseminate amessage that changes too often over time.
7.4.2 ZIKVandpublic health
In my thesis I identified several topics within the public health domain in which we need to
increase our understanding or take action:
1) We need to increase our understanding of the duration of immunity. Early evidence
indicates that ZIKV-specific antibodies might decline over time [68] and immunity might
not be lifelong, which implies that a next outbreak can occur quicker than expected. The
2015–2017 outbreak has affected many people. Up to two-thirds of populations in the
Americas may now have antibodies against ZIKV. Although this might protect individuals
and populations alike against reinfection in the coming decade, much is unknown about the
longer term. Thus, investigating and understanding the duration of immunity in populations
that have been in contact with ZIKV is essential. Cohorts from the Pacific region, Asia, or
Africa, might shine light on the issue in the near future. The outbreak in the Americas is still
too recent to expect conclusive results from re-sampling these populations.
2) We need to move the development of vaccines forward. With the work presented
in Chapter 6, we showed that vaccination of 15-year-old girls could form an attractive
intervention; introduction of vaccination within the next decade has the potential to extend
the herd immunity for the entire population. Shoukat et al. (2018) have shown the economic
feasibility of such an intervention [736]. With a later introduction of vaccination, the capacity
to extend the effect of the herd immunity is lost.
3) We need to document the complete set of sequelae caused by ZIKV infection. To get a full
overviewof the burden of the disease, follow-up of children affected by ZIKV is necessary. The
true impact of ZIKV infection lies in infants bornwith congenital abnormalities frommothers
infectedwithZIKV.Extendingtheworkonthestrengthofassociationwithbirthoutcome,with
outcomes associatedwith early childhood,will providemore insight into the true burden and
costs of the disease. Fortunately, several cohort studies have continued to follow-up infants
born from infectedmothers [737, 738].
4)We need to increase surveillance of adverse outcomes. The detection of adverse outcomes
has played a large role in identifying the disease. However, non of these adverse outcomes is
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unique. We often had limited knowledge of baseline incidence of these adverse outcomes,
making it difficult to establish whether an increased prevalence meant indeed a detection
of disease, or simply an increased surveillance effort. For early detection, symptomatic
surveillance on adverse outcomes might be feasible. However, research is needed to
determine the capacity to detect a signal in different settings. This will help us to understand
the true impact of ZIKV, also in endemic regions such as Asia and Africa.
5) We need to look at ZIKV from a social perspective. In the studies presented in this thesis
I focus on ZIKV infections, its transmission and the different adverse outcomes it causes. I
do not take into account risk factors that result from the social and environmental context
of disease occurrence. From a public health perspective, we cannot ignore the ‘causes’ of the
‘causes’ [739]: Underlying causes such as a low socio-economic position that help explain
why some individuals or populations are affected by disease and some are not. Similarly,
the capacity to respond and counter outbreaks depends on the wealth and public health
capacity of a region. Social determinants play an important role in disease emergence [740].
Thus, we should not ignore these societal causes. Infectious diseases remain too often the
diseases of the poor [741]. If the objective of public health is to improve the overall health of a
population, reducing inequalities is possibly themost important intervention [739]. I believe
that throughout the Zika virus outbreak response, this theme has been largely neglected.
More emphasis and identification of these causes of causes will help target underlying
problems.
7.4.3 The effect of diagnostic uncertainty
Throughout the work, I have discussed the diagnostic uncertainty and the potential bias
introduced by not knowing the exact exposure status of individuals. Capturing the diagnostic
uncertainty in a formal way would bemore appropriate. Since many studies assess exposure
using different techniques and comparative studies assessing diagnostic performance are
becoming available [707, 730], we could use this information, for example, in latent-class
models [742]. It remains a challenge that diagnostic performance is dependent on other
co-factors, such as timing of diagnosis and previous exposure to other flaviviruses. Ideally,
one has access to individual based data, where exposure status has been measured using
different techniques and relevant co-factors are collected aswell. Stored samples can provide
additional information, as diagnostic methods continue to improve and samples could thus
be re-assessed to establish diagnostic test accuracies.
7.4.4 Better data andbetter data sharing
As Wade Hampton Frost already noted in 1918 that “statistics of disease have never before
been possible on such a large scale. Their collection and tabulation, even if they do not lead
to immediate results of value, will undoubtedly prove of great importance to students of
later epidemics” [723]. The same holds true a century later: The capacity to collect data keeps
increasing and properly collected data, if shared, will always be of great value to the scientific
community.
The quality of epidemiological research is for a large part determined by the quality of the
available data. The causal research would greatly benefit from data that is collected in a
uniform and unbiased way. We need data on adverse outcomes as a result of ZIKV infection,
where potential confounders are measured as well. Uniform, per protocol collection of
these data, facilitates the joint analysis of individual patient data in an individual patient
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data meta-analysis [743]. This would increase the power of the meta-analysis presented
in Chapter 4 and allow the stratification and analysis of the effect of confounders. This
way we can investigate the effect of – for example – previous exposure to other flaviviruses
and socio-economic status. This would help explain the large heterogeneity we have seen
between studies.
Likewise, for the prediction of future ZIKV risk (Chapter 5), one would ideally have access to
representativedataon thepresenceofantibodiesagainstZIKV inhumans indifferent regions,
allowing amore precise assessment of protective immunity throughout the population. This
helps to identify populations that remain vulnerable to outbreaks, and helps model the risk
of a new ZIKV outbreak on a larger scale, e.g. country- or even continent-wide. Resampling
populations over timewill increaseour understandingof thedurationof protective immunity.
The loss of protective immunity, as early evidencemight indicate [68], could increase the risk
of new outbreaks.
Studies that assess the prevalence of ZIKV antibodies in humans can also serve to answer
open questions about sexual transmission. Populations that consist predominantly of
travellers, such as soldiers stationed in endemic regions who travel back and forth to
non-endemic regions, can serve as a valuable source of information. Investigating them
and their sexual partners can help quantify the risk of both symptomatic and asymptomatic
sexual transmission. In an endemic setting household contacts have already been shown to
bemore likely symptomatic after sexual contactwith seropositive householdmembers [744].
It remains unclear what an appropriate measure of infectiousness is. Additional data from
observational studies and in vitro studies are needed to provide further insight.
7.4.5 Future outbreaks
Implementing lessons learnt from previous outbreaks helps to improve the response in a
next disease outbreak. The WHO has identified several diseases that pose a risk for future
outbreaks or re-emergence. On this so-called blueprint disease list, ‘disease X’ is added to
mark a next outbreak of an unknown or unexpected disease [745]. Disease X might cause
adverse outcome Y, and thus the lessons learned fromZIKV causing adverse outcomes can be
directly applied. The transmission routeofdiseaseXmightbenewornotwell understoodand
the transmission framework couldhelp to identify keyparameters and identify researchgaps.
We canuse the frameworks described in this thesis for the systematic collation of all available
evidence. Living systematic reviews form a suitable instrument in the outbreak response
toolbox when evidence accumulates rapidly. However, we still need a standardization of
methods and critical assessment of its use, since living systematic reviews are more resource
intensive than classic systematic reviews.
Every new outbreak increases the collective knowledge about how to respond to a next
outbreak; the lessons learnt from Ebola have resulted in a more streamlined outbreak
response by the WHO of which the ZIKV outbreak response benefited [746]. Although
attempts have been made to rapidly share data through online repositories and websites
[94, 183], this can be greatly improved during next outbreaks. Publishing a preprint of study
results can reduce publications delays by a fewmonths (Chapter 2). However, every outbreak
poses its context-specific challenges, and tailoring the response to the unique setting will be
necessary. Responding to disease outbreaks requiresmuchmore than the understanding the
epidemiology of the disease and requires a transdisciplinary approach [747].
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7.5 Conclusion
In this thesis, I established and used different frameworks andmethods that helped tomake
sense of the limited evidence that is available during disease outbreaks. With the ZIKV
epidemic, the virus has been introduced on the American continent and is likely there to stay.
Due to the climate crisis, we are facing a future where our European temperate region also
becomes more suitable for vectors and thus vector-borne disease such as ZIKV [748]. With
the ZIKV epidemic on the wane, we now have time to consolidate findings and implement
the lessons learnt. We need to be prepared for the re-emergence of ZIKV but also for the
emergence of disease X. The tools and methods presented in this thesis help us to be more
prepared for a next outbreak.
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Supplementary chapters
Chapters 8.1, 8.2 and 8.3 are publications to which I have contributed as a co-author and that
provide additional context to thework presented in this thesis.

Chapter 8.1
WHOGuidelines on sexual
transmission of ZIKV
This publication is published on theWHOwebsite: WHO reference number: WHO/RHR/19.4.
Contribution: I collected and synthesised the evidence, I presented the evidence to a WHO
expert group, I contributed to writing of the draft of the guidelines, and to the writing of the
report.
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8.1.1 Introduction
Zika virus is an arthropod-borne flavivirus, which is transmitted primarily by mosquitoes of
the Aedes genus, but can also be transmitted through sexual intercourse. In 2016, the World
HealthOrganization (WHO) concluded thatZika virus infectionduringpregnancy is a causeof
congenital abnormalities, includingmicrocephaly. The proportion of affected neonates born
tomothers infectedwith Zika virus during pregnancy has not been establishedwith certainty.
Published estimates range from 6% of infants born to women with and without symptoms
of possible Zika virus infection in the United States of America (USA) to 42% of infants born
to women with symptoms of skin rash in pregnancy in Brazil. WHO also concluded that
Zika virus can trigger Guillain-Barre syndrome (GBS), an immune-mediated neurological
condition. A multi-country assessment estimated that two of 10,000 Zika virus infections
result in GBS (95% credible Interval: 0.5–4.5/10,000). Prevention of the sexual transmission
of Zika virus can therefore prevent acute infection and neurological complications in a sexual
partner, and prevention of transmission to a pregnant womanwould prevent congenital Zika
virus infection.
As of February 2018, 86 countries and territories have had evidence of Zika virus transmission
and, as of January2018, over 500,000 suspected caseshadbeen reported in LatinAmerica and
the Caribbean. In the USA, as of 15 April 2018, 52 of 5,672 reported cases of Zika virus disease
were presumed to have been acquired through sexual transmission. In the European Union
and European Economic Area, as of 13 March 2017, 20 of 1,737 cases with a known route of
transmissionwere acquired through sexual transmission.
Sexual transmissionofZikavirus ismuchmore likely frommentowomenthanfromwomento
men, and same-sex transmission, fromman toman, has only been documented once. Where
documented, the longest time period between the onset of symptoms in one sexual partner
and the other is 44 days, with half of the sexual partners developing symptoms by 12 days.
The longest time period for which infectious Zika virus has been detected by viral culture in
semen is 69 days. However, Zika virus geneticmaterial in semen has clearedwithin 50 days in
most cases; it is not knownwhether geneticmaterial detected for longer durations represents
infectious virus.
Recommendations for the prevention of sexual transmission of Zika virus need to take into
account the risk of ongoing mosquito-borne transmission of Zika virus in geographic areas.
In areas with ongoing transmission, people are much more likely to become infected by
Zika virus through bites from infected mosquitoes and the contribution of condom use to
overall prevention of infection will be low. In areas with no autochthonous mosquito-borne
Zika virus transmission, sexual transmission from returning travellers is one of the main
routes of transmission. Travellers returning from areas with ongoing Zika virus transmission
can therefore substantially reduce the risk of subsequent infections through the correct and
consistentuseof condoms. Areaswithongoingtransmissionaredefinedas regionswithactive
circulation of mosquito-borne Zika virus. These are areas where disease surveillance detects
circulation of Zika virus, in accordance with periodic epidemiological updates fromWHO. In
the absence of adequate disease surveillance, the definition of areas of ongoing transmission
depends on the availability of local risk assessments. Adoption of the precautionary principle
could result in designation of areas with known previous transmission as areas with ongoing
transmission. Areas without ongoing transmission have no active circulation or suspected
active circulation of Zika virus.
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8.1.1.1 Rationale for the guidelines
WHO published interim guidelines on the prevention of sexual transmission of Zika virus
in September 2016 [1], based on a limited amount of evidence under an emergency process
during a public health emergency of international concern. The body of evidence has grown
considerably since then and WHO experts concluded, at a meeting in March 2017, that
the guidelines should be developed under the formal WHO guideline process [2].These
guidelines contain updated recommendations on the prevention of sexual transmission of
Zika virus, based on the best available evidence as of June 2018.
8.1.1.2 Rationale for the update of interimguidelines
At the time of issuance of the interim guidance, very few data on sexual transmission of
Zika virus were available and recommendations were developed under emergency response
procedures. In March 2017, WHO convened an expert meeting to review the evidence and
identify the research gaps surrounding sexual transmission of Zika virus. At this meeting,
participantsdiscussedaconceptual framework. Thesexual transmission frameworkdescribes
key events in sexual transmission of Zika virus between humans, based on variables and time
periods that apply to all infectious diseases.
8.1.1.3 What is new in this guideline?
• For the new recommended duration for correct and consistent use of condoms or
abstinence to prevent sexual transmission of Zika virus, a distinction is made between
men and women, and the recommended duration has been reduced from 6 to 3
months formen, 2months for women.
• The risk groups women or couples planning to conceive or having sex that could
result in conception and pregnant women, are more explicitly targeted in these new
recommendations.
• For this guideline, systematic reviews were conducted to assess available evidence on
the sexual transmissionof Zika virus andall evidenceoneffectiveness of condomuse to
prevent sexual transmission of Zika virus.
8.1.1.4 Goal and objectives
Theoverallgoalof theseguidelines is toprovideguidanceandevidence-basedrecommendations
about the prevention of sexual transmission of Zika virus. The absolute risks of different
clinical complications of Zika virus are not fully known and the prevention measures may
differ. Nevertheless, it is essential for individuals to have information about the risks of sexual
intercourse as amode of transmission in itself. These guidelines are informedby an update of
the evidence underpinning the interim guidance and follow the requirements of the formal
WHOguideline development process.The specific objectives are:
• to provide recommendations about the prevention of sexual transmission of Zika virus,
rather than about the prevention of specific complications or about the prevention of
mosquito-borne transmission;
• to update the interim guidelines in accordance with the formal WHO guidelines
development process;
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• tooffer safeandeffectiveoptions for thepreventionof sexual transmissionofZikavirus;
and
• to provide evidence summaries about the risks of sexual transmission of Zika virus and
the effectiveness of condoms for the prevention of sexual transmission of Zika virus.
8.1.1.5 Target audience
These guidelines aim to inform national and sub-national policy-makers, health care
providers, other healthcare stakeholders and the general public.
8.1.2 Methods
These guidelines were developed as outlined in the second edition of the WHO handbook
for guideline development [3]. Members of the guideline development group, which
included experts in sexually transmitted infections, virology, epidemiology, gynaecology,
condoms and sexual behaviour, developed key questions to guide the guideline development
process. All members declared conflict of interests according to WHO procedures. For
each key question, an evidence team from the University of Bern conducted systematic
reviews, synthesized the retrieved evidence and assessed its certainty using the Grading of
Recommendations, Assessment, Development and Evaluation (GRADE) framework. The
guideline development group, based on an evidence-to-decision framework, developed
and finalized the recommendations and justifications during a web conference in May 2018
and through subsequent communication by email. Recommendations were formulated
as “strong” or “conditional” using the evidence-to-decision framework. The strength of
individual recommendations is indicated after the recommendation in parentheses.The
quality of the body of evidence was assessed using the GRADE framework. After external
review, these guidelines were published.
8.1.3 Recommendations
1. Recommendations for individuals living in areas with ongoing transmission of Zika
virus
(a) Recommendations for all sexually active women andmen
i. All women and men with Zika virus infection and their sexual partners,
particularly pregnant women [4], should receive information about the
risks of sexual transmission of Zika virus (strong recommendation, very low
certainty of evidence).
ii. All women andmen should be offered a full range of contraceptives and be
counselled to be able tomake an informed choice about whether andwhen
to prevent pregnancy in order to avoid possible adverse outcomes of Zika
virus infection during pregnancy (strong recommendation, best practice
recommendation).
iii. Men should be informed about the possible risk of sexual transmission
of Zika virus during the 3 months after known or presumptive infection.1
Men should be informed about the correct and consistent use of condoms
or abstinence during that time period to prevent Zika virus infection
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through sexual transmission (conditional recommendation, low certainty
of evidence).
iv. Women should be informed about the possible risk of sexual transmission
of Zika virus during the 2 months after known or presumptive infection.1
Women should be informed about the correct and consistent use of
condoms or abstinence during that time period to prevent Zika virus
infection through sexual transmission (conditional recommendation, very
low certainty of evidence).
(b) Recommendations for women or couples planning to conceive or having sex that
could result in conception
i. Women who have had sex that could result in conception and do not wish
to become pregnant due to concerns about Zika virus infection should have
ready access to emergency contraceptive services and counselling (best
practice).
ii. Women should receive information about the possible risk of vertical
transmission of Zika virus to the foetus. Women should avoid sex that could
result in conception for 2 months after known or presumptive infection,1
to ensure that a possible Zika virus infection has cleared before becoming
pregnant (strong recommendation, very low certainty of evidence).
iii. Male sexual partners should receive information about the possible risk
of sexual transmission of Zika virus during the 3 months after known or
presumptive infection.1Men should use condoms correctly and consistently
or abstain from having sex for that time period to prevent Zika virus
infection through sexual transmission (strong recommendation, low
certainty of evidence).
iv. Taking into account current and projected local transmission rates2 of Zika
virus, women or couples planning to conceive should be informed about the
option to delay conception until the risk of Zika virus infection in the local
area has substantially decreased, in accordance with local risk assessment
(conditional recommendation, very low certainty of evidence).
(c) Recommendations for pregnant women [4] and their sexual partners
i. Pregnant women and their sexual partners should use condoms correctly
and consistently or abstain from sex for the whole duration of the
pregnancy to prevent Zika virus infection through sexual transmission
and possible adverse outcomes of Zika virus infection during pregnancy
(strong recommendation, very low certainty of evidence).
2. Recommendations for individuals living in areas without ongoing transmission of Zika
virus travelling to or from areas with ongoing Zika virus transmission
(a) Recommendations for all sexually active women and men returning from areas
with ongoing Zika virus transmission
i. All women andmen travelling to or returning from areas with ongoing Zika
virus transmission,and their sexual partners, particularly pregnant women
[4], should receive information about the risks of sexual transmission of Zika
virus (strong recommendation, very low certainty of evidence).
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ii. All women and men travelling to or returning from areas with ongoing
transmission of Zika virus should be offered a full range of contraceptives
and be counselled to be able to make an informed choice about whether
andwhen to prevent pregnancy in order to avoid possible adverse outcomes
of Zika virus infection during pregnancy (strong recommendation, very low
certainty of evidence).
iii. Men returning from areas with ongoing Zika virus transmission and their
sexual partners should use condoms correctly and consistently or abstain
from sex for at least 3 months after the last possible exposure1to prevent
Zika virus infection through sexual transmission (strong recommendation,
low certainty of evidence).
iv. Women returning fromareaswithongoingZika virus transmissionand their
sexual partners should use condoms correctly and consistently or abstain
from sex for at least 2 months after the last possible exposure3 to prevent
Zika virus infection through sexual transmission (strong recommendation,
very low certainty of evidence).
(b) Recommendations for women or couples planning to conceive or having sex
that could result in conception and returning from areas with ongoing Zika virus
transmission
i. Women returning from areas with ongoing Zika virus transmission should
avoid sex that could result in conception for at least 2 months after the
last possible exposure3 (strong recommendation, very low certainty of
evidence).
ii. Male sexual partners returning from areas with ongoing Zika virus
transmission should use condoms correctly and consistently or abstain
from sex for at least 3 months after the last possible exposure1to prevent
Zika virus infection through sexual transmission and reduce the risk of
conception (strong recommendation, low certainty of evidence).
(c) Recommendations forpregnantwomen [4] and their sexual partners travelling to
or returning from areas with ongoing Zika virus transmission
i. Pregnant women and their sexual partners should use condoms correctly
and consistently or abstain fromsex for thewhole duration of the pregnancy
if the sexual partner is returning from areas with ongoing Zika virus
transmission. This recommendation aims to prevent Zika virus infection
through sexual transmission and possible adverse pregnancy and foetal
outcomes (strong recommendation, very low certainty of evidence).
ii. Pregnant women should consider delaying non-essential travel to areas
with ongoing Zika virus transmission (conditional recommendation, very
low certainty of evidence).
3. Recommendations about safer sex WHO always recommends the use of safer sexual
practices. Safer sex is a behavioural concept that promotes the reduction of sexual
risk-taking behaviour. It emphasizes measures to reduce the risk of contracting or
spreading sexually transmitted infections (STIs), including postponing sexual debut,
non-penetrative sex, correct and consistent use of male or female condoms, and
reducing the number of sexual partners. Men and women should receive counselling,
and be informed, about safer sex. Health authorities should ensure affordable and
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equitable access to condoms and other contraception methods, especially in the
context of Zika virus transmission and other STIs. The correct and consistent use of
condoms reduces the risk of an unintended pregnancy as well as STIs, including the
human immunodeficiency virus (HIV).
8.1.4 References
1. Prevention of sexual transmission of Zika virus: interim guidance update. Geneva:
WorldHealth Organization; 2016 (WHO/ZIKV/MOC/16.1 Rev.3).
2. Kim CR, CounotteM, Bernstein K, Deal C,Mayaud P, LowN et al. Investigating the
sexual transmission of Zika virus. Lancet GlobHealth. 2018;6(1):e24-e5.
3. WHOhandbook for guideline development, second edition. Geneva: WorldHealth
Organization; 2014
4. Pregnancymanagement in the context of Zika virus infection. Geneva;WorldHealth
Organization; 2016 (WHO/ZIKV/MOC/16.2 Rev.1).
5. Laboratory testing for Zika virus infection: interim guidance. Geneva: WorldHealth
Organization; 2016 (WHO/ZIKV/LAB/16.1).
1 After known or presumptive infection: after onset of symptoms compatible with Zika virus infection or, if asymptomatic,
a positive test result for Zika virus. Most Zika virus infections are asymptomatic. Sexual transmission from a partner with
asymptomatic Zika virus infection has been reported. Whether a person is infected or not may be hard to establish, given the
low diagnostic accuracy of some available tests and the absence of resources for testing in some areas. Further guidance on the
diagnosis of Zika virus infection can be found in reference [5].
2 Local or projected transmission rates: in areaswithhigh levels of current ongoingZika virus transmission, delaying conception
until the transmission rate decreases can reduce the risk of Zika virus infection during pregnancy.
3After the last possible exposure: after the last day of stay in an area with ongoing Zika virus transmission or the last day of
sexual contact with a possibly Zika virus-infected person.
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8.2.1 Investigating sexual transmission of ZIKV
The sexual transmissibility of Zika virus, a pathogen that is transmitted primarily by Aedes
mosquitoes, has important implications [749], particularly for women because infection
during pregnancy causes adverse pregnancy and fetal outcomes, including microcephaly
[29]. WHO has included transmission through sexual intercourse and bodily fluids as a
priority in its Zika Virus Research Agenda, which was a crucial component of the public
health response to the 2015–16 Zika virus outbreak in South America. However, in the
absence of methodologically rigorous population-based studies, the epidemiology of
sexually transmitted Zika virus remains poorly understood. To help to understand and
quantify aspects of sexual transmission, theWHO Zika Sexual Transmission Research Group
developed a sexual transmission framework (appendix). The proposed framework describes
seven variables and their inter-relationships: incubation period, serial interval, duration of
infectiousness, probability of transmission per sex act, reproductive number, transmission
rate through sexual contact, and susceptibility to Zika virus infection through sexual contact
[750]. Through a combination of empirical research and modelling, this framework aims
to determine the transmission dynamics of sexually transmitted Zika virus and thereby
establish its epidemic potential.
To discuss the applicability of the framework and to address the dearth of data and research
related to sexually transmissible Zika virus, a meeting of experts was convened in Geneva,
Switzerland, on March 20–21, 2017. Experts in the fields of sexually transmitted infections,
mathematical modelling, reproductive health, public health, and arboviral biology from
public health and academic institutions reviewed the existing evidence about sexual
transmission of Zika virus, identified critical research gaps, and discussed methods for
investigation of sexual transmission. This Comment summarises the main findings of the
meeting.
Evidence from epidemiological, biological, and animal studies was reviewed. First, a
systematic review of 18 observational studies and case reports summarised evidence of
sexual transmission of Zika virus in 27 sexual partnerships [568]. No studies of sexual
transmission in endemic areas have been identified to date; the cases of sexual transmission
were identified in sexual partners of travellers returning from areas affected by Zika virus.
Second, a prospective cohort study in Puerto Rico [49] showed more frequent and longer
persistence of Zika virus RNA in semen than in vaginal fluid when detected by quantitative
reverse transcription PCR (qRT-PCR). Experimental studies in a mouse model have shown
that the virus persists in the testis and can infect vaginalmucosa, yet onlymale-to-female, not
female-to-male, sexual transmissionhasbeendocumented in thismodel [592]. Third, animal
studies have provided additional insights into the role of immunity and the correlation
between the detection of Zika virus RNA through RT-PCR and infectiousness as determined
by culture [592]. A review of the pathophysiology of the virus noted that the limited
understanding of the identity of cellular receptors that mediate Zika virus entry might have
implications for research on sexual transmissibility and diagnostics.
The Zika virus sexual transmission framework served as a springboard for discussion to
highlight existing gaps in the evidence for sexual transmission and to identify research
questions. Key questions include: how can episodes of sexual transmission be differentiated
from vector transmission? Is RT-PCR positivity a predictor of infectiousness? Do coexisting
sexually transmitted infectionsandHIVaffectdurationofviralpersistenceor thesusceptibility
to acquisition? Is there a difference between sexual and mosquito-borne acquisition of
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infection regarding effects on fetal development? Furthermore, as viral persistence studies
include mostly male participants, more data are needed to understand viral localisation and
persistence in the female reproductive tract [751]. Investigation of these research questions is
complicated by the asymptomatic nature ofmany Zika virus infections and the need formore
accurate diagnostic tests.
Methodological approaches to address the research gaps were also discussed. In
Zika-virus-endemic areas, studies of the risk of sexual transmission should require enrolment
of couples who live, work, or travel in distinct geographical areas with or without risk of
mosquitoborne Zika virus transmission (eg, in areas with the vector or at elevation and
without the vector). Observational epidemiological studies should be conducted among
discordant couples with Zika virus infection, household contacts of people with diagnosed
Zika virus infection returning to areas where there is nomosquito-borne transmission of Zika
virus, and groups at high risk of sexually transmitted infections and HIV. A working group
has been established to develop a standardised protocol to address the methodological
challenges of this issue that could be easily adapted and implemented should newepidemics
of Zika virus arise. Particular attention will be given to methods for the valid and consistent
collection of sensitive information about sexual practices between partners. Finally,
experimental animal and basic science studies were also identified as essential to determine
whether the presence of distinct genital mucosal receptors, viral RNA signatures, or immune
responses correlates with themode of transmission.
Theexpertgroupunderlinedthecomplementary rolesofbasic science, animal, epidemiological,
and mathematical modelling studies. They also highlighted the importance of mobilising
adequate funds tomove this research agenda forward. Amultidisciplinary research approach
and adaptation of the sexual transmission framework will not only inform the current
questions on Zika virus, but can serve as a template to study and to anticipate the sexual
transmission of other emerging pathogens.
8.2.2 SupplementaryMaterial
Supplementary material is available online in the published version of the manuscript http:
//doi.org/10.1016/S2214-109X(17)30419-9.
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8.3.1 Summary points
• Determining sexual contact as a mode of pathogen transmission and quantifying the
risk of sexual transmission pose epidemiologic challenges.
• Prior experiences with nontraditional sexually transmitted infections present valuable
epidemiologic lessons, including comparisons of disease rates by sex, molecular
analyses among sexually linked clusters, and methods to control for other potential
modes of transmission.
• Applying lessons learned from prior infections might be critical for rapid and effective
detection, prevention, and control of other reemerging and newly recognized sexually
transmitted infections.
8.3.2 Introduction
The spectrum of pathogens that have a sexually transmitted component is broad. Globally,
there are more than 30 recognized sexually transmitted infections (STIs), including those
transmitted primarily by sexual contact and those that are sexually transmissible but
whose primary mode of transmission is by food, vector, or droplet [752]. This latter group
of nontraditional STIs poses unique methodologic and epidemiologic challenges for public
health practitioners and researchers, who need to anticipate, identify, and contain the
next new STI outbreak. In this paper, we explore these challenges using examples of
nontraditional STIs, including 2 (shigellosis and Neisseria meningitidis) that have recently
reemerged as sexually transmissible and 2 (Zika and Ebola) that are newly recognized as
being sexually transmissible (Table 8.3.1).
8.3.3 Shigella: Raised male-to-female ratios in routine
surveillance data
Shigellosis is a diarrheal illness caused by several species of the bacterium Shigella. Shigella
is transmitted by direct or indirect contact with human feces, often via contaminated food,
water, or fomites [753]. Prior to the 1970s, Shigella incidence was highest among children
<5 years of age, their caretakers, and travelers to less developed countries. Recognition
of Shigella as a potential STI began in the 1970s with outbreaks among men who have sex
with men (MSM) in the US [754–757]. Sexual transmission of Shigella likely occurs during
oral-anal sex (e.g., anilingus or rimming) or digital-anal sex (e.g., fisting) [758, 759]. During
the 1970s and 1980s, Shigella flexneri rates increased in the US among adult males, even as
overall rates and rates among children declined [760]. Routine case reports for Shigella do
not include information about sexual practices, but the widening disparity between adult
male and female case rates strongly suggested male-male sexual transmission. Increases
in Shigella among men in the US and England between 2004 and 2015—despite declining
or steady rates among women and children—support the reemergence of Shigella as an STI
amongMSM[761, 762]. Shigella strains amongMSMhavedemonstrated increasingmultidrug
resistance over the past 5 years [763–770], and recent genomic analyses suggest international
spread of an antimicrobial-resistant S. flexneri serotype amongMSM [765].
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8.3.4 N.meningitidis: The role of dyad and cluster analyses
N. meningitidis, the bacterium that causes invasive meningococcal disease (IMD), spreads
primarily by droplet transmission and infection of respiratory mucosa. Approximately
5%–10% of healthy adults are nasopharyngeal carriers. N. meningitidis has been isolated
from men with urethritis [773]. A 1972 study described the transmission of N. meningitidis
from a male chimpanzee’s nasopharynx to his own urethra via oral-genital autoinoculation
[779]. The authors concluded that N. meningitidis in the human urogenital tract might
be the result of oral-genital sexual contact. Dyad and cluster analyses showing related
strains of meningococci among partners epidemiologically linked by female-to-male oral
sex strengthen the argument for sexual transmission leading to meningococcal urethritis
[780, 781]. Recent molecular analyses suggest that N. meningitidis has genetically adapted
to the urogenital tract [782]. Recent IMD outbreaks among MSM in Europe, Canada, and
the US have also raised questions about the role that sexual networks play in N. meningitidis
transmission [783–788]. Droplet transmission within MSM sexual networks could explain
consistently higher N. meningitidis nasopharyngeal carriage rates relative to heterosexual
men [789, 790]. It remains challenging, however, to determine whether the primarymode of
transmission in IMD outbreaks among MSM is oral-genital contact, open-mouth kissing, or
droplet transmission via “close contact,” including the sharing of living and sleeping spaces.
8.3.5 Ebola virus: Viral persistence in semen and genetic
epidemiology
The largest outbreak of Ebola virus disease started in December 2013 in West Africa and
led to >28,000 confirmed cases and 11,310 deaths [791]. Almost all infections resulted from
exposure to acutely symptomatic infected persons or recently deceased Ebola patients.
Concern about possible sexual transmission of Ebola grew as the outbreak continued [792].
Anecdotal reports of new Ebola infections occurring among persons not in close proximity to
a symptomatic or recently deceased person were followed by a report of a Liberian woman
with Ebola, whose only possible source of infection was her husband, a convalescing Ebola
survivor [793]. The husband had a positive PCR test for Ebola RNA in his semen 199 days
after symptom onset, and the homology between genetic sequences of the Ebola RNA from
the man and woman suggested that the only possible source of her infection was through
sexual transmission [793, 794]. Ebola virus persistence in the semen of male survivors was
documented in previous sporadic outbreaks [795, 796]. However, in the most recent West
African outbreak, more robust systematic assessments foundmale survivors with Ebola virus
RNA detected by PCR up to 565 days after symptom onset [796–798]. There is little evidence
supporting viral persistence inotherbodyfluids [792]. Female-to-male sexual transmissionof
Ebola is likely inefficient, but data are limited. Although the risk of transmission from semen
exposure is considered small, the sheer number ofmale Ebola survivors raised concern about
potential flare-ups and new clusters as theWest African outbreak waned [799, 800]. Little is
known about the public health impact of Ebola persistence among high-risk groups such as
sexworkers andMSM.
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8.3.6 Zika virus: Infections in sexual partners of travelers
returning fromendemic areas
A large outbreak of Zika virus in Latin America and the Caribbean in 2015–2016 drew
international attention because of its reported association with microcephaly. By 2017, 84
countries and territories had evidence of Zika transmission [292]. While the predominant
mode of Zika transmission is through the bite of an infected Aedes spp. mosquito, sexual
transmission was documented when a scientist returned to the US from Senegal in 2008
and transmitted Zika to his female sex partner who had not travelled [44]. Case reports
from 13 countries have since described probable sexual transmission of Zika—via oral,
anal, and vaginal sex—to partners of travelers returning from endemic areas. Suspected
male-to-female sexual transmission was reported in 27 couples, while only 1 case of
female-to-male and 1 case of male-to-male sexual transmission have been documented
[568]. Most sexual transmission events occurred in symptomatic couples, but the timing of
suspected transmission relative to symptomonset ranges greatly.
Persistent detection of Zika in genital fluids by reverse transcriptase (RT)-PCR and culture
provides additional evidence for the biological plausibility of sexual transmission. In Puerto
Rico, Zika was detected in the semen of 56% of convalescing men, with a median of 34
days between symptom onset and undetectable virus levels [49]. The maximum reported
durations of RNA detection in genital fluids are as follows: 188 days in semen by RT-PCR
[661], 69 days in semen by culture [621], 3 days in vaginal fluid in RT-PCR, and 11 days in
cervical mucus by RT-PCR [665]. Investigation of Zika sexual transmission is complicated
by several factors, including difficulty distinguishing vector and sexual transmission in
endemic settings and difficulty obtaining viral cultures to confirm that viral persistence
represents infectiousness. It is unclear whether controlling sexual transmission of Zika will
contribute substantially to overall control of Zika epidemics; mathematical models estimate
the population attributable risk of sexual transmission to be from 3% to 23% [168, 169].
Sustained sexual transmission of Zika is unlikely in a general population, but clusters may
occur within high-risk sexual networks [749].
8.3.7 Lessons learned to inform future efforts
Lessons learned from the STIs discussed above can help the public health community identify
newly emerging STIs and estimate the potential for an epidemic by sexual transmission.
Sexual transmissibility of Zika and Ebola viruses was identified when infections were
detected in persons who could only have been infected through sexual intercourse. In the
case of meningococcal urethritis, detection of the pathogen in an unexpected anatomic
niche and molecular linkage between index patients and their sexual partners established
sexual transmissibility. Sexual transmission of Shigella was identified by attention to
epidemiological changes in the affected populations. M. genitalium, another predominantly
sexually transmitted pathogen, was discovered in 1981 by scientists searching for causes of
nonspecific urethritis (Table 8.3.1) [774]. This discussion harkens back to the global HIV/AIDS
epidemic. HIV crossed a species barrier and spread undetected as a new pathogen and STI
among humans for years, before its identification as AIDS inMSMwith unexplained immune
suppression in San Francisco in 1981 [771, 772].
Now is the optimal time to establish methods to assess whether an infectious agent
is sexually transmissible and prepare for a new STI with pandemic potential. New or
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reemerging pathogens that are sexually transmissible will continue to arise. Since HIV
was discovered, new molecular tools, such as phylogenetics and the omics, have become
available to complement etiological epidemiological investigations of causal associations.
For example, genotypic data were critical in linking sexual partners in the context of Ebola
[794] and Shigella [765]. Standardized definitions and approaches to the investigation of
sexual transmission of infectious agents and criteria for considering apathogen to be sexually
transmissible would greatly aid this effort. For example, is transmission by close, intimate
contact (i.e., skin-to-skin) considered sexual transmission? Bradford Hill’s classic viewpoints
about causation could be adapted; for example, molecular concordance of strains between
sexual partners might be a requirement for demonstrating specificity of association. The
establishment of an objective criteria for determining the necessary components to consider
a pathogen sexually transmitted could complement the existing framework developed by
Hill. If sexual transmission is established, quantitative information about parameters such
as incubation period, serial interval, transmission probability per coital act, and reproductive
number will be needed for mathematical modelling studies of transmission dynamics, the
proportion of cases attributable to sexual transmission, the potential for epidemic spread,
and the effects of control measures. These quantities are particularly difficult to estimate
when the agent has an alternative, predominant mode of transmission in endemic areas,
e.g., mosquito-borne Zika. Developing criteria and methodologic approaches to sexual
transmission could prove invaluable if they can be applied to key pathogens with epidemic
potential, including those that theWorld Health Organization has published in its blueprint
of action to prevent epidemics [61]. A proactive initiative to understand the potential for
sexual transmission of such pathogenswill help us to stay ahead of the curve.
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